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Intelligence Enabled Innovation 
Abstract 
Given the recent proliferation of digitization and increase in data availability, this dissertation, comprised 
of three essays, examines the influence of modern information technologies, data-driven analytics and 
artificial intelligence (AI), on facilitating innovation. In spite of the growing expectation that technological 
improvements can accelerate the development of innovation, a collective set of evidence suggested 
considerable slowdown of innovation productivity in recent years: innovative ideas are getting harder to 
find (Bloom et al. 2020). Through large-scale empirical analyses, this dissertation studies under what 
conditions data analytics and AI-related technologies can facilitate innovation in firms and whether they 
can mitigate the recent innovation decline. In the first essay, we investigate the extent to which the rise of 
data analytics can reduce declines in firms’ innovative performance after an initial public offerings (IPO) 
event. It shows that through the increased use of data analytics, post-IPO firms can mitigate substantial 
reductions in some types of innovation: those innovations that involve new combinations of existing 
knowledge and that leverage existing knowledge in new problem domains. The second and third essays 
examine the effect of AI on one of the most complex innovation processes - drug innovation in the global 
pharmaceutical industry. Despite substantial research and development (R&D) spending by 
pharmaceutical firms, drug innovation has slowed down in terms of finding new drugs with new chemical 
properties. In the second essay, we first differentiate the impact of AI on different stages of drug 
innovation process. We find that AI can primarily support the early compound discovery and pre-clinical 
trials stages, but AI is less useful in later stages when human engagements, judgements, and 
organizational decisions are essential. Furthermore, we examine the conditions on when AI is most 
effective in aiding drug discovery. We find that AI has an advantage in discovering drugs whose 
mechanism of impact on a disease is known and drugs at the medium level of chemical novelty. In the 
third essay, we explore how AI can affect the value of R&D alliances, characterized by exchange and share 
of information among firms in the pharmaceutical industry. We find that drug innovation at the 
intermediate level of novelty can be best achieved through the complementarity between firms’ 
investments in AI and R&D alliances. Overall, this dissertation demonstrates the capabilities that analytics 
and AI can provide to partially alleviate the decline in innovation, and in particular, accelerate the 
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Given the recent proliferation of digitization and increase in data availability, this 
dissertation, comprised of three essays, examines the influence of modern information 
technologies, data-driven analytics and artificial intelligence (AI), on facilitating 
innovation. In spite of the growing expectation that technological improvements can 
accelerate the development of innovation, a collective set of evidence suggested 
considerable slowdown of innovation productivity in recent years: innovative ideas are 
getting harder to find (Bloom et al. 2020). Through large-scale empirical analyses, this 
dissertation studies under what conditions data analytics and AI-related technologies can 
facilitate innovation in firms and whether they can mitigate the recent innovation decline.  
In the first essay, we investigate the extent to which the rise of data analytics can 
reduce declines in firms’ innovative performance after an initial public offerings (IPO) 
event. It shows that through the increased use of data analytics, post-IPO firms can 
mitigate substantial reductions in some types of innovation: those innovations that 
involve new combinations of existing knowledge and that leverage existing knowledge in 




The second and third essays examine the effect of AI on one of the most complex 
innovation processes - drug innovation in the global pharmaceutical industry. Despite 
substantial research and development (R&D) spending by pharmaceutical firms, drug 
innovation has slowed down in terms of finding new drugs with new chemical properties. 
In the second essay, we first differentiate the impact of AI on different stages of drug 
innovation process. We find that AI can primarily support the early compound discovery 
and pre-clinical trials stages, but AI is less useful in later stages when human 
engagements, judgements, and organizational decisions are essential. Furthermore, we 
examine the conditions on when AI is most effective in aiding drug discovery. We find 
that AI has an advantage in discovering drugs whose mechanism of impact on a disease is 
known and drugs at the medium level of chemical novelty.  
In the third essay, we explore how AI can affect the value of R&D alliances, 
characterized by exchange and share of information among firms in the pharmaceutical 
industry. We find that drug innovation at the intermediate level of novelty can be best 
achieved through the complementarity between firms’ investments in AI and R&D 
alliances.  
Overall, this dissertation demonstrates the capabilities that analytics and AI can 
provide to partially alleviate the decline in innovation, and in particular, accelerate the 
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CHAPTER 1 : INTRODUCTION 
Innovation plays a crucial role in advancing economy in general, and acts as a key 
enabler of a firm’s overall performance (Wu et al. 2020). Given the recent proliferation of 
digitization and increase in data availability, one area that received renewed interests in 
the information-technology (IT) value literature is how modern information technologies 
driven by the proliferation of digital data can be used to foster innovation (Kleis et al. 
2012). The ability to leverage the data using data analytics and artificial intelligence 
technologies could bring enormous competitive advantage to firms (McAfee and 
Brynjolfsson 2017). This dissertation examines how data analytics and AI technologies 
can facilitate innovation. 
We broadly define analytics capabilities as the ability to process, analyze, and 
transform data to detect patterns, find useful insights, and support decision making (Hitt 
et al. 2018; Ridsdale et al. 2015; Wu et al. 2020). It has been vastly improved by recent 
advances in AI (Brynjolfsson and Mitchell 2017; Brynjolfsson et al. 2018). Collectively, 
AI is a set of powerful technologies and tools with the objective to learn from human 
intelligence in performing innovative tasks. With advances in machine learning, AI 
algorithms can “correctly interpret external data, to learn from such data, and to use those 
learnings to achieve specific goals and tasks through flexible adaptation” (Kaplan and 
Haenlein 2019).1 Fueled by explosive growth in digitization, computational power and 
algorithmic design, data analytics and AI technologies can facilitate the process of 
                                                          




mining, aggregating and learning diverse knowledge, which enables the reuse of existing 
knowledge in a new problem domain or creating combinations from existing knowledge 
in new ways (Wu et al. 2020). 
As potentially new general-purpose technologies (Trajtenberg 2018), data 
analytics and artificial intelligence (AI)-related technologies have already led to a number 
of innovations across various fields such as cancer research, materials design, drug 
discovery and automobile design (Chen et al. 2016; Mullin 2017; Wallach et al. 2015; 
Wu et al. 2019; Zhavoronkov et al. 2019), and disrupted many industry sectors (Dixon et 
al. 2020; McAfee and Brynjolfsson 2017). For example, IBM’s Watson deployed AI and 
analyzed 23 million scientific papers across many different disciplines to find 
information related to a protein called p53, a tumor suppressor that is associated with half 
of all cancers. Watson was able to uncover six new kinases that affect the p53 protein in 
one month, a feat that would have taken researchers about 6 years to accomplish (Chen et 
al. 2016). As a result, many venture activities in the pharmaceutical industry have 
focused on using AI to find new drug targets and chemical compounds, recognizing that 
data analytics and AI technologies can identify patterns in data by operating at a faster 
rate and on a larger scale to generate a sea change in innovation. 
However, in spite of the growing expectation that technological improvements 
can accelerate the development of innovation, a collective set of empirical evidence 
suggested considerable slowdown in the rate of generating innovation: innovative ideas 




between the promise of analytics and AI-related technologies to accelerate innovation 
and the observed decline in innovation mirrors the IT-productivity paradox coined by 
Robert Solow in a 1987 remark, “we see IT everywhere, but not in the productivity 
statistics.” Replacing “IT” with “analytics” or “AI” and “productivity” with “innovation,” 
we can likewise argue, “we see analytics or AI everywhere, but not in the innovation 
statistics.” In explaining the modern productivity paradox, it is important to examine how 
the capabilities that data-driven analytics and AI can provide in affecting innovation. 
The three essays in the dissertation document some of the AI-innovation paradox 
and attempt to uncover the factors and conditions that contribute to the paradox. In the 
first essay, we begin by examining how the rise of analytics can provide a mechanism for 
alleviating the post-IPO innovation decline. By accelerating the rate of creating reuse and 
new combinations in innovation, analytics could potentially mitigate some of the 
innovation decline for firms that have gone through an IPO without requiring complex 
financial restructuring activities (Aggarwal and Hsu 2013; Bernstein 2015; Wies and 
Moorman 2015). In the second and third essays, we examine the effect of AI on one of 
the most complex innovation processes - drug innovation in the global pharmaceutical 
industry. The pharmaceutical industry has also experienced a decline in drug innovation 
despite increases in AI investment. We differentiate the impact of AI on different stages 
of drug innovation process and examine the conditions on when AI is most effective in 
aiding the innovation. We also explore how firms can leverage information obtained from 
partners through R&D alliances for their innovation. A synopsis of each essay in the 




Essay 1- Innovation Strategy After IPO: How Data Analytics Mitigates the Post-
IPO Decline in Innovation  
We examine the role of data analytics in facilitating innovation in firms that have 
gone through an initial public offering (IPO). It has been documented that an IPO is 
associated with a decline in innovation despite the infusion of capital from the IPO that 
should have spurred innovation. Using patent data for over 2,000 firms, we find that 
firms that possess or acquire data analytics capability experience a smaller decline in 
innovation compared to similar firms that have not acquired that capability. Moreover, 
we find this sustained rate of innovation is driven principally by the continued 
development of innovations that either combine existing technologies into new ones or 
reuse existing innovations by applying them to new problem domains—both forms of 
innovation that are especially well-supported by analytics. Our results suggest that the 
increased deployment of analytics may reduce some of the innovation decline of IPOs, 
and that investors and managers can potentially mitigate post-IPO reductions in 
innovative output by directing newly acquired capital to the acquisition of analytics 
capabilities. 
Essay 2- Artificial Intelligence on Drugs: A Large-Scale Examination of AI and 
Drug Innovation 
As a potential general-purpose technology, AI has been touted to accelerate drug 
discovery. Yet, despite substantial investment, drug development has slowed down in 




drug discovery, we examine and differentiate its effects on different stages of drug 
development. Using patents and job postings to measure AI, we find that AI can 
primarily affect the earliest stage on compound discovery when tasks are heavily 
dependent on automatic data processing and reasoning to identify drug-target pairs. 
However, AI is less useful in later stages when human engagements, judgements, and 
organizational decisions are essential. Furthermore, despite discovering more drug 
candidates at the early stage, AI has not discovered higher quality drugs that are more 
likely to get approved than others. Thus, with the bottleneck of drug development 
remaining in the later stages, AI has not changed the overall number of drugs that clear 
final approval. To further examine the conditions on when AI is most effective in aiding 
drug discovery, we find AI has an advantage in discovering drugs whose mechanism of 
impact on a disease is known and drugs at the medium level of chemical novelty. AI is 
less helpful in discovering drugs when there is no existing therapy or drugs at either 
extreme end of the novelty spectrum—those that are either entirely novel or those that are 
incremental “me-too” drugs. Taken together, our study sheds light on both the advantages 
and the limitations of using AI in drug development.  
Essay 3- Artificial Intelligence, R&D Alliances and Firm Innovation: An 
Exploratory Analysis 
Firms increasingly rely on R&D alliances to innovate in knowledge-intensive 
environments. As the use of such alliances is increasing in both scope and scale, we 




challenges of processing knowledge that comes from these R&D alliances in order to 
innovate. We study this in the context of the global pharmaceutical industry. Specifically, 
we document the complementarity between firms’ AI capabilities and external R&D 
alliances: firms with greater AI capabilities engage in more R&D alliances and can reap 
greater innovation benefits. AI is particularly useful in leveraging information from 
partners participating in the alliances. We also find that innovation at the intermediate 
level of novelty (versus very incremental or highly novel levels of innovation) can be best 
achieved through firms’ investments in AI and R&D alliances. Overall, this study sheds 
light on the value of joint development in technological capabilities and external 
activities to improve innovation.  
Contribution 
The main contributions of this dissertation are threefold. First, by focusing on the 
firms transitioning to public status and the firms in the pharmaceutical industry, we base 
the three studies on specific settings where emerging technologies such as data-driven 
analytics and new advances in AI can play a critical role in reducing innovation declines. 
The studied research context can enrich our understanding of the contemporary 
productivity paradox that highlights the increasing adoption of advanced technologies but 
considerable slowdown of innovation productivity in recent years. The insights derived 
from the studies can also be applicable to other research contexts where technologies are 




Second, this dissertation bridges innovation management literature and IT value 
literature. The innovation management literature has extensively provided novel insights 
about effective ways of managing innovation activities or improving entrepreneurial 
outcomes through knowledge creation, organizational configuration and learning but 
overlooked the role of technology per se in fostering innovation. At the same time, only a 
handful of studies in IT value literature have examined how firms’ adoption of new types 
of information technologies can act as a key input factor to drive their innovation (Kleis 
et al. 2012).  
Lastly, this dissertation entails empirical studies on the phenomena at large scale. 
The effort in collecting massive granular data from disparate sources to capture firms’ 
adoption of new types of information technologies and innovation outcomes can 
substantively improve sample coverage (both public and private firms for cross-section 
and time-series analysis), as well as operationalization of variables on all fronts. For 
example, in the first essay we implement more fine-grained metrics of innovation 
outcomes that distinguish three different types of innovation (reuse, new combination, 
novelty) and whether they are new to the firm (local) or new to the greater environment 
(global). In the second and third essays, we advance measurements of AI by using both 
patents and employee skills. Compared to early IT value literature that primarily 
measures IT using dollars invested, our analyses of AI on drug discovery use a multi-
dimensional measure on AI capabilities (Santhanam and Hartono 2003; Tambe and Hitt 
2012). To determine chemical novelty, we draw on domain knowledge in the field of 




structures. To ensure the validity of empirical results estimated on large samples, this 
dissertation uses a variety of econometric approaches to resolve certain selection bias 
issues and address potential endogeneity concerns when linking firms’ technology 






CHAPTER 2 : INNOVATION STRATEGY AFTER IPO: HOW DATA 
ANALYTICS MITIGATES THE POST-IPO DECLINE IN INNOVATION 
2.1 Introduction 
Early-stage firms are important contributors to innovation, especially in critical 
sectors such as information technology and life sciences (Haltiwanger et al. 2013). It has 
been noted, however, as early-stage firms develop and go public, the quality of their 
innovative output declines after their IPO (Aggarwal and Hsu 2013; Bernstein 2015; 
Wies and Moorman 2015). Three primary reasons for the decline in innovation quality 
have been identified in prior work: (1) the financial market pressure to meet short-term 
earnings targets, (2) the disclosure requirement imposed on public firms, and (3) 
managerial incentives that shift investments to incremental innovation. These effects are 
shown to be independent of accounting choices or the life cycle of the firm in which post-
IPO firms may choose to capitalize on their existing innovations instead of developing 
new ones (Asker et al. 2014). Individually or collectively, these reasons may encourage 
newly public firms to focus on the production of less risky, incremental innovations that 
are more likely to be related to their existing stock of knowledge rather than the 
production of novel or breakthrough innovation.  
Recognizing the potential innovation decline as a result of going public, firms 
have responded in different ways, most of which have been costly. For instance, Ikea, one 
of the most successful furniture chains, has remained private so it can focus on long-term 
innovation and business development as opposed to meeting short-term financial targets  
(Kamprad 2011). Roche, a healthcare company that created Valium and the first synthetic 
10 
 
vitamin C, had chosen to remain private for more than 100 years before its IPO in 2003, 
so it could focus on long-term innovations even at the expense of limiting its access to 
public capital markets (Claret 2016). Public firms often acquire early-stage companies to 
improve their own innovation portfolio but this strategy is not only costly but challenging 
in the long run due to differences in corporate cultures and the difficulties in retaining 
key personnel after the acquisition (see e.g., Nahavandi and Malekzadeh (1988) and 
Aggarwal and Hsu (2013)). Furthermore, the acquired firms may soon experience a 
similar innovation quality decline as a part of a publicly traded firm, and thus the 
acquisition provides only a temporary relief from the innovation decline for the acquiring 
firm. 
Recent advances in data analytics, enabled by new artificial intelligence 
capabilities and increased digitization efforts, could potentially mitigate some of the 
innovation decline in quality that has been documented in public firms (Aggarwal and 
Hsu 2013; Bernstein 2015; Wies and Moorman 2015) without requiring complex 
financial restructuring activities such as mergers and acquisitions (M&A), leveraged 
buyouts (LBO), or both. In particular, recent work has shown that analytics capabilities 
(including recent advances in artificial intelligence) can facilitate the process of 
searching, aggregating, and mining diverse knowledge which enables the reuse of 
existing knowledge in a new problem domain or creating new combinations from existing 
technologies (Wu et al. 2020). For example, analytics helped repurpose (or reuse) a 
chemotherapy drug that was discovered to be effective in treating Parkinson’s. Similarly, 
by combining knowledge from different domains, Autodesk used analytics to create a 
new type of chassis (new combination). Thus, by accelerating the rate of creating reuse 
11 
 
and new combinations in innovation, analytics could potentially mitigate some of the 
innovation decline for firms that have gone through an IPO.  
The primary focus of this paper is to examine A) whether acquiring analytics 
capabilities offsets the decline in innovation quality following an IPO, and B) whether 
this improvement (if present) is consistent with our hypothesized mechanism of 
improving two types of innovation: new combinations and reuse of existing knowledge. 
First, we measure the decline in innovation quality by collecting data on patents and their 
citations. Then we look at how having data analytics capabilities has an impact on 
reducing the decline by examining firms that have gone through an IPO and have filed 
patents from 1988 to 2013. Based on the recommended framework in the literature, we 
first replicate findings using our sample by linking IPOs to innovation declines as 
measured by citation metrics. We then use newer innovation metrics (reuse, new 
combination, novel) to further distinguish the effects on different types of innovations 
(Akcigit et al. 2013; Wu et al. 2020). We define reuse innovation as a reuse or a 
reapplication of an existing technology in a new domain, new combination as the first 
innovation that use a particular combination of technologies, and novel innovation as a 
new basic technological element that can be used for future combinations. We show that 
the greatest innovation decline occurs in two types: the development of technologies that 
involve the reuse of existing technologies and the discovery of new combinations of 
existing technologies. We then find that the increased use of analytics by post-IPO firms 
can offset a substantial reduction in these types of innovation. However, this mitigation 
effect does not extend to novel innovation—that is, technologies that are completely 
different from past technology classes are not helped by data analytics. In fact, the use of 
12 
 
analytics may further reduce the generation of completely novel innovation. These results 
are robust using various methods (difference-in-difference, firm-level fixed effects, 
instrumental variables, the Heckman two-stage estimation, and matching estimators) to 
address potential selection and reverse causality bias issues of our sample. To further 
support the evidence that analytics can mitigate the innovation decline post-IPO, we track 
the changes in hiring employees with analytics skills before and after IPO. We find that 
post-IPO firms are using capital raised from the IPO to ramp up hiring for employees 
with analytics skills, especially in the first 5 years after the IPO event. This evidence 
further suggests that analytics is increasingly used in post-IPO firms to offset the quality 
decline in innovation to some extent. Collectively, these results suggest that increasing 
data capabilities acquired through hiring data analytics talent can provide an alternative 
mechanism to maintain the pre-IPO innovativeness that is likely to be a much less 
disruptive solution than the current alternatives (e.g. financial restructuring), especially 
for the types of innovation that analytics is well-positioned to support.  
2.2 IPO and Innovation Outcomes 
The effect of an IPO on firm innovation and productivity has received renewed 
attention in recent years. Despite (and possibly because of) having access to capital from 
the public sale of their stock in the market, it has been documented that firms often 
experience negative effects on operation effectiveness, sales growth, and overall 
productivity following their IPO (Chemmanur et al. 2009; Jain and Kini 1994). Prior 
research suggests that the decline in performance post-IPO is not due to accounting 
choices or public firms being in different life-cycle stages (e.g., maturing firms in stable 
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industries) but is related to firms becoming less likely to respond to market opportunities 
after becoming public.  
What is most striking about these findings is that there are numerous reasons why 
an IPO should facilitate a rise in innovation rather than the decline found by research into 
the issue. For instance, an increase in the availability of capital provided by IPO should 
increase incentives to engage in risky innovation (reducing or eliminating the bankruptcy 
risk from failed large-scale projects), although this does not appear to be empirically 
supported (Hall and Lerner 2010). Similarly, the reputational effect of successfully 
completing an IPO can also engender many intangible benefits, including making it more 
feasible to acquire talented and innovative employees, strengthening bargaining power 
with suppliers, and signaling quality to consumers. These factors, at least theoretically, 
should further provide more freedom for firms to experiment and to take on riskier 
innovation projects (Cyert and March 1963; Wies and Moorman 2015). 
The current literature offers three main explanations for the somewhat 
counterintuitive finding that innovation declines rather than rises. First, IPO events may 
force firms to focus on short term financial goals, discouraging risky investments and 
causing firms to target innovations with a high probability, near-term payoffs (Hall and 
Lerner 2010). This is compounded by the fact that it is often difficult for external 
investors to evaluate long-term innovations that would require deep subject expertise 
about the innovation (Ferreira et al. 2012) thus creating a moral hazard problem, 
preventing innovative firms from being suitably rewarded for these investments prior to 
the creation of observable financial benefits.  
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Second, publicly traded firms also face stronger financial disclosure requirements 
from the market. This includes mandatory stock exchange disclosure rules and demands 
from investors and analysts for information to properly value the firm. This type of 
disclosure reduces the potential rents from innovation (Brau and Fawcett 2006) especially 
given that imitation is less costly, faster and carries lower risk than innovation (Teece 
1986). The combination of public scrutiny and potential spillovers of sensitive 
information to competitors could further reduce incentives of a firm to innovate, 
especially on risky projects that may take many years to demonstrate success. 
Finally, the incentives of the innovators can also change after an IPO. Dilution in 
ownership may lead inventors to avoid risky projects when the reward is now shared with 
a much larger group. Similarly, post-IPO firms often have difficulties in retaining key 
innovators because these innovators may prefer a private firm where they can receive a 
larger share of the returns for their innovations (Aggarwal and Hsu 2013; Bernstein 
2015). Even for inventors who stay after the IPO, retention can be a problem as new 
opportunities arise (e.g., spinoffs) that enable them to pursue innovation without the 
constraints of different ownership (Bernstein 2015). Furthermore, as the company 
becomes bigger, it is also harder for owners to monitor managerial performance to 
distinguish between poor luck and poor managerial skills for long-term or risky activities 
that ultimately fail, creating further disincentives for high-impact breakthrough 
innovation (Aghion et al. 2013).  
Thus, there are strong incentives for post-IPO firms to invest in incremental 
innovation as opposed to long-term and novel innovations that substantially differ from 
past technologies. Firms appear to act on these incentives. Bernstein (2015) and 
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Aggarwal and Hsu (2013) use patent data and citations to measure innovation quantity 
and quality. They show that post-IPO firms did not necessarily reduce the overall number 
of patents, but these patents have less impact as measured by citation metrics. Similarly, 
Wies and Moorman (2015) use product categories in the consumer product industry to 
show that publicly traded firms tend to invest in incremental innovations that are closely 
related to their own knowledge as opposed to exploring novel innovation that deviates 
from their existing product lines. Some public firms try to mitigate the lack of internal 
innovation by acquiring other start-ups (Bernstein 2015) for their knowledge assets, 
intellectual properties, and human capital. Alternatively, anecdotal evidence suggests that 
some firms have made deliberate efforts to maintain their innovation position, incurring 
substantial real or opportunity costs, such as remaining private or engaging in costly 
financial restructuring to convert from public to private. For example, the founder of 
Ikea, Ingvar Kamprad, said, “Keeping companies like IKEA in private hands would 
secure the freedom to have a long-term view on investments and in business 
development” (Kamprad 2011). Tellis (2013, p239) documented the negative effect of 
stock market on managerial decisions because of “the pressure from investors causes 
managers to cut investments in innovation to boost current earnings and stock prices, at 
the cost of future innovation, growth, and long-term market cap.” Therefore, there is 
potentially considerable value in identifying less costly ways for firms to maintain their 




2.3 Data Analytics and Innovation  
We broadly define analytics capabilities as the ability to process, analyze, and 
transform data to detect patterns, find useful insights, and support decision making (Hitt 
et al. 2018; Ridsdale et al. 2015; Wu et al. 2020). It has been vastly improved by 
advances in artificial intelligence and digitization (Brynjolfsson and Mitchell 2017; 
Brynjolfsson et al. 2018). The recent rise of data analytics may provide a mechanism for 
alleviating the post-IPO innovation decline. It can serve as a major new driver of 
innovation (Wu et al. 2020), suggesting data analytics is a good place to look for a 
solution in addressing the innovation declines. Examples of innovation abound in part 
due to the digitization of various social, economic and individual behaviors that provide 
the necessary inputs for the application of large-scale data analytics. By keeping track of 
what is already known inside the firm and identifying and integrating external knowledge 
as it becomes available, analytics has accelerated the rate of innovation through 
combining existing knowledge in new ways or by enabling disparate ideas external to the 
firm to be combined to solve problems in a new domain (Wu et al. 2020). For example, 
Autodesk collaborated with engineers and car drivers to deploy numerous, low-cost 
sensors on racing cars and to collect vast amounts of new data that might affect the 
performance of the chassis. Combining the new sensor data with engineering design 
principles, Autodesk deployed data analytics, specifically machine learning algorithms, to 
generate an entirely new chassis design that is asymmetrical, reflecting the fact that 
racing on a track, cars turn in one direction more often than the other. While it was also 
possible for humans to create similar solutions, machine learning vastly shortened the 
required time scale. Similarly, IBM’s Watson deployed AI and analytics and discovered 6 
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new kinases associated with p53 proteins that could suppress cancer; Watson did in one 
month what would have taken human researchers more than 5 years. The acceleration in 
finding hidden patterns in data coupled with human intuition and judgement can increase 
the rate of scientific discoveries (Cockburn et al. 2018). As a result, many venture 
activities in the pharmaceutical industry have focused on using analytics to find new drug 
targets and chemical compounds. Increasingly it is being recognized that data analytics, 
in particular machine learning algorithms, can recognize patterns in data by operating at a 
faster rate and on a larger scale, considering more scenarios than would be possible 
without modern computing and data acquisition capability. 
Digitalization of data that makes data analytics possible can also facilitate the 
reuse of an existing innovation in entirely different ways. The recent push to digitize 
patient records, clinical trials and gene sequences has enabled advanced data analytics to 
discover many ways to repurpose existing drugs to new applications and diseases. In 
particular, large-population clinical trials often include subjects with health conditions 
other than those addressed in the study, and analytics can potentially discover incidental 
effects of drugs on these conditions that can form the basis of future studies (Cooper and 
Van Raamsdonk 2018). For example, research using data analytics has found that a group 
of Parkinson’s patients who had gone through chemotherapy for an unrelated diagnosis of 
cancer also experienced a slowdown in the progression of their Parkinson’s disease. This 
led to the use of the chemotherapy drug Sargramostim to treat Parkinson’s (Gendelman et 
al. 2017). By effectively tracking and managing existing knowledge in the field, analytics 
can substantially broaden the search space for potential solutions that may already exist 
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in other domains. As a result, analytics can help firms accelerate at least one type of 
innovation: the reuse of existing knowledge by applying them to new problem domains. 
2.4 Data Analytics and Post-IPO Innovation 
Thus, the ability of data analytics to track, process, analyze, and transform 
existing knowledge across divergent sources to detect patterns, find useful insights, and 
support decision making should help firms innovate because analytics can facilitate 
finding new ways to combine and reuse existing technologies (Wu et al. 2020). These 
types of innovation often involve combining knowledge from distant domains and tend to 
be less incremental and have higher impacts than delta improvements on existing projects 
or technologies (Hargadon and Sutton 1997; Henderson and Clark 1990). While data 
analytics can help all firms innovate, post-IPO firms may benefit from using analytics 
more than other firms because post-IPO firms face a more acute innovation decline than 
others, especially when the decline is in the two types of innovation that data analytics 
supports most effectively: new combination and reuse.  
While data analytics cannot address all organizational and incentives issues that 
post-IPO firms face in investing in long-term innovation, acquiring analytics skills can 
alleviate some of the disincentives by accelerating discoveries and creating new ones 
humans would have missed through exploiting hidden patterns and linkages within 
diverse data. Indeed, analytics has the potential to address each of the three main factors 
that discourage innovation in newly public firms. First, analytics can accelerate 
innovation, reducing problems associated with short term financial pressure, and it can 
broaden the search space which diversifies risk and improves resource allocation by 
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identifying dead-end projects more quickly. Second, the increased rate of innovation as 
well as the opacity of many types of machine learning or other analytics activities may 
reduce the rent dissipation and competitive spillovers of public disclosure. That is, it can 
lead to reduced disclosure of the process by which an innovation is being pursued (which 
is harder to protect and perhaps easier to imitate than the outcome which is more 
defensible by conventional intellectual property protection). Finally, managerial self-
interest for taking on risky projects is less threatened when the resource commitment to 
any particular idea is lower and the time to identify unpromising ideas is shortened.  
In addition, the use of analytics can be supported by IPOs because newly public 
firms may have new financial resources to acquire analytics talent that was previously out 
of reach due to the high compensation required to hire employees who have proven data 
analytics ability.2 Changing the skill mix of existing staff is likely to be less disruptive 
and considerably less expensive than engaging in alternatives such as financial 
restructuring (e.g. such as LBOs), especially since these efforts also entail significant 
organizational change (Aggarwal and Hsu 2013; Nahavandi and Malekzadeh 1988).  
Thus, we hypothesize that data analytics can help post-IPO firms to innovate. As 
analytics is particularly effective at reusing and combining existing knowledge in a new 
way, we expect analytics to mitigate the decline in innovation for post-IPO firms in these 
aspects. Simply stated, we posit that: Data analytics mitigates the post-IPO innovation 
decline by combining and reusing existing technologies. 
                                                          
2 https://www.forbes.com/sites/gilpress/2018/05/04/the-salaries-of-data-scientists-remain-steady-but-still-
sexy-with-ai-on-the-horizon/#333ae4d9733d   
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2.5 Data and Measurement 
To understand how analytics can mitigate the innovation quality for post-IPO firms, we 
need to measure (1) the level of innovation activity before and after the IPO (2) the 
analytics capability in a firm before and after IPO, and (3) the financial performance 
before and after the IPO event. 
Innovation Quality: Patent analysis has been extensively adopted as a tool in economics 
and management research to measure innovation and technological progress. We 
combine the latest version of the NBER Patent Citation Data File that contains detailed 
firm-level patent data through 2006 with the more recent patent data from the USPTO 
(2007-2013) that we process using an identical approach (Hall et al. 2001).3 To measure 
innovative outcomes at firms, we start with a firm’s patent count, calculated as the 
number of patents filed by the firm in a given year (Aggarwal and Hsu 2013; Saunders 
2011) that are eventually granted by the USPTO. We use the application year of the 
patent rather than the issue year because the filing date more closely approximates when 
the firm produced and started using the innovation proposed in the patent application.  
Patents are not equally valuable and the existing literature articulates a concept of 
patent or innovation “quality” to capture these differences, although the measurement of 
this concept varies. To measure innovation quality we calculate two widely used metrics 
(Hall et al. 2001): originality, or technological diversity (Kaplan and Vakili 2015; Wu et 
al. 2020) as measured by backward citations (that is, all citations to the prior art in the 
                                                          
3 https://sites.google.com/site/patentdataproject/Home covers the 1976-2006 patents. We also use other data 
sources, including the earlier version of the data available at http://www.nber.org/patents/, USPTO, and 
patents stored on Google, for patents before 1976. 
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focal patent, and measures the diversity in the set of knowledge that a patent draws from) 
and generality as measured by forward citations (that is, all the future patents that cite the 
focal patent and measures how widely this patent is cited by others). These metrics have 
been used extensively in the R&D literature (Hall et al. 2001; Trajtenberg et al. 1997) as 
well as quantifying innovation quality in the corporate finance literature. We further 
refined our measures of innovation quality by constructing three additional measures to 
capture different types of innovation in each patent: (1) novelty, (2) new combination, 
and (3) reuse. Specifically, we use patent subclasses of the focal patent and those that it 
cites which provide a very fine-grained measurement of the technology domain of a 
patent (as of 2015, the USPTO defined 475 classes and 165,000 patent subclasses).4 A 
patent qualifies as reuse if it has the same class or the same combination of technology 
classes as an existing patent. A patent is a new combination if it is the first to combine an 
existing set of technology classes in a new way (that is, all the prior technology classes 
exist, but not in that particular combination). A novel patent is the first patent under a 
specific patent class, and hence the first innovation to create the new patent class.  
To investigate the scope of innovation processes, we further categorize the three 
innovations types above (reuse, combination, and novelty) into local (within a firm) and 
global (all firms) levels. For instance, a patent is novel for a firm (local) if it is the first 
time that firm has created a patent in that class. However, if that firm is also the first 
patent ever to be in a patent class, the patent would be considered novel globally, not just 
locally. The metrics for the other types of innovation are defined analogously. In sum, we 
have 3x2 matrix of innovation types along two dimensions: (1) reuse, new combination, 
                                                          
4 https://www.uspto.gov/web/offices/ac/ido/oeip/taf/cbcby.htm  
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and novelty and (2) local vs. global. We then aggregate the measures for all m patents in a 
firm-year. 
Reuse =  ∑ 1(𝑒𝑥𝑖𝑠𝑡𝑖𝑛𝑔 𝑡𝑒𝑐ℎ𝑛𝑜𝑙𝑜𝑔𝑦 𝑜𝑟 𝑐𝑜𝑚𝑏𝑖𝑛𝑎𝑡𝑖𝑜𝑛𝑗)
𝑚
𝑗=1  . (1) 
New-combination =  ∑ 1(𝑛𝑒𝑤 𝑐𝑜𝑚𝑏𝑖𝑛𝑎𝑡𝑖𝑜𝑛𝑗)
𝑚
𝑗=1 .   (2) 
Novelty =  ∑ 1(𝑛𝑜𝑣𝑒𝑙 𝑡𝑒𝑐ℎ𝑛𝑜𝑙𝑜𝑔𝑦𝑗)
𝑚
𝑗=1 .                (3) 
Data Analytics: We measure a firm’s data analytics capability by calculating the total 
number of employees who possess relevant data analytics skills for each firm. We use 
two different data sources to comprehensively measure the overall analytics capabilities 
in firms from 1988 to 2013. First, we use six million individual resumes that depict the 
career trajectory of these sampled employees from 1988 to 2007. This dataset is similar 
to other large-scale datasets of resumes exploited in prior IT value literature (Tambe and 
Hitt 2012; Wu et al. 2017). It provides a detailed timestamp of employment and job 
history, including detailed job descriptions and has good coverage of both public and 
private firms (Tambe and Hitt 2012). To obtain more recent data about data analytics 
capabilities in firms, we use job review data from 2008 to 2013 from a large online job 
review platform that contains the job title of a current or a former employee who 
provided the review. 
We first use text-mining and skills-based semantic-matching algorithms to map 
free-form text to a taxonomy of data skills. Our approach uses both direct matches on 
general keywords such as “data analytics,” as well as indirect matches based on analytics 
concepts such as “regression modeling,” “machine learning,” and “Hadoop” that 
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represent particular algorithms or technologies associated with data analytics (Appendix). 
We also rely on the classification used by Saunders and Tambe (2015) to refine and 
validate our data-related keywords. Using a few variants of these keywords does not lead 
to significant differences for our measurement. We corroborate this measure using the job 
titles from the O*NET5 (a government database that maps jobs to the skills these jobs 
require) and find the two measures and the outcome of employing these measures in our 
models to be consistent. Once the relevant skills are identified, we examine when the skill 
was in use and the employer where it was used. To measure the analytics capability for 
the firm, we aggregate all the employees within the firm in a particular year who were 
identified as having data analytics skills. Because not all employees are observed in our 
data, we estimate the number of employees with data analytics skills by using a firm-




, where 𝑥𝑖 is the number of employees across all 
occupations in our sample for firm i, and 𝐿𝑖 is the total number of employees for firm i as 
provided by Compustat. In this estimation procedure we assume that the observed 
employees are sampled from the underlying population of all workers in the firm, as well 
as that firm and occupation-specific factors regarding the likelihood of posting career 
trajectories or job titles are uncorrelated. In earlier research the same method is 
recommended and used to capture analytics skills and IT skills (Tambe and Hitt 2012; 
Wu et al. 2020). 
                                                          
5 We search for the word “data” in the Occupation Search box provided by https://www.onetonline.org/, 
and obtain a list of job titles ranked according to how well these job titles matched the keyword “data,” 
according to the matching process in https://www.onetonline.org/help/online/search#keyword. A total of 
576 primary data-related job titles are generated, with detailed reports on the requisite technology skills and 
general skills. An additional 212 alternate occupation titles are found from the primary job titles. For 
example, the occupation “Database Administrator” has several alternate job titles, such as data engineer, 
data miner and data center manager. We count a person as having data analytics skills if any of the skills in 
that job title is related to data. 
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To examine a firm’s investment in data analytics skills in a more recent time 
period from 2008 to 2013, we gather more than 3.7 million job reviews with metadata 
including the job title, the employer, and the length of employment; the data are from a 
leading online job posting and review platform. These online reviews are written by 
current and former employees. Because they are less fine-grained than the resumes that 
have detailed job descriptions including skills, we identify data analytics skills using the 
job titles in each review and then aggregate them at the firm level. We rely on the 
Occupational Information Network (O*NET) and perform an occupation search on that 
platform to find job titles that are related to data analytics. Each employee is identified as 
having data analytics skills if any of the skills listed under their job titles are related to 
data analytics.6 We also complement the O*NET-based classification by using a simple 
search of analytics-related keywords in job titles (“data”, “statistics”, “business 
analytics”). As with the resume data, we identify the time of various employment spells 
at a particular employer, aggregate employees with data-related skills by time for each 
employer and then adjust by a firm-specific sampling rate in each year.  
To reconcile the potential differences between the two data sources, we compute 
appropriate scales to convert measures from one data source to the other and capture 
firm-specific scaling ratios by using the common periods between the two data sources 
(Appendix). A dummy variable for a data source can be used to control for the potential 
heterogeneity arising from how data analytics is measured, but the dummy is subsumed 
by the yearly dummies as the data sources do not overlap in time. In addition, Chow tests 
                                                          
6 We also use weighted skills based on job titles as some job titles list more data-related skills, which do not 
change our main results. 
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ensure the merging of two data sources is valid for our empirical models. Lastly, we 
adopt a single job title classification based on O*NET and our results are very similar and 
corroborate earlier studies that use similar methods (Wu et al. 2020). 
Firm IPO and Other Financial Characteristics: We use the Thomson Reuters SDC New 
Issues database to measure IPO events from 1988 to 2013 and capture other relevant 
financial and firm characteristics that may affect IPO events (Aggarwal and Hsu 2013; 
Bernstein 2015; Wies and Moorman 2015). First, our key measure of the IPO event is 
Public, which is zero for the years before an IPO and 1 for the years of the IPO and 
subsequent years. We focus on the three years before and five years after the IPO filing 
as recommended by Bernstein (2015) to understand innovation activities around the time 
of the IPO event.7 We use the logarithm of a firm’s total assets to control for firm size 
and use firm age and stock of venture capital (VC) inflows to control for firm-level 
quality and life-cycle factors that may affect IPO decisions (Aggarwal and Hsu 2013; 
Bernstein 2015). As suggested by the literature, we also take intangible assets into 
consideration including advertising assets and labor quality (such as the number of 
employees with at least a college degree) that may affect a firm’s innovation capabilities. 
Firm age data is collected and verified using EDGAR, Moody’s, Renaissance Capital and 
Thomson Financial Securities Data.8 Cumulative VC investment is measured as the 
                                                          
7 We drop firms with zero successful patent applications during their observation period, and remove 
financial firms with SIC between 6000 and 6999, as recommended by Wies and Moorman (2015). 
8 See https://site.warrington.ufl.edu/ritter/files/2018/04/FoundingDates.pdf for a downloadable dataset; 
details about the data collection process can be found in Appendix A of Loughran and Ritter (2004). If 
firms are not found in that list and their founding years are still missing in our sample, we search them in 
the ReferenceUSA database, or resort to the first entry in the CRSP database, whichever one is available for 
their establishment year (Wies and Moorman 2015). 
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aggregate VC financing received by the firm prior to the observation year, collected from 
the Thomson Reuters SDC VentureXpert database.  
Table 1 reports summary statistics and variable descriptions for 2,366 firms from 
1988 to 2013, and Table 2 shows the correlations between these variables. Table 3 shows 
the industry breakdown for the firms in our sample which spans a variety of industries. 
We compare publicly traded firms with private firms in our sample (Appendix) and 
address concerns about sample selections using matching estimators, Heckman 
selections, and instrumental variables, as described below. 
2.6 Empirical Approach and Identification 
To examine the pattern of corporate innovation activities around an IPO event and 
how a firm’s data analytics capability affects these activities, we extend prior empirical 
strategies that are used to study the effect of an IPO on firm performance (Chemmanur et 
al. 2009; Wies and Moorman 2015) by incorporating data analytics capabilities as well as 
their interaction with the IPO event. First, in our basic model, we relate various corporate 
innovative outputs to a firm’s ownership status (Public), data analytics capability (Data), 
controlling for years (yt) which can address temporal innovation shocks and fluctuations 
in market movements that may impact IPO decisions (Chemmanur et al. 2009). Firm-
fixed effects are also used in all models (γi) to account for ex-ante differences in 
innovation and the use of analytics (thus, we can interpret our results as the marginal 
effect of changes in analytics). We control for firm age, VC investment, total assets, labor 
quality, patent stock, and advertising (measured as the stock of cumulative advertising). 
Our primary estimating equation is thus: 
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ln(𝐼𝑛𝑛𝑜𝑣𝑎𝑡𝑖𝑜𝑛 𝑄𝑢𝑎𝑙𝑖𝑡𝑦)𝑖𝑡 = 𝛽0 + 𝛽1𝑃𝑢𝑏𝑙𝑖𝑐𝑖𝑡 + 𝛽2 ln(𝐷𝑎𝑡𝑎)𝑖𝑡 +
                                𝛽3𝐷𝑎𝑡𝑎𝑖𝑡 × 𝑃𝑢𝑏𝑙𝑖𝑐𝑖𝑡 + 𝑦𝑡 + 𝛾𝑖 + 𝐶𝑜𝑛𝑡𝑟𝑜𝑙𝑠 + 𝜖𝑖𝑡.  (4) 
The focus of our analysis, 𝛽3, measures the effect of data analytics skills on 
innovation quality after a firm has gone through an IPO. Here we measure innovation 
quality using 9 different metrics: (1) originality, (2) generality, (3) forward citations 
within 4 years of the year in which the patent application was filed, (4) global novelty, (5) 
local novelty, (6) global new combination, (7) local new combination, (8) global reuse, 
and (9) local reuse. The first three metrics are traditional R&D metrics used extensively 
in the prior literature and we replicate earlier findings using our data. The next six metrics 
are more detailed metrics that allow us to explore precisely the types of innovation that 
analytics can help post-IPO firms to create (Akcigit et al. 2013; Wu et al. 2020). 
There are several sources of endogeneity associated with Equation 4 as the IPO 
decision is discretionary, made conditional on a variety of firm and market factors. The 
decision to invest in data analytics is also subject to similar issues in reverse causality and 
selection biases such as the “free cash flow” hypothesis that firms with greater resources 
could choose to invest in analytics. 
To address potential selection biases on the choice of going through an IPO, we 
follow a recommended framework in the existing literature that uses matching estimators, 
specifically propensity score matching (PSM), to find a comparable sample of firms that 
are similar to the IPO firms but didn’t go through an IPO (Aggarwal and Hsu 2013; 
Bernstein 2015; Wies and Moorman 2015) including those that filed for an IPO but did 
not complete it. We also use a Heckman two-stage estimation to further address the 
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selection biases that relate to the choice to file for an IPO. The first-stage probit model 
predicts the probability of firms going public after controlling for firm age, firm size (we 
use a firm’s total assets as a proxy), VC financing and firm location, industry dummies 
(Wies and Moorman 2015; Xiong and Bharadwaj 2011). We then use the inverse Mills 
ratio calculated from the first stage to correct for selection bias (Wooldridge 2010) in the 
second stage regression, as recommended in the literature (Aggarwal and Hsu 2013; 
Bernstein 2015; Wies and Moorman 2015). 
To address the reverse causality of IPO firms choosing to pursue more 
incremental innovation, we identify firms with a lower probability of going public (from 
the probit model) yet still complete an IPO filing and construct an indicator variable, 
unanticipated IPO (UIPO), for such firms. This indicator becomes 1 if the firm i 
unexpectedly goes public at time t and 0 otherwise. We then regress the one-period lag of 
innovation outcomes on this indicator variable. We find that this indicator does not 
predict innovation outcomes, suggesting that past corporate innovation decisions are not 
related to IPO decisions (Brau and Fawcett 2006). This corroborates findings from earlier 
work that use the same method to show that reverse causality is not a serious concern in 
linking IPO events to innovation (Wies and Moorman 2015). 
Next, we use instrumental variables to address the potential reverse causality of 
data analytics on innovation outcomes. It is possible that innovative firms with slack 
resources could recruit more employees with data analytics skills which could be 
observationally equivalent to our preferred interpretation that analytics supports 
innovation. We use three sets of instrumental variables derived from a firm’s hiring 
network (firms that hire from each other) to create instrumental variables for analytics 
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skills: 1) the total number and fraction of employees with data analytics skills in a firm’s 
hiring network; 2) the adoption of an enterprise resource planning (ERP) system by 
neighboring firms in the network and the total number and the proportion of neighbors 
starting to use ERP systems; 3) the neighboring firms’ adoption of a Human Capital 
Management (HCM) system in the hiring network and the total number and the 
proportion of neighbors starting to use HCM systems. These instrumental variables are 
similarly used to address endogeneity related to firm-level decisions to invest in analytics 
(Wu et al. 2020).9 
As a further check, we note that if there is indeed a reverse causality issue in 
which more innovative firms disproportionally use resources from an IPO to invest in 
analytics, we would expect that analytics and IPO to positively interact to improve 
innovation quality for all types of innovation outcomes. If we only observe the effect in 
some types of innovation but not in others, this should help rule out certain simple cases 
of selection effects such as innovative firms generally choosing to invest in analytics.  
 Finally, if it is optimal for post-IPO firms to invest in analytics to innovate, we 
would expect firms to acquire more analytics capabilities post IPO. To examine the 
dynamic change of a firm’s demand in data analytics around its IPO event, we adopt a 
                                                          
9 The first instrumental variable is a Hausman-type instrument, based on the neighboring firm’s (firms that 
hire from each other) existing data talent. It measures the potential labor pool accessible to the firm through 
employee mobility, which reflects the cost of acquiring additional analytics talent. The second and third 
instrumental variables are derived from measures of the adoption of ERP systems broadly and the HCM 
module by firms in the same labor pool. These large enterprise-IT systems often involve the extensive 
application of data analytics, and its use in a firm could create a shift in skill composition that can change 
the overall access to data analytics skills for firms that share the same labor pool as the focal firm. As the 
ERP adopting firms acquire employees with these skills during implementation and employees transfer 
these skills through job-hopping, the neighbor firms in the hiring network could also experience a change in 
access to analytics talent without going through any change on their own. The ERP measure is based on the 
presence of ERP-related keywords in employees’ resumes. The HCM measure is based on the reported 
adoption of the HCM module in customer data from a large ERP vendor. 
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similar regression framework to the one proposed by Bernstein (2015) to identify changes 
in firm capabilities in analytics. If investing in data analytics capabilities can help firms 
innovate post-IPO, we would expect the firms to increase data analytics investments over 
time. Instead of a binary description of firm’s ownership status, we use 
𝐸𝑣𝑒𝑛𝑡 𝑌𝑒𝑎𝑟𝑖,𝑘 that is a dummy variable indicating k years before and after a firm i’s IPO 
event. Analogous to Equation 4, we control for firm fixed effects (𝛾𝑖), year fixed effects 
(𝑦𝑡) and time-varying variables of firm characteristics including firm age, VC investment, 
total assets and labor quality controls. 




𝐸𝑣𝑒𝑛𝑡 𝑌𝑒𝑎𝑟𝑖,𝑘 + 𝑦𝑡 + 𝛾𝑖 + 𝐶𝑜𝑛𝑡𝑟𝑜𝑙𝑠 + 𝜖𝑖𝑡. (5) 
2.7 Results 
First, we examine the relationship between corporate innovation quality and the 
public or private status of firm ownership by replicating earlier work using our data. 
Earlier work uses patent-level analysis (Bernstein 2015, pp 1374) to measure the impact 
of an IPO on using the citation characteristics of each patent.10 Consistent with Bernstein 
(2015), we find that patent originality (based on backward citations), generality (based on 
forward citations) and forward citations themselves gradually decline starting from one 
year after a firm’s IPO, as shown in Table 4. For example, compared to the year of IPO, 
there are already six fewer forward citations by the fifth year after the IPO (Column 3). 
                                                          
10 Regression specification of patent-level innovation around firm IPO: 𝑌𝑖𝑡 = 𝛽0 +




, where 𝐸𝑣𝑒𝑛𝑡 𝑌𝑒𝑎𝑟𝑖,𝑘 is a dummy variable that indicates relative 
k years around an IPO when a patent application is filed by firm i in year t. 𝜏𝑖 is the firm fixed effects and 
𝜇𝑡 indicates year fixed effects. The dependent variable is innovation quality. Here we use the originality, 
generality and forward citations of a successful patent application by firm i in year t. We also add necessary 




Following Aggarwal and Hsu (2013), we also examine an IPO’s effect on the aggregate 
patent characteristics at the firm level. Originality, generality, and forward citations 
within a 4-year period after the patent’s application year have all declined post IPO 
(Table 5). Exploring an IPO’s effect on forward citations over time (Columns 3 to 9), we 
find effect worsens over time (the results are consistent if we consider beyond 10 years – 
see Column 10). Overall, both patent- and firm-level analyses are consistent with earlier 
studies that document a general decline in innovation post-IPO.  
Next, we show how having data analytics capability could moderate the 
innovation decline post-IPO (Table 6) at the firm-level using Equation 4 (Aggarwal and 
Hsu 2013). We aggregate patent characteristics of all patents produced in a firm in a 
particular year and control for the total patent stock to account for the fact that firms with 
more patents can have mechanically higher scores on some patent metrics (e.g., total 
forward citations). Patent stock can also serve to control for a firm’s general investments 
in innovation. In Column 1-3, we show that going public is associated with a decrease of 
8% in the overall originality score, a 7% decrease in the generality score, and a 16% 
decrease in forward citations.11 However, we find that data analytics skills can mitigate 
some of the declines. We find that on average, a public firm receives a 1.96% increase in 
its patent originality for every standard deviation increase in data skills above the mean 
(Column 1). However, our initial analysis shows that analytics does not seem to have a 
statistically significant effect on improving generality or forward citations (Column 2-3) 
for post-IPO firms. This could be due to not having enough statistical power to estimate 
these effects precisely or it could be that citation-related metrics are too crude to detect 
                                                          
11 We follow Aggarwal and Hsu (2013) that uses forward citations within 4 years of the application date. 
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changes in novelty (Boudreau et al. 2011). The subsequent analyses using matching 
estimators, 2SLS and Heckman selection models, alleviate some of these measurement 
concerns as the interaction effect between analytics and IPO is positive for both 
originality and generality in these models. However, the effect on forward citations is still 
statistically insignificant.  
To explore more precisely how data analytics can mitigate the innovation decline, 
we estimate the effects of analytics on innovation for post-IPO firms using more fine-
grained metrics of innovation that distinguish three different types of innovation (reuse, 
new combination, novelty) and whether they are new to the firm (local) or new to the 
greater environment (global) (see Equation 1-3). First, we examine the effect of analytics 
on generating innovations that reuse technologies from the greater environment. As 
shown in Column 4, we find that having analytics capabilities can significantly reduce the 
decline of this type of innovation following an IPO (βpublic = -0.0354 and βpublicXdata = 
0.0246). This result suggests that analytics is particularly helpful for integrating 
knowledge from outside of the firm. We find similar effects for innovations that reuse 
information within the firm (Column 5).  
Next, we examine the effect of analytics in aiding post-IPO firms in creating 
innovations that are new combinations of existing technologies. Columns 6 and 7 show 
that analytics can mitigate the post-IPO decline in innovations that are a new combination 
of existing ideas. On average, a one-standard-deviation increase in data analytics is 
associated with a 1.6% increase in new combinations relative to the greater environment 
and a 1.8% increase in new combinations relative to the firm’s own knowledge.  
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We then examine the effect of analytics on novel innovation, the ability to 
produce the first patent in a new technology class in the patent classification system 
(Columns 8 and 9). Rather than mitigating the innovation decline, we find that analytics 
has a negative and statistically significant effect on generating novel innovations that are 
new to the greater environment (across all firms), suggesting the limitations of using 
analytics to innovate technologies that deviate substantially from prior art. For novel 
innovation relative to a firm’s knowledge (local novelty), we find the effect to be 
statistically insignificant. Overall, these results suggest caution in using analytics to help 
mitigate the post-IPO decline in novel innovation. A possible reason could be that there 
may be less data for the firm to integrate in creating truly novel innovations (Wu et al. 
2020). It is also possible that post-IPO firms rely on data analytics for more conservative 
and more incremental innovation for the same reasons that innovation declines generally 
after an IPO (Wies and Moorman 2015).  
Table 6 shows that having analytics capabilities can primarily mitigate the decline 
in innovation after an IPO in creating innovations that use external knowledge to find 
new combinations or to reuse information in a new way. This is consistent with the 
finding that analytics can facilitate the aggregation of external information, mine patterns 
within divergent data and reuse and combine existing knowledge in new ways to support 
innovation and decision making. However, while post-IPO firms also experience declines 
in novel innovation, data analytics not only fails to mitigate the negative effect, it can 
worsen the decline for novel technologies, a type of innovation that analytics may not 
naturally support.  
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  It is possible that our results are driven by selection biases – that firms that go 
public are already poised for a decline in innovation. To address this concern, we follow 
methods used in the existing literature to address the selection issues around the IPO. 
Specifically, we conduct propensity score matching (PSM) that balances the sample of 
IPO and non-IPO firms based on observable characteristics including firm age, firm size, 
and VC financing12 (Aggarwal and Hsu 2013; Bernstein 2015; Wies and Moorman 
2015). The summary statistics for pre-matched and post-matched samples are shown in 
the Appendix. In Table 7, we continue to find consistent results: while most types of 
innovation have declined post-IPO, data analytics can mitigate the decline in innovations 
that combine existing technologies as well as those that reuse existing technologies in 
new areas. Analytics also continues to have a limited or a negative effect on mitigating 
the decline in novel innovation. 
To rule out selection biases and reverse causality problems associated with a 
firm’s decision to go public, we also use a Heckman two-stage estimation. The Heckman 
procedure begins with a probit first-stage regression in which we predict the decision to 
go public with the same variables we utilized in PSM. The inverse Mills ratio from the 
first stage is then added to a second-stage regression to correct for the selection bias. 
Table 8 shows results consistent with earlier estimates. We observe that analytics can 
mitigate the post-IPO innovation decline for patent originality that captures general 
abilities of firms in creating diverse recombination of existing technologies, and patent 
generality that captures the diversification of the forward citations. While analytics can 
                                                          
12 These variables are also used in the first stage of the Heckman estimation procedure to predict a firm’s 
decision to go public. 
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mitigate declines in innovations that are new combinations and reuse of existing 
technologies, it does not mitigate declines in generating novel innovations. 
We then adopt a 2SLS estimation approach following our regression specification 
(Equation 4) to address the potential endogeneity arising from firms’ choice to invest in 
data analytics skills. The associated first-stage F statistics pass the weak instrument test 
(F(12, 11110) = 34.27) and satisfy the over-identification test (Sargan statistic: 𝜒2 =
14.588, 𝑝 ≤ 0.148). In Table 9, the 2SLS estimates continue to show that data analytics 
supports originality and generality. Consistent with earlier results, we find evidence that 
data analytics facilitates innovations that reuse existing technologies in a new way and 
create new combinations of existing technologies. We also use a propensity matching 
estimation method in conjunction with instrumental variables and find very similar 
results, as shown in Table 10. Results are also similar using 2SLS with Heckman 
corrections after bootstrapping the standard errors (Appendix). Overall, these results 
show that IPOs lower innovation quality, but analytics can mitigate the decline in 
innovation that combines or reuses existing knowledge. It can also improve traditional 
patent metrics in originality and generality. However, analytics cannot mitigate the post-
IPO decline in novel innovations and can even have a negative effect when used in 
attempts to create novel innovations. 
Lastly, if investing in analytics is an optimal investment decision for post-IPO 
firms, we would expect firms to use the resources from their IPO to acquire analytics 
capabilities. Using an event study framework similar to Bernstein (2015), we examine the 
dynamic changes in data analytics around an IPO event using Equation 5. We measure 
the changes in data analytics skills from three years before an IPO to five years after the 
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IPO. In Table 11, we find that the years after an IPO are positively associated with an 
increase in analytics capabilities in firms, and the size of the effect becomes larger and 
more statistically significant over time, peaking at around four to five years after an IPO 
event. These results imply that firms are optimally directing resources raised from IPOs 
to acquire analytics capabilities, potentially to mitigate the post-IPO innovation decline.  
2.8 Conclusion 
While our work confirms prior work on the post-IPO decline in innovation, our 
main finding is that data analytics can mitigate that decline for two types of innovation: 
combining existing technologies into new ones or reusing existing innovations by 
applying them to new problem domains. Our work is consistent with prior work that 
identified a general decline in citation metrics of patents after IPO. Prior work identifies a 
focus on short-term results, the need for regular public disclosures and a managerial 
preference for incremental innovation as explanations for the decline. Mitigating this 
decline has become an important consideration as private firms need to balance the 
innovation decline with the advantages of the cash infusion from an IPO. Firms have 
tried to address the decline through complex financial instruments such as M&As and 
LBOs, but these remedies are often very expensive and may provide only temporary 
relief. However, analytics could provide an alternative and perhaps a cheaper way to 
reduce the innovation decline.  
Using a sample of more than 2,000 firms that have gone through an IPO or have 
remained private as well as measuring their innovative output three years before and five 
years after an IPO, we find data analytics, as measured by the skillsets of employees, can 
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help post-IPO firms reduce the innovation decline by generating innovations that are a 
new combination of existing technologies as well as ones that are a reuse of an existing 
innovation in a different problem domain. However, we do not find evidence that 
analytics can help firms create more novel innovations that substantially differ from 
existing technologies. Our results are robust to instrumental variables, matching 
estimators, and Heckman selection models. Furthermore, we also find evidence that firms 
are increasing their investments in data analytics post-IPO, suggesting the importance of 
using analytics to shape corporate innovation strategy and allocating IPO resources to 
data analytics.  
These results are consistent with earlier findings about the types of innovations 
that analytics can help and suggest limitations on using analytics to address some 
innovation challenges faced by post-IPO firms. Creating novel innovation that 
substantially deviates from past technologies remains a challenge for post-IPO firms and 
has limited remedies. Post-IPO firms should continue to develop strategies to mitigate the 
decline in novel innovation perhaps through exploring new technological advances or 
other organizational incentives. However, for innovation that creates a new combination 
or a reuse of existing technologies, analytics could be a viable and perhaps superior 
alternative to other ways of deploying capital to foster innovation.  
While the innovation and entrepreneurship literature has rarely focused on the 
role of technology in affecting innovation or entrepreneurship outcomes, our work is one 
of the first to examine the role of analytics and related emerging technologies as an 
important input to innovation outcomes. Similarly, the IT literature has not extensively 
explored technology investments as a key enabler of innovation. By showing how 
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analytics can mitigate the innovation decline post IPO, we bridge both the IT literature 
and the innovation literature and show the importance of examining technology as a 
critical input factor in innovation. Our work also differs from other large-scale studies on 
data analytics and related emerging technologies by focusing on private firms especially 
during their transition to becoming publicly traded. Examining these firms at the crucial 
time of an IPO is particularly important because start-ups and private firms often have 
different organizational needs from publicly traded ones.  
Overall, our findings support our main hypothesis that data analytics mitigates the 
innovation decline in post-IPO firms by combining and reusing existing technologies. 
Furthermore, we do not find evidence that analytics can mitigate declines for novel 
innovation. While analytics cannot be used to address all forms of innovation declines, 
future work could productively explore how advances in artificial intelligence, a 
potentially new general-purpose technologies, could further aid innovation especially for 
mitigating the innovation decline for post-IPO firms. It is likely that these relationships 
will continue to evolve as new capabilities in analytics such as in artificial intelligence 
are developed. Firms with certain capabilities, such as analytics, may be especially suited 









    
Variables Description Mean Std. dev. 
    
Originality Total originality of patents applied by firm i in year t 12.28 75.99 
Generality Total generality of patents applied by firm i in year t 9.717 61.59 
Forward citations, 
Within 4 years 
Total number of future citations to firm i’s patents within 4 years for 




Number of patent applications classified as new-tech type at a global 





Number of patent applications classified as new-combination type at 




Number of patent applications classified as reuse type at a global 




Number of patent applications classified as new-tech type at a local 





Number of patent applications classified as new-combination type at 




Number of patent applications classified as reuse type at a local firm 
level by firm i in year t 
5.435 39.87 
Data analytics Number of firm i’s employees with data analytics skills in year t 1,723 10,327 
Total assets (in $M) Total book value of assets of firm i in year t 2,600 13,525 
Firm age Age of firm i since its establishment in year t 13.60 16.77 
VC inflows stock (in 
$M) 
Total amount of VC funding acquired by firm i till year t 8.588 23.33 
Emp w/ college+ Total number of employees with at least a college degree at firm i in 
year t 
5,966 27,294 
Public A binary variable which is equal to 1 when firm i is in public status 
and 0 in private status in year t 
0.575 0.494 







Table 2 : Correlation Table 
 
 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
1. Originality 1               
2. Generality 0.898 1              
3. Forward citations,  
Within 4 years 0.849 0.975 1             
4. New-tech,  
Global 0.565 0.646 0.623 1            
5. New-combination,  
Global 0.987 0.938 0.893 0.619 1           
6. Reuse,  
Global 0.931 0.720 0.663 0.464 0.893 1          
7. New-tech,  
Local 0.806 0.828 0.783 0.633 0.842 0.705 1         
8. New-combination,  
Local 0.991 0.920 0.875 0.601 0.998 0.911 0.814 1        
9. Reuse,  
Local 0.914 0.702 0.644 0.454 0.872 0.995 0.675 0.889 1       
10. Public -0.115 -0.108 -0.0904 -0.0900 -0.121 -0.110 -0.123 -0.119 -0.107 1      
11. Data 0.483 0.516 0.516 0.339 0.501 0.389 0.475 0.494 0.364 -0.0969 1     
12. Firm age 0.0871 0.0684 0.0656 0.0472 0.0826 0.0872 0.0823 0.0826 0.0854 -0.170 0.0867 1    
13. VC inflows stock -0.0367 -0.0372 -0.0299 -0.0295 -0.0403 -0.0352 -0.0378 -0.0397 -0.0348 0.137 -0.0501 -0.115 1   
14. Total assets 0.386 0.335 0.307 0.265 0.389 0.369 0.396 0.386 0.354 -0.139 0.416 0.0947 -0.0614 1  




Table 3 : Industry Breakdown 
 
Industry by 1.5digit SIC Number of Firms Percentage of Firms 
Agriculture, Forestry & Fishing 8 0.34% 
Computer, Software 457 19.32% 
Construction 9 0.38% 
Durable Manufacturing 1,069 45.18% 
Mining 16 0.68% 
Non-durable Manufacturing 536 22.65% 
Public Administration 15 0.63% 
Retail Trade 25 1.06% 
Services, except Financial 118 4.99% 
Transportation 15 0.63% 
Utilities 75 3.17% 
Wholesale Trade 23 0.97% 
Total 2,366 100.00% 
 
Note: Our sample covers both public and private firms. The industry classification uses the Standard 








Table 4 : Patent-level Analyses on Innovation Quality around IPO 
 
 (1) (2) (3) 
DV Originality Generality Forward citations 
    
Event Year -3 0.00996 0.0166 -0.290 
 (0.0187) (0.0243) (1.234) 
Event Year -2 -0.0131 0.0122 0.726 
 (0.0103) (0.0137) (0.698) 
Event Year -1 0.0100* 0.00812 0.493 
 (0.00597) (0.00790) (0.401) 
Event Year +1 -0.00662 -0.00933 -1.856*** 
 (0.00551) (0.00727) (0.369) 
Event Year +2 -0.0143* -0.0181* -3.102*** 
 (0.00778) (0.0103) (0.521) 
Event Year +3 -0.0182* -0.0374*** -4.120*** 
 (0.0105) (0.0138) (0.700) 
Event Year +4 -0.0270** -0.0488*** -5.314*** 
 (0.0133) (0.0175) (0.887) 
Event Year +5 -0.0355** -0.0707*** -6.657*** 
 (0.0162) (0.0214) (1.086) 
    
Observations 33,845 43,496 43,496 
R-squared 0.209 0.183 0.361 
Firm FE YES YES YES 
Year FE YES YES YES 
 
Note:  




, where 𝐸𝑣𝑒𝑛𝑡 𝑌𝑒𝑎𝑟𝑖,𝑘 is a 
dummy variable that indicates relative k years around IPO when a patent is applied by firm i in year t. 𝜏𝑖 
represents firm fixed effects and 𝜇𝑡 indicates year fixed effects. The dependent variable is originality, 
generality or all forward citations of successful patent applications by firm i in year t. We keep the sample 
with non-missing generality scores.  
(2). Firm controls: 1) logarithm of firm age 2) logarithm of VC inflows stock 3) logarithm of total assets 4) 
logarithm of total number of employees with at least a college degree. Firms’ relevant intangible asset such 
as advertising asset is also controlled. 









Table 5 : Firm-level Analyses on Innovation Quality around IPO 
 
Model: FE (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) 
















        w/in 4yrs)    w/in 5yrs)    w/in 6yrs)    w/in 7yrs)    w/in 8yrs)    w/in 9yrs)      w/in 10yrs) all) 
           
Public -0.0818*** -0.0686*** -0.163*** -0.168*** -0.172*** -0.174*** -0.178*** -0.183*** -0.185*** -0.191*** 
 (0.0200) (0.0201) (0.0502) (0.0519) (0.0532) (0.0543) (0.0552) (0.0559) (0.0566) (0.0586) 
           
Observations 16,198 16,198 16,198 16,198 16,198 16,198 16,198 16,198 16,198 16,198 
# of firms 2,366 2,366 2,366 2,366 2,366 2,366 2,366 2,366 2,366 2,366 
R-squared 0.855 0.834 0.714 0.709 0.705 0.703 0.700 0.698 0.696 0.689 
Year FE YES YES YES YES YES YES YES YES YES YES 
Firm FE YES YES YES YES YES YES YES YES YES YES 
 
Note: 
(1). Firm controls: 1) logarithm of firm age 2) logarithm of VC inflows stock 3) logarithm of total assets 4) logarithm of total number of employees with at least a 
college-level degree. Firms’ total number of patents and relevant intangible asset such as advertising asset are also controlled. 








Table 6 : Data Analytics, Firm Public Status and Innovation Quality 
 
Model: FE (1) (2) (3) (4) (5) (6) (7) (8) (9) 
DV ln(Orig) ln(Gen) ln(Fwd citations, ln(Reuse ln(Reuse ln(New-comb ln(New-comb ln(Novelty ln(Novelty 
   w/in 4 yrs) Global) Local) Global) Local) Global) Local) 
          
Public -0.0801*** -0.0685*** -0.164*** -0.0354* -0.00763 -0.0882*** -0.0760*** -0.00379 -0.0580*** 
 (0.0200) (0.0201) (0.0503) (0.0187) (0.0164) (0.0226) (0.0205) (0.00447) (0.0200) 
ln(Data) 0.00123 0.00406** 0.00229 -0.00138 -0.000565 0.00207 9.6010-5 0.000973** 0.00264 
 (0.00201) (0.00202) (0.00504) (0.00187) (0.00164) (0.00227) (0.00205) (0.000448) (0.00201) 
Data X Public 0.0196*** 0.00103 -0.00361 0.0246*** 0.0185*** 0.0157** 0.0182*** -0.00354*** 0.00867 
 (0.00556) (0.00559) (0.0139) (0.00518) (0.00454) (0.00628) (0.00568) (0.00124) (0.00556) 
ln(Firm age) 0.105*** 0.126*** 0.181*** 0.0714*** 0.0430*** 0.140*** 0.116*** 0.0229*** 0.127*** 
 (0.0178) (0.0179) (0.0448) (0.0166) (0.0146) (0.0201) (0.0182) (0.00398) (0.0178) 
ln(VC inflows stock) -0.0363** -0.0136 -0.0763* -0.0239 -0.0203 -0.0177 -0.0146 -0.00312 -0.0119 
(0.0174) (0.0175) (0.0437) (0.0163) (0.0142) (0.0197) (0.0178) (0.00389) (0.0174) 
ln(Total assets) 0.136*** 0.119*** 0.246*** 0.101*** 0.0747*** 0.135*** 0.123*** 0.00509*** 0.0899*** 
 (0.00760) (0.00765) (0.0191) (0.00709) (0.00621) (0.00859) (0.00777) (0.00170) (0.00761) 
ln(Emp w/ college+) 0.00690** 0.00835*** 0.0206** 0.00948*** 0.00771*** 0.0107*** 0.00732** 0.00112 0.0110*** 
(0.00319) (0.00321) (0.00801) (0.00297) (0.00261) (0.00360) (0.00326) (0.000712) (0.00319) 
          
Observations 16,198 16,198 16,198 16,198 16,198 16,198 16,198 16,198 16,198 
# of firms 2,366 2,366 2,366 2,366 2,366 2,366 2,366 2,366 2,366 
R-squared 0.855 0.834 0.714 0.842 0.852 0.843 0.866 0.630 0.751 
Year FE YES YES YES YES YES YES YES YES YES 
Firm FE YES YES YES YES YES YES YES YES YES 
 
Note:  
(1). All models also control for firms’ total number of patents as well as relevant intangible asset such as advertising asset, but including them or not does not 
change our results.  
(2). All interactions are appropriately centered. 
















Table 7 : Data Analytics, Firm Public Status and Innovation Quality (PSM) 
 
Model: FE/PSM (1) (2) (3) (4) (5) (6) (7) (8) (9) 
   ln(Fwd citations, ln(Reuse ln(Reuse ln(New-comb ln(New-comb ln(Novelty ln(Novelty 
DV ln(Orig) ln(Gen) w/in 4yrs) Global) Local) Global) Local) Global) Local) 
          
Public -0.0705*** -0.0512** -0.144*** -0.0266 -0.00215 -0.0761*** -0.0662*** 0.00120 -0.0403* 
 (0.0203) (0.0204) (0.0534) (0.0190) (0.0165) (0.0232) (0.0209) (0.00377) (0.0207) 
ln(Data) 0.000368 0.000536 -0.000344 -0.00114 -0.000471 0.000770 0.000148 0.000509 0.00110 
 (0.00223) (0.00224) (0.00586) (0.00208) (0.00181) (0.00254) (0.00229) (0.000413) (0.00227) 
Data X Public 0.0210*** 0.00933 0.00597 0.0236*** 0.0172*** 0.0173** 0.0182*** -0.00228** 0.0103 
 (0.00621) (0.00622) (0.0163) (0.00579) (0.00504) (0.00707) (0.00637) (0.00115) (0.00632) 
ln(Firm age) 0.131*** 0.134*** 0.260*** 0.0960*** 0.0659*** 0.165*** 0.126*** 0.0125*** 0.142*** 
 (0.0200) (0.0200) (0.0524) (0.0186) (0.0162) (0.0227) (0.0205) (0.00370) (0.0203) 
ln(VC inflows stock) -0.0219 -0.00268 -0.0521 -0.0197 -0.0153 -0.00208 -0.00619 0.00121 0.00259 
 (0.0185) (0.0186) (0.0487) (0.0173) (0.0151) (0.0211) (0.0190) (0.00344) (0.0189) 
ln(Total assets) 0.133*** 0.115*** 0.254*** 0.0985*** 0.0751*** 0.132*** 0.119*** 0.00315** 0.0853*** 
 (0.00843) (0.00845) (0.0221) (0.00787) (0.00684) (0.00961) (0.00865) (0.00156) (0.00859) 
ln(Emp w/ college+) 0.00397 0.00552 0.0117 0.00746** 0.00495 0.00665 0.00638* 0.000148 0.00606 
 (0.00374) (0.00375) (0.00982) (0.00349) (0.00304) (0.00426) (0.00384) (0.000693) (0.00381) 
          
Observations 13,494 13,494 13,494 13,494 13,494 13,494 13,494 13,494 13,494 
# of firms 2,349 2,349 2,349 2,349 2,349 2,349 2,349 2,349 2,349 
R-squared 0.835 0.817 0.695 0.814 0.821 0.822 0.845 0.567 0.723 
Year FE YES YES YES YES YES YES YES YES YES 
Firm FE YES YES YES YES YES YES YES YES YES 
 
Note: 
(1). All models also control for firms’ total number of patents as well as relevant intangible asset such as advertising asset, but including them or not does not 
change our results.  
(2). All interactions are appropriately centered. 









Table 8 : Data Analytics, Firm Public Status and Innovation Quality (Heckman) 
 
Model: Heckman (1) (2) (3) (4) (5) (6) (7) (8) (9) 
   ln(Fwd citations,  ln(Reuse ln(Reuse ln(New-comb ln(New-comb ln(Novelty ln(Novelty 
DV ln(Orig) ln(Gen)      w/in 4yrs) Global) Local) Global) Local) Global) Local) 
          
Public -0.0888*** -0.0830*** -0.210*** -0.0366*** -0.0183 -0.0998*** -0.0769*** -0.00366 -0.0631*** 
 (0.0196) (0.0270) (0.0635) (0.00262) (0.0168) (0.0222) (0.0280) (0.00481) (0.0161) 
ln(Data) 0.000989 -0.000352 -0.00407 0.000152 0.00142 0.00195 0.000224 1.9810-6 0.00263 
 (0.00556) (0.00561) (0.0140) (0.00288) (0.00103) (0.00675) (0.00619) (0.000247) (0.00491) 
Data X Public 0.0112*** 0.0105** 0.00350 0.0163** 0.00850* 0.00672*** 0.0105*** -0.00194 0.00538 
 (0.00209) (0.00445) (0.00919) (0.00754) (0.00506) (0.00215) (0.00380) (0.00138) (0.00468) 
ln(Firm age) 0.0872 0.0996 -0.0479 0.0962 0.0815 0.137* 0.149 -0.00132 0.0917* 
 (0.0934) (0.111) (0.187) (0.100) (0.0993) (0.0817) (0.0927) (0.00458) (0.0477) 
ln(VC inflows stock) -0.0603 -0.0362 -0.0270 -0.0662 -0.0607 -0.0548*** -0.0736* -0.000728 -0.0189*** 
 (0.0407) (0.0422) (0.0917) (0.0551) (0.0504) (0.0200) (0.0413) (0.00351) (0.00679) 
ln(Total assets) 0.115*** 0.102*** 0.293*** 0.0720** 0.0488* 0.106*** 0.0833*** 0.00203 0.0703*** 
 (0.0250) (0.0288) (0.0491) (0.0310) (0.0258) (0.0274) (0.0290) (0.00235) (0.0156) 
ln(Emp w/ college+) 0.000193 0.00323 0.00777 0.00267 0.00218 0.00507 0.00182 -0.000327 0.00350 
 (0.00553) (0.00698) (0.0185) (0.00527) (0.00267) (0.00683) (0.00669) (0.000327) (0.00629) 
IMR -0.338 -0.299 0.978 -0.602 -0.627 -0.465 -0.750 0.0529 -0.149 
 (0.717) (0.800) (1.668) (0.744) (0.738) (0.710) (0.728) (0.0376) (0.346) 
          
Observations 13,262 13,262 13,262 13,262 13,262 13,262 13,262 13,262 13,262 
# of firms 2,113 2,113 2,113 2,113 2,113 2,113 2,113 2,113 2,113 
Year FE YES YES YES YES YES YES YES YES YES 
Firm FE YES YES YES YES YES YES YES YES YES 
 
Note: 
(1). All models also control for firms’ total number of patents as well as relevant intangible asset such as advertising asset, but including them or not does not 
change our results.  
(2). All interactions are appropriately centered. 
(3). IMR: inverse Mills ratio calculated from the probit model to predict the probability of a firm’s going public. 
(4). Standard errors are bootstrapped and reported in parentheses. 









Table 9 : Data Analytics, Firm Public Status and Innovation Quality (2SLS) 
 
Model: 2SLS (1) (2) (3) (4) (5) (6) (7) (8) (9) 
   ln(Fwd citations, ln(Reuse ln(Reuse ln(New-comb ln(New-comb ln(Novelty ln(Novelty 
DV ln(Orig) ln(Gen)  w/in 4 yrs) Global) Local) Global) Local) Global) Local) 
          
Public -0.0724*** -0.0662*** -0.174*** -0.0279 -0.00485 -0.0788*** -0.0628*** -0.00268 -0.0527** 
 (0.0208) (0.0201) (0.0513) (0.0194) (0.0172) (0.0229) (0.0210) (0.00441) (0.0206) 
ln(Data) 0.0626 -0.0255 -0.00926 0.0635* 0.0667** 0.0143 0.0447 -0.0111 -0.0404 
 (0.0404) (0.0390) (0.0996) (0.0377) (0.0333) (0.0445) (0.0407) (0.00855) (0.0400) 
Data X Public 0.0768** 0.0665* -0.0584 0.0934*** 0.0771** 0.0791* 0.104*** -0.0225*** 0.0387 
 (0.0381) (0.0368) (0.0940) (0.0356) (0.0315) (0.0420) (0.0384) (0.00807) (0.0378) 
ln(Firm age) 0.108*** 0.0995*** 0.204*** 0.0697*** 0.0450** 0.131*** 0.104*** 0.0144*** 0.108*** 
 (0.0225) (0.0217) (0.0554) (0.0210) (0.0185) (0.0247) (0.0226) (0.00476) (0.0223) 
ln(VC inflows stock) -0.0351* -0.0164 -0.0721 -0.0259 -0.0208 -0.0165 -0.0134 -0.00171 -0.0152 
(0.0184) (0.0178) (0.0455) (0.0172) (0.0152) (0.0203) (0.0186) (0.00391) (0.0183) 
ln(Total assets) 0.116*** 0.136*** 0.271*** 0.0797*** 0.0546*** 0.133*** 0.107*** 0.00879** 0.109*** 
 (0.0183) (0.0176) (0.0450) (0.0171) (0.0151) (0.0201) (0.0184) (0.00387) (0.0181) 
ln(Emp w/ college+) -0.00129 0.00916 0.0123 0.000180 -0.00243 0.00922 0.00172 0.00229* 0.0137** 
(0.00581) (0.00561) (0.0143) (0.00543) (0.00480) (0.00640) (0.00586) (0.00123) (0.00576) 
          
Observations 15,447 15,447 15,447 15,447 15,447 15,447 15,447 15,447 15,447 
# of firms 2,303 2,303 2,303 2,303 2,303 2,303 2,303 2,303 2,303 
Year FE YES YES YES YES YES YES YES YES YES 
Firm FE YES YES YES YES YES YES YES YES YES 
 
Note: 
(1). Instrumental variables for data analytics: 1) total number and fraction of employees with data analytics skills in a firm’s existing hiring network; 2) total 
number and fraction of neighbors that started to use an enterprise resource planning (ERP) 3) total number and fraction of neighbors that started to use Human 
Capital Management (HCM) systems. 
(2). All models also control for firms’ total number of patents as well as relevant intangible asset such as advertising asset, but including them or not does not 
change our results.  
(3). All interactions are appropriately centered. 








Table 10 : Data Analytics, Firm Public Status and Innovation Quality (PSM with 2SLS) 
 
Model: PSM/IV (1) (2) (3) (4) (5) (6) (7) (8) (9) 
   ln(Fwd citations,  ln(Reuse ln(Reuse ln(New-comb ln(New-comb ln(Novelty ln(Novelty 
DV ln(Orig) ln(Gen) w/in 4yrs) Global) Local) Global) Local) Global) Local) 
          
Public -0.0572*** -0.0456** -0.145** -0.0128 0.00696 -0.0597** -0.0473** 0.000767 -0.0309 
 (0.0214) (0.0210) (0.0569) (0.0210) (0.0188) (0.0244) (0.0225) (0.00380) (0.0215) 
ln(Data) 0.0417 0.0245 -0.152 0.0868 0.0931 0.0417 0.0655 0.00346 0.0227 
 (0.111) (0.108) (0.294) (0.109) (0.0975) (0.126) (0.116) (0.0196) (0.111) 
Data X Public 0.110*** 0.0906** 0.0504 0.0908** 0.0773** 0.113** 0.119*** -0.0213*** 0.0558 
 (0.0424) (0.0415) (0.113) (0.0416) (0.0373) (0.0482) (0.0444) (0.00751) (0.0424) 
ln(Firm age) 0.125*** 0.128*** 0.226* 0.0981** 0.0748* 0.163*** 0.121** 0.0143* 0.141*** 
 (0.0466) (0.0456) (0.124) (0.0458) (0.0410) (0.0530) (0.0488) (0.00826) (0.0467) 
ln(VC inflows stock) -0.0239 -0.00197 -0.0638 -0.0202 -0.0136 0.000439 -0.00394 0.00159 0.00334 
 (0.0215) (0.0211) (0.0571) (0.0211) (0.0189) (0.0245) (0.0225) (0.00381) (0.0215) 
ln(Total assets) 0.116** 0.106** 0.323*** 0.0636 0.0395 0.114** 0.0905* 0.000718 0.0755* 
 (0.0454) (0.0445) (0.121) (0.0446) (0.0400) (0.0517) (0.0476) (0.00805) (0.0455) 
ln(Emp w/ college+) -0.000941 0.000848 0.0192 -0.00274 -0.00566 0.00343 0.000115 0.000257 0.00209 
 (0.0115) (0.0112) (0.0305) (0.0113) (0.0101) (0.0130) (0.0120) (0.00203) (0.0115) 
          
Observations 13,033 13,033 13,033 13,033 13,033 13,033 13,033 13,033 13,033 
# of firms 2,273 2,273 2,273 2,273 2,273 2,273 2,273 2,273 2,273 
Year FE YES YES YES YES YES YES YES YES YES 
Firm FE YES YES YES YES YES YES YES YES YES 
 
Note: 
(1). Instrumental variables for data analytics: 1) total number and fraction of employees with data analytics skills in a firm’s existing hiring network; 2) total 
number and fraction of neighbors that started to use an enterprise resource planning (ERP) 3) total number and fraction of neighbors that started to use Human 
Capital Management (HCM) systems. 
(2). All models also control for firms’ total number of patents as well as relevant intangible asset such as advertising asset, but including them or not does not 
change our results.  
(3). All interactions are appropriately centered. 




Table 11 : Data Analytics Before and After IPO 
 
Model: FE (1) (2) 
DV ln(Data) ln(Data) 
   
Event Year -3 0.00946 0.000408 
 (0.417) (0.413) 
Event Year -2 -0.402* -0.187 
 (0.232) (0.233) 
Event Year -1 -0.166* 0.0751 
 (0.0937) (0.0970) 
Event Year +1 0.145* 0.119 
 (0.0752) (0.0756) 
Event Year +2 0.127 0.109 
 (0.0787) (0.0810) 
Event Year +3 0.149* 0.140 
 (0.0822) (0.0863) 
Event Year +4 0.221** 0.214** 
 (0.0867) (0.0922) 
Event Year +5 0.305*** 0.279*** 
 (0.0913) (0.0980) 
ln(Firm age)  -0.253*** 
  (0.0868) 
ln(VC inflows stock)  -0.0860 
  (0.0766) 
ln(Total assets)  0.343*** 
  (0.0333) 
ln(Emp w/ college+)  0.145*** 
  (0.0140) 
   
Observations 16,198 16,198 
# of firms 2,366 2,366 
R-squared 0.594 0.603 
Year FE YES YES 
Firm FE YES YES 
 
Note: 
(1). All models also control for firms’ relevant intangible asset such as advertising asset, but including them 
or not does not change our results.  












CHAPTER 3 : ARTIFICIAL INTELLIGENCE ON DRUGS: A LARGE-SCALE 
EXAMINATION OF AI AND DRUG INNOVATION 
3.1 Introduction 
Advances in Artificial Intelligence (AI), especially in its subfield of machine 
learning, have empowered a wide variety of innovative business applications. AI can 
automate predictions by finding hidden patterns within large data sets (Agrawal et al. 
2018). As a result, both biotech startups and established pharmaceutical companies have 
invested in AI to accelerate the drug discovery process. For example, Atomwise, a 
biomedical startup that pioneered deep learning models to optimize drug designs, claimed 
to substantially shorten the process of discovering new chemical compounds. It was able 
to screen over 8 million compounds and predict which compound could address a 
particular disease target (Wallach et al. 2015).13 Another firm, BenevolentAI developed a 
deep learning platform that uses academic publications, patents, and clinical trials to 
identify potential drug candidates and validate them to some extent by predicting the 
interplay between chemical and biological entities (Fleming 2018). Compounds 
discovered using AI have shown potential to treat amyotrophic lateral sclerosis (ALS), 
glioblastoma, and Parkinson’s disease, among others. In these cases, AI has been touted 
for shortening the time required to find new drug candidates eligible for clinical trials by 
as much as 60%.14  
                                                          
13 This Is Your Disease on Drugs: How an AI Startup Could Defeat Now Unbeatable Bugs, 
https://blogs.nvidia.com/blog/2018/05/14/new-medications-atomwise/ 





Despite the promise of AI as a general-purpose technology (GPT) to accelerate 
scientific discovery, empirical evidence documents a decline in innovation and 
productivity especially in recent years (Bloom et al. 2020; Gordon 2017; Jones 2010).15 
In the case of drug discovery, both the number of drugs and their chemical novelty have 
declined even though research and development (R&D) spending has increased (Krieger 
et al. 2018; Pammolli et al. 2011; Scannell et al. 2012). Yet drugs played a critical role in 
driving up healthcare costs (Naci et al. 2015). The contradiction between the promise of 
AI to accelerate drug discovery and the observed decline in the quality of innovation 
mirrors the IT-productivity paradox coined by Robert Solow in a 1987 remark, “we see 
IT everywhere but not in the productivity statistics.” Replacing “IT” with “AI” and 
“productivity” with “drug innovation,” we can likewise argue, “we see AI everywhere 
but not in the drug innovation statistics.” In explaining the modern productivity paradox 
on drugs, it is important to examine the new capabilities AI provides, what the 
requirements are, and how they differ from past generations of IT in affecting drug 
innovation. 
Examining how AI affects drug discovery is important because drug development 
is expensive and time consuming. Moreover, findings on general innovation may not be 
directly applicable to drug discovery because of the many idiosyncrasies specific to drug 
development (Henderson and Cockburn 1993; Hess and Rothaermel 2011). Drug 
discovery also has many well-defined stages of development, allowing us to examine 
                                                          
15 Deloitte center for health solutions released a report: Ten years on: Measuring the return from 
pharmaceutical innovation 2019 from https://www2.deloitte.com/us/en/pages/life-sciences-and-health-
care/articles/measuring-return-from-pharmaceutical-innovation.html. It tracks a dozen of large 
biopharmaceutical companies and suggests a similar declining trend that the returns to R&D investment in 




how AI affects different stages of scientific discovery, a feature that is not possible when 
only final outputs are observed (Garud et al. 2013). Not only does each innovation stage 
have its own challenges and varying degrees of complexity, the stages are also 
interrelated and dynamically evolving. Thus, it is important to observe all parts of the 
process to discern AI’s true effects. For example, AI could speed up an early stage of the 
process but not the later stages where the bottlenecks occur. This could increase 
intermediate outputs without changing the final outcome, potentially misattributing the 
effect of AI. Lastly, focusing on a single industry where innovation is critical for 
productivity and competitive advantage, we can reduce the heterogeneity inherent in 
examining innovations across all industries.  
To the best of our knowledge, our study is the first to systematically and 
empirically examine the link between AI capabilities and drug development on a large 
scale. We measure AI capability in each firm using patents and job postings. Patents are a 
key indicator used to measure innovation in the pharmaceutical and biotechnology 
industry. AI patents can thus measure the ability of firms to innovate new AI 
technologies as well as the ability to use AI to innovate in general. AI job postings can 
capture a different aspect of AI capabilities, in measuring the demand for AI skills 
(Alekseeva et al. 2019). We use patents and skills together to estimate the effect of AI on 
drug outcomes (both quantity and quality) at different stages in the drug development 
process.  
We find that AI can primarily support the earliest drug development periods 
comprising the discovery and pre-clinical research stage of pairing a drug with a disease 




than it is for other drugs that receive no input from AI. Furthermore, we do not observe a 
significant impact of AI on the intermediate phases of clinical trials or on the final stage 
of getting Food and Drug Administration (FDA) approval. With the bottleneck remaining 
at the later stages for which AI has proven to be of limited use, we find that AI has not 
affected the total number of drug approvals by the FDA despite AI aiding in the 
discovery of more drug candidates early in the pipeline. These findings suggest that 
although AI has the promise of becoming an important GPT to facilitate drug discovery, 
we find AI works best at the compound discovery stage and is least helpful at later stages. 
Within the compound discovery stage, we discover a further refinement: AI works best 
for drugs aimed at an intermediate level of novelty that is neither too novel nor too 
incremental and for drugs whose mechanism for attacking the disease is known. These 
results suggest there are limitations to exploiting AI for developing drugs that are either 
too novel or, conversely, too incremental. 
It is possible that this result could change when we observe the outcomes of the 
current crop of drug candidates after they finish going through clinical trials. But given 
that we find that the current AI technology has limited effect in the early stage of clinical 
trials, the data truncation problem is unlikely to affect our core results. It is also possible 
that AI could have a significant effect when downstream factors that constraint later 
stages (the lack of financial, organizational incentives) are drastically reduced such as 
during major public health crises. In the case of the COVID-19 pandemics, a vast amount 
of resources is invested to find effective treatments and they have received the highest 
priority for clinical trials and FDA attention.16 Accordingly, this has relieved the 





constraints for running more clinical trials, allowing more drug candidates to be 
considered for treating COVID-19. 
So far, our results suggest that the current state of AI is not mature enough or is 
not sufficiently customized enough to produce all types of drugs, and AI does not raise 
the probability of a drug succeeding in clinical trials than drugs that received no inputs 
from AI. Given the long panel of our study, the prevalence of machine learning 
techniques used for discovering drugs in recent years, as well as the detailed examination 
of the limitations of using AI to facilitate drug development, our results are a caution for 
some of the excessively optimistic views about using AI for developing drugs that 
receive approval. Our results suggest AI investment for drug research should be used 
selectively, that distinctions should be made about when it can be used with likely 
success and when use of AI can lead to be a waste of resources. They contribute to the 
growing debate about the modern productivity paradox relating to AI: the observation 
that the adoption of AI has not yielded productivity increases (Brynjolfsson et al. 2017).  
3.2 Theory and Hypotheses 
Firms have used information technology (IT) to gain competitive advantage 
(Bharadwaj 2000; Brynjolfsson and Hitt 1996; Santhanam and Hartono 2003) and 
innovation plays a key role in achieving these goals. Research has shown a generally 
positive relationship between IT capabilities and R&D productivity (Bardhan et al. 2013; 
Joshi et al. 2010; Kleis et al. 2012; Pavlou and El Sawy 2006). These capabilities include 
IT-related infrastructure, spending, practices, and employee skills that are critical for 




and Hitt 2012). However, the exponential growth in digital data poses a challenge to 
traditional IT not only in storing and managing the data but also in generating novel 
insights from the data (Agarwal and Dhar 2014). AI, on the other hand, becomes more 
effective with more data and richer data (Agrawal et al. 2018). Recent advances in 
machine learning, a branch of AI, are able to take advantage of the massive digitized data 
across a variety of disciplines and settings. They have accelerated the ability to uncover 
hidden patterns and make predictions (Agrawal et al. 2018; Wu et al. 2020). Furthermore, 
AI does not require explicit instructions to make these predictions; it can learn the 
patterns itself through reviewing a massive number of examples. Accordingly, AI is 
predicted to generate a sea change in business practices, innovation and decision-making. 
As a potentially new general-purpose technology (Trajtenberg 2018), AI has 
already disrupted many industries such as automobile, manufacturing, and healthcare 
(Dixon et al. 2020; McAfee and Brynjolfsson 2017). With the rapid adoption of AI in the 
pharmaceutical industry in recent years, AI has the potential to significantly change the 
drug development process (Ekins et al. 2019; Fleming 2018). For example, using 
machine learning, researchers at MIT were able to quickly find and verify novel 
antibiotics. Without introducing prior knowledge, machine learning can quickly discern 
patterns from existing drug molecules possessing known antibacterial activities and then 
iteratively identify new promising drug molecules out of a database of more than 100 
million molecules in a matter of days. In the MIT example, the identified molecule is 
structurally distinct from existing antibiotics, can neutralize many species of antibiotic-
resistant bacteria (Marchant 2020) and has since been validated in animal tests (Stokes et 




become a public health issue. Despite investing millions of dollars, traditional methods 
have failed to yield results and yet AI was able to discover one with strong antibacterial 
activity in a fraction of the time.  
However, AI’s success in antibiotics may not translate into finding other types of 
drugs. In essence, machine learning is a massive correlation machine that can find both 
true and spurious correlations (Marcus and Davis 2019). While prior IT can also find 
correlations to make predictions, AI can do this much faster and at a much lower costs, 
shifting the competitive advantage towards using AI to make more predictions than 
before (Agrawal et al. 2018). Thus, disambiguating spurious correlations from causal 
ones is the key to AI’s effective use. As with all new technologies, it is critical to 
understand the conditions under which AI should be applied to innovation and when it 
should not be applied. There are reasons to believe that heterogeneity exists in how AI 
affects innovations of varying degrees of complexity, and this heterogeneity may differ 
from that associated with other types of IT (Wu et al. 2019).  
3.2.1 Stages of Drug Development Processes 
Developing drugs is perhaps one of the most expensive and riskiest processes in 
the world, costing over $2 billion for a typical drug (DiMasi et al. 2016) with 90% of 
them failing to attain FDA approval. The drug development process is inherently slow 
because it involves searching for chemical compounds in a large space spanning multiple 
scientific disciplines. It can range from genetics to protein synthesis, from biological and 
chemical synthetic processes to drug mechanisms (Dougherty and Dunne 2012; 




human biological system consisting of 25,000 genes and millions of proteins, all of which 
can create complex interactions with each other (Pisano 2006). Difficulty in managing 
this complexity is a key reason for the high failure rate of developing drugs (Dougherty 
and Dunne 2012). Furthermore, demonstrating safety and efficacy in clinical trials is 
risky and costly and thus drugs may fail despite showing early signs of promise 
(Henderson and Cockburn 1993). Yet, despite the costly risks, it is critical for 
pharmaceutical firms to stay competitive by continuously developing novel drugs.  
Drug development typically has three main stages. The first is the discovery and 
pre-clinical trials stage that often involves animal testing where drug candidates are 
proposed to address certain biological targets that cause the disease. Once a drug 
candidate-target pair is found and verified during the pre-clinical trial phase, the drug 
enters the clinical trials stage where the focus shifts toward human testing for drug safety 
and efficacy, complying with FDA regulations, communicating with patients, and 
ensuring the integrity of the process. The clinical trial stage involves three phases (Phase 
I/Phase II/Phase III), with each subsequent phase becoming increasingly more expensive 
and difficult. Lastly, if the drug succeeds in these trials, the final stage involves the FDA 
deciding whether to grant final approval. While the failure rate at each of the stages is 
high, the reasons for the failures differ. Each phase of a clinical trial has different sample 
sizes, safety, dosage and efficacy requirements. These efforts all require substantial 
interactions with the trial participants to understand their health conditions, treatment 
regimens, and the potential side effects. Because developing a drug can cost billions of 




2011), the pharmaceutical sector has the largest share of domestic R&D expenditure 
(Kinch 2016). 
3.2.2 AI and Drug Development Processes 
Using IT to find new chemical compounds and to advance drug discovery started 
decades ago. Although it is an underpinning in the fields of cheminformatics and 
bioinformatics studies, information technologies have had only limited success in 
discovering new drugs (Brown 1998; Drews 2000; Lo et al. 2018). However, it is 
suggested that recent advances in machine learning are fundamentally transforming drug 
discovery by uncovering hidden patterns in data without explicit instructions 
(Zhavoronkov et al. 2019). The digitization of scientific knowledge has substantially 
enlarged the search space for identifying drug candidates (Drews 2000; Jayaraj and 
Gittelman 2018) and machine learning is especially suited for taking advantage of large 
datasets (Agrawal et al. 2018; Harrer et al. 2019). By automatically collecting, digesting, 
analyzing, and detecting complex patterns in the existing data on chemical compounds 
and human biological reactions, machine learning algorithms can generate a large feature 
space to find hidden linkages. Through many examples of input-output pairs, supervised 
learning (an area of machine learning) can accurately uncover linkages and make better 
predictions than any human in many settings (He et al. 2015; Hu et al. 2018). Not only 
can machine learning find more correlations, it can do it in a fraction of the time 
(Agrawal et al. 2018). Machine learning can thus aid the preclinical trial stages where the 
bottleneck lies in scientific discovery of suitable drug candidates (Gashaw et al. 2011; 
Hughes et al. 2011). The resulting drug candidates could then stand at useful starting 




expect AI to have a strong effect on the early pre-clinical trial stage of identifying pairs of 
drugs and their targets in the drug development process.  
Hypothesis 1: AI has a positive effect on the early stage of drug-target 
identification in the drug development process. 
After the discovery and the preclinical stage, clinical trials are used to test both 
the safety and efficacy of the drug on human subjects (Junod 2014), because it is difficult 
to predict how the human body will react to a drug, and what dosage regimens are most 
effective. As stated in Northrup (2005), what is not understood about the human body and 
how it functions is far greater than what is understood (Dougherty and Dunne 2012). This 
is further compounded by temporal changes, varying demographics and health conditions 
in patients. Even with promising results from earlier stages, clinical trials can present 
conflicting findings due to factors such as the complexity of the trial design and 
inconsistent evaluation criteria (Horwitz 1987). To cite a recent example of this 
complexity, Remdesivir, an antiviral drug with promise to treat the novel coronavirus 
disease (COVID-19) received conflicting clinical trial outcomes when conducted on 
different groups of patients. The clinical trials with drug tests on patients in China with 
severe COVID-19 show that Remdesivir is not effective, while the trials launched in the 
United States show a significantly faster time to recovery compared to those given a 
placebo (National Institute of Allergy and Infectious Diseases (NIAID) 2020; Thompson 
2020; Wang et al. 2020). Thus, the incomplete nature of the data makes it very difficult 
for machine learning to produce reliable predictions. In addition, clinical trials still rely 
heavily on human judgment and clinical expertise that requires intuition, creativity and 




Although recent work suggests that AI has the potential to accelerate human 
subjects recruitments in clinical trials through mining a vast amount of medical records 
(Harrer et al. 2019), organizational, managerial and financial concerns in later stages may 
still prohibit a drug candidate from being selected for clinical trials in the first place. 
Compared to early stages, scientific discovery is not the sole criterion for progressing to 
later stages. Downstream organizational concerns can derail a drug from progressing to 
clinical trials (Kapoor and Klueter 2015). For example, a drug that is too expensive to 
produce for the market it serves may fail to advance despite showing early promises. 
Other organizational factors such as market competition, regulatory environments, 
marketing needs, and market size can all prohibit a drug from advancing to later stages 
(Eklund 2018). AI is extremely limited in addressing these types of human and 
organizational factors (Marcus and Davis 2019). Moreover, miscommunication with the 
FDA about drug safety and efficacy can put a program at risk (Junod 2014; Sacks et al. 
2014). Regulatory changes and their interpretations often require changes that AI is ill-
suited to facilitate (Adams 1993; Kuan 2019). Thus, we expect the effect of AI in 
facilitating clinical trials and FDA approvals to be limited.  
Hypothesis 2: AI has a limited effect on the stages following pre-clinical drug 
development.  
If AI affects the early stage but not the later stages of drug discovery, the overall 
effect of AI on finding a marketable drug depends on the drug quality and where the 
biggest bottleneck is. If the most problematic bottleneck in drug development is in the 
later stages and AI is not able to improve the drug quality, this would result in limiting 




bottleneck is at the early stage and having more drug candidates at that stage would lead 
to more clinical trials and more FDA approvals, we would expect AI to lead to more 
drugs being approved. The process could accelerate more if the quality of these AI-driven 
drugs is better and thus raises the chance of successfully completing all clinical trials. 
However, AI could have a negative effect on the final outcome if it produces lower-
quality drugs. These low-quality drugs would crowd out the better candidates for clinical 
trials, which would in turn lower the number of drugs approved. Thus, examining the 
effect of AI on overall drug discovery is an empirical question. 
Hypothesis 3a: On average, AI raises the chances that a drug receives FDA 
approval. 
Hypothesis 3b: The rise in the chances of FDA approval that AI provides a drug 
is limited. 
3.2.3 AI and Drug Novelty 
While AI does not need exact rules to make predictions, it requires abundant 
examples for it to detect correlations and learn the underlying patterns. But it also has the 
overfitting problem and the need to sort through the many spurious correlations it finds. 
Known drug mechanisms and treatments can help disambiguate these spurious 
correlations from the true ones (“Mechanism matters” 2010). Experts can have more 
confidence in identifying and verifying drug candidates for clinical trials if the drug 
mechanisms are known. Furthermore, when these mechanisms are digitized, data 
analytics can also automate the disambiguation process. However, without intuition and 




spurious correlations for indications that a drug candidate is valid. This could hurt the 
overall drug discovery process if faulty drugs are selected for clinical trials and later 
proven to be ineffective. For the same reason, having a well-documented mechanism on 
bacterial infections and treatments could be the reason why machine learning succeeded 
in finding new antibiotics while it can be more difficult to find drugs to treat viral 
infections that we have relative scant knowledge about. Furthermore, having a large 
amount of training data is essential for machine learning to make predictions, and 
diseases with known mechanisms and treatments are more likely to fulfill that data 
requirement. Lastly, for certain discoveries, it is more important to use creativity or 
deeper insights derived from small but rich data, situations for which AI is not 
particularly well suited (Wu et al. 2020). Thus, we expect that AI is more likely to 
discover drugs that can treat disease with known mechanisms. 
Hypothesis 4: AI can help in discovering drug candidates with known drug 
mechanism better than it can help those without. 
While AI can accelerate the discovery of drug candidates at the earliest stage, it is 
unclear whether the drug candidates they discover represent incremental or large 
improvements on existing drugs. Research has shown that discovering drug candidates 
aimed at novel therapies that represent big leaps is much harder than discovering 
incremental improvements (“me-too” drugs), but on average, the return on these drugs is 
substantially higher than on “me-too” drugs once they gained FDA approvals (Krieger et 
al. 2018). Although it is difficult to assess a drug’s therapeutic impact at the early stage, 




ante measure of drug quality. Thus, finding drugs with novel chemical properties is 
important for both firm competition and public health. 
As discussed above, AI can help in identifying new molecules when there are 
abundant data available for AI to search for hidden patterns. For example, IBM’s Watson 
uncovered six new kinases that can affect the p53 protein, a tumor suppressor associated 
with half of all cancers in one month which would have taken researchers about six years 
to accomplish (Chen et al. 2016). The accelerated discovery was possible because there 
were kinases with established properties that were already well-known to interact with 
the p53 protein, so it is relatively easy for AI to find other types of p53-related kinases 
that matched existing patterns. However, novel drugs that differ radically from existing 
compounds have almost no precedents, and machine learning is ill-suited to support this 
effort (Wu et al. 2020). Inferences based on limited data may depend heavily on tacit 
knowledge that is inherently costly to collect and transfer, and therefore be difficult to 
digitize for AI consumption (Nonaka and Von Krogh 2009; Von Hippel 1994). 
Developing sufficiently novel drugs also requires deeper understanding of a narrow 
domain with tacit knowledge to which AI can add limited benefit. This is because AI is 
proficient in tasks that involve broad searches across multiple domains as opposed to a 
few narrow ones (Taylor and Greve 2006; Weisberg 1999).  
For example, the discovery of artemisinin for treating malaria was fundamentally 
driven by limited data and human ingenuity. The only reference to the drug treatment 
appeared in one sentence in an ancient book written in the 3rd century that was not 
directly related to malaria. Dr. Youyou Tu, the inventor of artemisinin, combined her 




development (Tu 2011). Current AI technology is not capable of understanding the 
meanings in the ancient texts needed to make the necessary link to treating disease 
(Marcus and Davis 2019). Even if it could, a single data point would not help machine 
learning make useful inferences. 
Turning to the other end of the innovation spectrum, we expect AI to have 
similarly limited effects on facilitating the development of incremental drugs because 
many firms could have already developed capabilities to discover such drugs (Krieger et 
al. 2018) without requiring advanced technology to do so. Compared to very novel drugs, 
our argument for AI’s limited effect on incremental drugs is not on abilities but on cost. 
Applying AI to finding incremental drugs may be too expensive, especially given the 
required substantial upfront investments and strategic planning needed for the required 
digital transformation (Bughin et al. 2017; WIPO 2019). In addition, there are also 
recurring costs of employing AI specialists to train the algorithms and curate the data for 
AI to consume. Using AI to discover incremental drugs would thus provide low marginal 
benefits. As a result of looking at the extreme ends of the innovation spectrum, the high-
end novel treatments and the low-end incremental improvements, we expect AI is most 
effective in developing drugs that are of intermediate novelty—those that are not too 
radically different and those that are not too incremental. These drug candidates can 
benefit more from broad searches and linkages of diverse data that AI can support.  
Hypothesis 5: AI contributes to the development of drugs at the intermediate level 




3.3 Data and Measurement 
We first discuss how we measure outcomes at different stages of drug 
development followed by measurements on drug novelty and whether a drug has known 
drug mechanisms. We then discuss how we measure AI and IT capabilities. 
Drug Development: We focus primarily on the global pharmaceutical industry, which has 
a well-established process for developing new drugs (Kapoor and Klueter 2015). Figure 1 
shows the drug development life cycle. We collect drug development data from two 
sources: the Informa Pharmaprojects database and the investigational drug database from 
Clarivate Analytics. Our dataset spans a full quarter century, from 1995 through 2019, 
which covers the most recent period of rapid digitization and AI advances (WIPO 2019). 
We use data from two leading sources of global drug development that have been widely 
used to study the pharmaceutical industry (Hess and Rothaermel 2011; Kapoor and 
Klueter 2015; Krieger et al. 2018). They provide a comprehensive coverage of drug 
candidates and track all their development stages. In addition, our data include the 
originators and licensees and all other firms involved in the development process.  
For our goal of investigating AI’s effect on all stages of drug development, it is 
important to match drugs to firms that are responsible for their original development so 
we can correctly attribute AI’s effect in facilitating clinical trials from AI’s effect in 
identifying superior drug candidates at the early stage that raise the chance of success in 
clinical trials. This is not as straightforward a task as it may seem. Some drugs may start 
their development at small biotechnology firms before being sold or licensed to larger 




candidate can also change hands through mergers and acquisitions (M&A). We therefore 
account for the transfer of drug patents and the associated rights using the Securities Data 
Company (SDC) data to ensure that drugs in our drug databases are correctly matched to 
the firms responsible for their original development (Eklund 2018). Thus, at any given 
point in time, we can observe a firm’s drug portfolio and pipeline and the originators for 
each drug. 
Following the best practices in counting unique drugs, we include drug candidates 
with complete information about their development including progression through the 
various developmental stages starting at the initial pre-clinical stage. A drug candidate 
may fail at any time during the process and we record its progression up to its exit due to 
either failing a particular stage or achieving FDA approval. 
Existing Drug Mechanism: We create a binary variable measuring whether there is an 
existing treatment and whether a drug’s mechanism for a similar condition is known. 
Informa Pharmaprojects and the investigational drug database from Clarivate Analytics 
tie drugs to the disease conditions they treat over time. For each drug, we examine 
whether its associated indication or disease has any existing therapies that have at least 
reached the clinical trial stage. In addition, Informa Pharmaprojects provides information 
about each drug’s mechanism of action. When drugs are labeled as “Unidentified 
pharmacological activity” or “Not applicable,” we assume that they do not have a known 
drug mechanism. Furthermore, to ensure the drug mechanisms are correctly identified, 
we use the DrugBank database that contains comprehensive information about drug 




text description of “mechanism of action” from DrugBank, we can infer whether the 
mechanism is known.17 
Drug Novelty: We focus on small-molecule drugs with known chemical structures 
because they constitute over 80% of drugs on the market. Although novel chemical 
compounds do not perfectly predict therapeutic value, they are highly correlated with it 
(Krieger et al. 2018). Thus, the ability to find new small-molecule compounds is a good 
proxy for a firm’s ability to find drugs with high therapeutic value. In total, we measure 
the chemical novelty of 13,699 drugs based on their chemical structure.18 We use the 
chemical structure at the point when the drug candidate is initially developed to prevent 
conflating innovation quality with ex-post measurement of success (e.g. getting FDA 
approval). Using methods suggested in recent research literature on chemical informatics 
(Backman et al. 2011; Cao et al. 2008), we measure novelty by comparing the chemical 
structure of a drug candidate to structures of all prior drugs.  
 We measure the similarity of two molecules by drawing on a central concept in 
chemistry, the “Similarity Property Principle.” It states that structurally similar molecules 
should also have similar physicochemical properties and biological activities (Johnson & 
Wiley-Interscience, 1991). We measure drug similarities by finding their maximum 
common substructure (MCS), a characteristic which can be used to differentiate new 
                                                          
17 We can search for keywords “unclear,” or “unknown” to infer whether the drug mechanism is known. 
For example, Modafinil (https://www.drugbank.ca/drugs/DB00745) shows “The exact mechanism of action 
is unclear, although in vitro studies have shown it to inhibit the reuptake of dopamine ...” We can thus infer 
the drug mechanism for Modafinil to be unknown. 
18 Our databases provide detailed development historical records of over 60,000 drugs. But most 
compounds that never progress beyond the very early discovery stage don’t have chemical structure 
information available. Neither do large molecule drugs (known as biologics) that a more complicated 
synthesis of substances is needed for their manufacturing. The drugs provided with chemical structures are 
generally small molecule drugs mainly produced by chemical synthesis. Small molecule drugs make up 




chemical compounds that could potentially offer a new treatment from incremental 
compounds that are derivatives of existing drugs. We calculate the similarities of our 
focal drugs to all prior drugs and take the maximum pair-wise score to be the similarity 
score of the focal drug.19  
Specifically, we calculate the pair-wise similarity score between any two drugs, X 
and Y, using the “Tanimoto coefficient”, which is the ratio of the atoms in MCS that 
appears in both X and Y and all atoms that appear in both (Cao et al. 2008; Krieger et al. 
2018; Nikolova and Jaworska 2003):20  
𝑆𝑖𝑚𝑖𝑙𝑎𝑟𝑖𝑡𝑦𝑋,𝑌 =  
𝑁𝑋&𝑌
𝑁𝑋+ 𝑁𝑌− 𝑁𝑋&𝑌
,  (1) 
where 𝑁𝑋 and 𝑁𝑌 are the total number of atoms in chemical structures of drug X and drug 
Y respectively, and 𝑁𝑋&𝑌 is the total number of atoms in MCS that appears in both drugs 
X and Y.21 Thus, a similarity score of zero means that the two drugs have no common 
components. A similarity score of 1 indicates that they have the same set of atoms and 
bonding, although it does not imply that the two molecules are identical because MCS 
                                                          
19 As robustness checks, we also restrict the previous drugs to be those that are within a certain time range 
so that our novelty score is not automatically decreasing for irrelevant structural reasons as the base of 
comparison becomes larger over time. Our results using the 5-year range are similar. 
20 Conventionally any non-hydrogen atoms are included for computation. Our drug data provide the 
simplified molecular-input line-entry system (SMILES) codes, which is a chemical notation language 
mainly designed for digital processing (Weininger 1988). We convert the SMILES codes of each drug to 
their graph representation and use the graph to compute pairwise similarity scores. 
21 MCS is one of the most accurate ways to calculate similarity and additionally provides a more flexible 
and efficient way of identifying important local structures (Cao et al. 2008). Although many algorithms can 
compute MCS in general graphs (Conte et al. 2004), they can’t be applied to the study of chemical 
structures that tend to be represented as small and sparse graphs. Thus, we use a novel backtracking graph-
matching algorithm to pinpoint the MCS in our chemical graph representations. The core idea of this 
algorithm is to identify and enumerate all possible combinations of a node (for atom)/edge (for bond) 
mapping for a pair of chemical graphs, and then arrange these mappings into a tree-like representation with 
the leaf being the largest set of node/edge correspondences. The generated common substructure from this 
approach is then the largest overlap between the graphs of the chemical structures for our drugs. Our MCS 
approach eliminates any mismatches and is thus rigidly identified; it provides a lower bound for the pair-




does not take into account the orientation in space of each molecule. Although different 
orientations could give them different chemical properties, they are still more similar on 
average to each other than to other compounds. Because similarity is highly correlated 
with chemical novelty, it is widely used to screen for groups of related drugs, and to 
digitally quantify certain chemical properties without human or animal testing (Wawer et 
al. 2014).  
 For example, we show the similarity of two drugs, Imatinib mesylate22 and 
Bafetinib,23 with their MCS highlighted in colors (see Figure 2). Imatinib mesylate is a 
first-generation tyrosine kinase inhibitor for treating chronic myelogenous leukemia 
(CML). Bafetinib was developed as a more powerful treatment and an alternative for 
patients who have become resistant to Imatinib mesylate. In terms of the size of their 
chemical structures, they both contain 42 atoms in total, with 35 of them appearing in the 




This suggests 71.4% of their chemical substructure is common. After all pair-wise 
drug similarity scores are calculated, we find the maximum similarity score to all 
previously developed drug candidates and subtract it from 1 to calculate the novelty 
score. To identify a set of previously developed drugs, we use the time that development 
of the drug first began, and thus the novelty measure is based on the ex-ante chemical 
structure at the earliest development stage.  
                                                          
22 PubChem profile of Imatinib mesylate: https://pubchem.ncbi.nlm.nih.gov/compound/Imatinib_mesylate  




𝐷𝑟𝑢𝑔 𝑁𝑜𝑣𝑒𝑙𝑡𝑦𝑖 = 1 − max
𝑗∈𝑃𝑖
𝑆𝑖𝑚𝑖𝑙𝑎𝑟𝑖𝑡𝑦𝑖,𝑗,  (2) 
where 𝑃𝑖 is all drug candidates that have reached at least the Phase I stage of clinical 
trials prior to the initial development of the focal drug i (Krieger et al. 2018). Therefore, a 
novel drug candidate should have a higher novelty score and is likely to possess a 
molecular structure that is distinct from previous drug candidates.24 Figure 3 plots the 
distribution of the drug novelty scores. Consistent with findings in Krieger et al. (2018), 
novelty scores can capture a substantial number of variations in drug novelty and it has 
been extensively tested to show its effects on drug risks, revenues, and impact. Overall, 
while more novel drugs are less likely to be approved by the FDA, those that are 
approved are more likely to be clinically effective, generate more valuable patents, and 
have a higher impact on the firm’s market cap than are more incremental drugs (Krieger 
et al 2018).  
To measure drug novelty in each firm, we compute the total number of drugs on a 
spectrum of novelty in a particular year. We do not use the average of novelty scores of a 
firm’s drugs because some firms may not have developed any drugs in a particular year. 
We also separately calculate the number of drugs at each stage of the drug development 
process. 
Patent Stock: As a high-patenting industry, the pharmaceutical industry often uses 
patents to gauge the ability of a firm to innovate. New drugs are typically patented 
                                                          
24 Krieger et al. (2018) discuss several limitations to the Tanimoto similarity metric, but it is still widely 
used for measuring drug quality and novelty. Often the chemical properties of the most similar compound 
are used to estimate a newly discovered compound. Despite the broad coverage of drug information in our 
drug databases, we may still miss drugs at the earliest stage of development that are not recorded in the 
database. We address this issue by using a rolling 5-year window to compare a drug to prior drug 




(Abrams and Sampat 2017; Hemphill and Sampat 2011), because patents are the most 
effective way to prevent imitations and substitutions (Cohen et al. 2000; Levin et al. 
1987). Reverse engineering a drug to create a similar compound is much easier than 
inventing a new one. Patents can thus prevent firms from freeloading and underinvesting 
in R&D (Gilchrist 2016). We use global patents from a worldwide patent statistical 
database PATSTAT25 that offers bibliographical data for over 100 million patents from 
90 global patent-issuing authorities going back to the nineteenth century. Each patent 
record contains a detailed patent application, citations, a title, an abstract, and legal 
persons (e.g. firms or any organizations) filing the patent application. It identifies 
whether the patent owners are business enterprises, higher education institutions, 
governmental agencies or individuals (Du Plessis et al. 2009). It also develops a 
comprehensive approach to standardize the original name of patentees (Magerman et al. 
2006).  
We match the names of pharmaceutical firms from our drug database to patent 
assignees in PATSTAT.26 We also adjust the assignee names to represent the original 
company that filed the patent after accounting for their merger and acquisition (M&A) 
activities using Thomson Reuters SDC and the Zephyr database from Bureau Van Dijk. 
                                                          
25 We first harvest the PATSTAT data in the version 2017b to cover patent records till 2017. Since Google 
launched its public datasets of worldwide patents on BigQuery in 2017 
(https://cloud.google.com/blog/products/gcp/google-patents-public-datasets-connecting-public-paid-and-
private-patent-data), we further augment our data to cover the time period from 2017 to 2019 by retrieving 
records of global patents through Google Patents Public Datasets. Similar approaches are employed to 
match them to other datasets used in our analysis.  
26 We primarily use the PATSTAT standardized name (PSN_NAME) in the company sector 
(PSN_SECTOR is referred to as COMPANY) to determine the assignees of patents for pharmaceutical 
firms in our sample for this matching process. We also test our matching by using other harmonized names 
available, such as DOCDB standardized name, and the OECD HAN name as recorded in PATSTAT. As 
the accurate sector assignment is provided for the PATSTAT standardized name (PSN_SECTOR for 




Based on these matched pharmaceutical firms, we then retrieve their patent application 
documents from PATSTAT and extract filing years, titles, abstracts, and citations for 
these patents. Following the convention in the R&D literature (Griliches et al. 1986; Hall 
et al. 2001), we use the patent filing year (as opposed to the publication year) because it 
more closely approximates the date at which the firm produced and used the innovation. 
Thus, we can measure a firm’s general investment in patent inventions using the 
accumulated stock of patent applications by the firm with an annual depreciation rate of 
15% (Aggarwal and Hsu 2013; Hall 1990; Hall et al. 2005).27  
Artificial Intelligence (AI) Capability: We measure AI capability of each firm by using 
its patents and job postings. Since patents are a key indicator for innovation in 
pharmaceutical firms, we use AI-related patents that either use or advance AI 
technologies to comprehensively measure a firm’s ability to innovate using AI. Job 
postings measure AI skill demands, representing other uses of AI that patents may not be 
able to capture such as innovations that are not patentable. To measure AI, we include a 
wide range of related concepts, definitions, applications and fundamentals. We also 
distinguish machine learning, a subfield of AI, from general AI investments (Cockburn et 
al. 2018; WIPO 2019).  
We use both patent classes and natural language processing on the patent text to 
classify AI patents. The United States Patent and Trademark Office (USPTO) provides a 
                                                          
27 We apply a standard perpetual inventory equation with declining balance depreciation to measure patent 
stock (Hall 1990):  𝑃𝑡 = (1 − 𝛿)𝑃𝑡−1 + 𝑅𝑡, where 𝑃𝑡 is the end-of-period patent stock and 𝑅𝑡 is the 
contemporaneous patent inventions during the year 𝑡. We use the conventional 15% per year for 






clear patent class relating to technical components of AI. Class 706 for “Data Processing 
– Artificial Intelligence” consists of a large set of subclasses including “fuzzy logic 
hardware,” “neural networks,” and “machine learning.” Thus, we first classify all patents 
in this class as AI patents. However, the narrow scope of AI classification codes may 
miss patents that employ AI to solve problems in other domains without directly 
contributing advances in AI technology itself. Thus, we expand our classification to 
include patents in which the title and abstract match a glossary of validated words and 
phrases related to AI. This glossary includes words related to robotics, symbolic systems, 
and learning – the three interrelated technological subfields within AI (Cockburn et al. 
2018). We also follow a widely accepted Association of Computing Machinery (ACM) 
Computing Classification System (CCS) that accounts for the dynamic change of AI 
technologies (WIPO 2019). Because this method has been used for over 50 years to 
organize the concept and trends of technologies, it can significantly mitigate the 
subjective classification of AI.28 Furthermore, we also include phrases related to a variety 
of AI technologies from outside vendors because often firms use off-the-shelf AI 
technologies to develop drugs. Some well-known AI tools and systems include PyTorch 
and TensorFlow (Raymond et al. 2019). Lastly, we also test on several variants of these 
keywords in our dictionary, but they do not qualitatively change the classifications of AI 
patents. We provide a list of AI-related keywords we use to identify AI patents in the 
Appendix.  
                                                          
28 CCS provides three major hierarchies to develop AI-related phrases for classification. They are (i) the 
“artificial intelligence” hierarchy, comprised of AI functional applications such as natural language 
processing, computer vision, knowledge representation and reasoning, simulation of human cognitive tasks, 
and AI techniques used to realize those functions; (ii) a “machine learning” hierarchy that unveils 
numerous learning-based AI techniques; and (iii) a “life and medical sciences” hierarchy under the “applied 




In total, we found 7,433 AI patents by global pharmaceutical firms in our sample 
from 1995 to 2019. About one-third of the patents have been acquired by other firms. In 
Figure 4, we show an example of an AI patent used for compound discovery. It uses a 
logistic regression tree method to screen compounds. Similar to the way we measure 
general patent stock, we track the development of AI over time and use the accumulated 
AI patent stock with an annual depreciation rate of 15% (Hall 1990; Hall et al. 2005). Our 
stock-based measure also aligns with the spirit of the standard innovation production 
function that models new knowledge as a function of existing knowledge stock and 
resources devoted to produce the new knowledge (Jones 2005; Romer 1990). We plot the 
growth in AI patents in Figure 5 and distinguish the three different types of AI 
technologies: expert systems, machine learning, and other AI applications. Overall, we 
see a tremendous growth in AI-related patents, with patents related to machine learning 
growing fastest in recent years. 
In Figure 6, we plot the average number of molecular drugs developed by a firm 
(left subfigure) and the average number of molecular drugs at the mid-range in novelty 
(right subfigure). We graph them on a relative time scale before and after the time when 
the pharmaceutical firms were developing their first AI patents (at a relative year of 
zero). Accordingly, the negative relative years indicate the period before firms have filed 
AI patents, and the positive relative years show the period after. Overall, this model-free 
analysis suggests that there are more drugs developed at the pre-clinical stage in firms 





In addition to patents, we also use job postings to gauge skill demands in AI 
(Alekseeva et al. 2019). Job postings provide an informative way to capture the specific 
needs in using AI to develop drugs. We use a large-scale job posting dataset from a 
leading analytics company collecting from over 40,000 online job boards worldwide from 
2007 to 2019. We examine both the skill requirements and job titles listed in each of the 
job postings. Similar to the way we identify AI patents, we search for AI-related words in 
the skill requirement section of each job posting to identify AI skills. These job postings 
have a time stamp and identify hiring firms, allowing us to create an AI-skills metric for 
each firm in each year. We also use the job title classification from O*NET to identify 
AI-related positions, similar to how IT and analytics labor are distinguished from other 
employees in earlier work (Tambe and Hitt 2012; Wu et al. 2019). If any of the skills 
listed under the job title is related to AI, we assume anyone with that job title has AI 
skills. We aggregate these individual-level skills for each firm-year observation. We also 
assume that firm- and occupation-specific factors with respect to the likelihood of posting 
a job are uncorrelated.29 Thus, our firm-level sample rate could be estimated by ’j =xj /Lj 
where xj is the number of employees in all occupations from all job postings for firm j, 
and Lj is the total number of employees for firm j as provided by the Crunchbase, 
PitchBook and Bureau van Dijk Orbis databases. Finally, AI skills at firm j are estimated 
by scaling the number of AI employees who are found in-sample at firm j by the 
sampling rate 𝜃𝑗′. We then measure AI capability in a firm by standardizing each variable 
and adding them together.  
                                                          
29 To the extent such matchings vary systematically across firms, we can address the problem by using 




AI capability = std(std(AI patents) + std(AI skills)).  (3) 
IT Capability: We also construct a measure of IT capability for pharmaceutical firms 
(Bharadwaj 2000; Tambe and Hitt 2012) to distinguish the effect of AI investment from 
general IT investment. Similar to how we measure AI capabilities, we measure IT using 
IT patents (Forman et al. 2016), and job postings that require IT skills. To identify IT 
patents, we include patents in the areas of computer hardware & software, 
communications, computer peripherals, and information storage as identified by category 
2 developed in Hall et al. (2001).30 We identify IT skills by examining the skill 
requirements in the job postings as well as in the job titles. For example, IT skills listed in 
a job posting can include software development as well as hardware support. IT-related 
job titles can include software engineer or systems analyst. If the job posting also 
contains keywords such as computer, website, software, telecommunications, we identify 
it as requiring IT skills. This measurement of IT skills has been verified to represent IT 
capabilities in context of examining their effects on firm productivity (Tambe and Hitt 
2012). Similar to our construction of AI skills, we aggregate the talents with IT skills in 
each firm after adjusting for the sampling rate. To measure IT capability in each firm, we 
calculate the sum of the standardized value of each measure. 
Control Variables: We primarily rely on Crunchbase, PitchBook and Bureau van Dijk 
Orbis databases to incorporate firm characteristics into our empirical models. These three 
databases provide rich information about both public and private firms in the 
                                                          
30 We also use multiple alternative methods from Forman et al. (2016) such as incorporating electronics-
related patents about electrical and semiconductor devices identified from category 4 in Hall et al. (2001) 
and searching IT-related phrases on the titles and abstracts of patents. These approaches yield directionally 




pharmaceutical industry. Because entrepreneurial exits have been shown to affect 
organizational innovation outcomes (Aggarwal and Hsu 2013), we control for a firm’s 
financial ownership status over years (a dummy variable indicating whether it is publicly 
held). We also control for firm age, number of employees and R&D spending. The 
founding year of each pharmaceutical firm is also collected and verified using BCIQ data 
from BioCentury tailored for biopharmaceutical industry, as well as EDGAR, Moody’s, 
Renaissance Capital and Thomson Financial Securities Data. We control for workforce 
size and account for each firm’s R&D expenses invested in drug development from 
Compustat Global and BioCentury BCIQ database, in addition to the Bureau van Dijk 
Orbis database.  
3.4 Empirical Strategy and Identification 
Our empirical strategy uses both firm- and drug-level analyses to examine AI’s 
effect on drug development. Firm-level analysis can examine the quantity of new drug 
candidates that AI can help discover while drug-level analysis can show the quality of 
these drugs candidates in the extent to which they have progressed to later stages of drug 
development. 
Firm-level Analysis: Overall, our firm-year panel dataset has 2,059 global 
pharmaceutical firms from 1995 to 2019, of which, 650 firms have AI capabilities. First, 
we use the 650 firms with AI capabilities to examine whether having more AI capabilities 
leads to better drug innovation. We then use the full sample of 2,059 firms and further 
explore the effect of AI on drug development. Specifically, we estimate AI’s effect on the 




a given year (Equation 4). For example, the number of drugs in Phase III is the total 
number of drugs in development in that phase, meaning they have passed all prior stages: 
preclinical, and clinical trial Phases I and II. Due to the risky nature of drug development, 
the number of drug candidates at all stages is highly skewed, with many firms having no 
drug candidates at a particular stage in a typical year. This number is further skewed if 
we only use drugs with sufficient chemical novelty. Thus, we take the logarithm of one 
plus the raw number of drug candidates in our main analysis.31 We also include firm-
fixed effects 𝛾𝑖 to control for any unobserved time-invariant differences in firm 
characteristics, and year-fixed effects 𝑦𝑡 to account for temporal shocks. We control for a 
firm’s financial ownership structure to account for different innovation priorities between 
public and private firms. We also control for firm size (total employees), firm age, patent 
stock and R&D expenditure. Our main coefficient of interest is β1 that captures the 
marginal effect of the contemporaneous AI on drugs produced in a firm at a particular 
development stage. Within the discovery and preclinical trial stage, we also explore AI’s 
effect on drug novelty. We count the number of drugs in three categories of novelty that 
correspond to incremental, intermediate and highly novel drugs, and estimate Equation 4 
for each novelty range. 
ln(𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝐷𝑟𝑢𝑔𝑠)𝑖𝑡 = β0 +  β1 𝐴𝐼 𝐶𝑎𝑝𝑎𝑏𝑖𝑙𝑖𝑡𝑦𝑖𝑡 + 𝐶𝑜𝑛𝑡𝑟𝑜𝑙𝑠𝑖𝑡 + 𝑦𝑡 + 𝛾𝑖 +  𝜖𝑖𝑡.  (4) 
To estimate AI’s effect on the final stages (Phase III and FDA approval), we 
distinguish AI capabilities when the drug was first discovered at the preclinical stage 
from the current AI capabilities (Equation 5). This allows us to distinguish AI’s direct 
                                                          




effect in facilitating clinical trials (𝐴𝐼 𝐶𝑎𝑝𝑎𝑏𝑖𝑙𝑖𝑡𝑦𝑖𝑡) from its earlier effect in compound 
discovery (𝐴𝐼 𝐶𝑎𝑝𝑎𝑏𝑖𝑙𝑖𝑡𝑦𝑖,𝑝𝑟𝑒𝑐𝑙𝑖𝑛𝑖𝑐𝑎𝑙). On average the preclinical trial stage is 
approximately a 6-year lag from Phase III and an 8-year lag from FDA.32   
ln(𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝐷𝑟𝑢𝑔𝑠)𝑖𝑡 = β0 +  β1 𝐴𝐼 𝐶𝑎𝑝𝑎𝑏𝑖𝑙𝑖𝑡𝑦𝑖,𝑝𝑟𝑒𝑐𝑙𝑖𝑛𝑖𝑐𝑎𝑙 +  β2 𝐴𝐼 𝐶𝑎𝑝𝑎𝑏𝑖𝑙𝑖𝑡𝑦𝑖𝑡 +
𝐶𝑜𝑛𝑡𝑟𝑜𝑙𝑠𝑖𝑡 + 𝑦𝑡 + 𝛾𝑖 + 𝜖𝑖𝑡.  (5) 
There are several endogenous factors we need to consider in Equation 4 and 5. 
First, there could be an upward bias on the effect of AI if firms with more slack resources 
choose to invest in technology for innovation. We address this reverse causality using 
instrumental variables that are derived from a patent-citation network for each firm in our 
sample that has AI patents. We construct a firm-level citation network for each year in 
our sample: each node in the network is a firm, and each link is the aggregate patent 
citations. For example, if patents in firm A cited patents from firm B five times in the 
current year, a directed link between A and B would have a weight of 5. In this example, 
the relationship is not reciprocal: B’s patents don’t cite A’s patents. Thus, B is A’s 
neighbor because A has drawn knowledge from B, but A is not B’s neighbor since B did 
not cite A and thus there is no observed information flow from A to B. We use the total 
number of neighboring firms with AI capability to instrument for a focal firm’s AI 
capability. We also use two variations of these instrumental variables: (1) the average 
number of AI patents in the neighboring firms; (2) the average ratio of a firm’s AI patents 
to total patents for these neighbors. Similar to the network-based approaches for 
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instrument construction in Wu et al. (2017), our Hausman-type instruments focus on 
knowledge flows across firms. This can serve as a proxy for the cost of accessing AI-
related knowledge and reflects the ease of accessing external AI capability from 
neighboring firms (see Figure 8 for one example). We exclude direct competitors, defined 
as network neighbors that are in the same industry as the focal firm in the citation 
network. Thus, the neighbors used to create the instruments are firms that are not in 
pharmaceutical sectors. The citation neighbors also vary substantially in their industries 
and geographical locations and are thus less likely to be affected by common industry or 
region-specific shocks and competitive pressure. Accordingly, instrumental variables 
derived from “similar firms” in citation networks are less likely to face the Manski 
reflection issues that typically affect firms in similar industries or geographical locations 
(Manski 1993). 
Second, there could be selection biases towards firms choosing to invest more in 
AI. To address this concern, we use the Propensity Score Matching (PSM) and Coarsened 
Exact Matching (CEM) method to match AI and non-AI firms based on the firm’s patents 
and other firm characteristics used in our analyses (Blackwell et al. 2009; Ho et al. 2007; 
Rosenbaum and Rubin 1983). Therefore, firms that exhibit similar characteristics without 
AI capability could be added into our sample for estimations. Our analyses on two 
closely matched groups can more clearly reveal the effect of AI on drug development.  
Drug-level Analysis: The firm level analysis primarily examines whether AI can generate 
more new drug candidates for the firm; it is also important to explore the quality of these 
drugs. Thus, we use drug-level analysis to examine whether drug candidates discovered 




stages of drug development. We recognize that some drugs change ownership through 
licensing, M&As or other means. To understand the value of AI investment even as a 
drug may pass from being owned by one company to another, we conduct our analysis at 
the drug level, incorporating the AI capabilities of both the originator and the later 
owners (who currently possess the license) in the regression model.  
First, we use logit regression models after controlling for various time-varying 
characteristics of originators or licensees developing the drug, year fixed effect and drug 
fixed effect. The dependent variable indicates whether the drug candidate transitions from 
one stage to the next and beyond. 
𝑙𝑜𝑔𝑖𝑡(𝑝𝑖𝑡) =  𝛽0 + 𝛽1𝐴𝐼 𝐶𝑎𝑝𝑎𝑏𝑖𝑙𝑖𝑡𝑦𝑖𝑗𝑡 + 𝛽2𝐴𝐼 𝐶𝑎𝑝𝑎𝑏𝑖𝑙𝑖𝑡𝑦𝑖𝑘,𝑝𝑟𝑒𝑐𝑙𝑖𝑛𝑖𝑐𝑎𝑙 +
𝐶𝑜𝑛𝑡𝑟𝑜𝑙𝑠𝑖𝑗𝑡 +𝐶𝑜𝑛𝑡𝑟𝑜𝑙𝑠𝑖𝑘,𝑝𝑟𝑒𝑐𝑙𝑖𝑛𝑖𝑐𝑎𝑙 +  𝜃𝑖 + 𝑦𝑡 +  𝜖𝑖𝑡.  (6) 
In the specification in Equation 6, we estimate the probability of having drug 
candidate 𝑖 advance in a new stage at year t as a function of (i) the AI capability of the 
drug’s current owner (firm j) and (ii) the originator for the drug (firm k) at the pre-clinical 
trial stage. If the current owner is the originator then j=k, we use the current AI capability 
of firm j and its AI capability at the time of the pre-clinical trial stage. We control for drug 
and year fixed effects respectively, 𝜃𝑖 , 𝑦𝑡. Figure 7 shows a graph representation of the 
model that integrates the AI capabilities of both the originators and the licensees. In 
nonlinear models, we also include other time-varying firm characteristics such as firm age. 
We also apply Cox proportional hazards models to estimate the probability of a 
drug moving from one stage to the next (Cox 1972) using the same variables as in 




𝜆0(𝑡) captures the baseline hazard rate. As the fixed effect model may induce incidental 
parameter bias, the Cox model is mainly used to account for the random effect (Allison 
2002; Therneau 2015).  
𝜆𝑖(𝑡) =  𝜆0(𝑡)exp (𝛽1𝐴𝐼 𝐶𝑎𝑝𝑎𝑏𝑖𝑙𝑖𝑡𝑦𝑖𝑗(𝑡) + 𝛽2𝐴𝐼 𝐶𝑎𝑝𝑎𝑏𝑖𝑙𝑖𝑡𝑦𝑖𝑘(𝑝𝑟𝑒𝑐𝑙𝑖𝑛𝑖𝑐𝑎𝑙) 
+𝐶𝑜𝑛𝑡𝑟𝑜𝑙𝑠𝑖𝑗(𝑡)  + 𝐶𝑜𝑛𝑡𝑟𝑜𝑙𝑠𝑖𝑘(𝑝𝑟𝑒𝑐𝑙𝑖𝑛𝑖𝑐𝑎𝑙)).  (7) 
3.5 Results 
Table 12 shows the summary statistics and the correlations of all the variables for 
the 650 firms with AI-capabilities. The full sample statistics are shown in the Appendix. 
Firms with more AI capabilities are in general more likely to produce more drugs. We 
observe that the number of drug candidates decreases substantially as they progress from 
the pre-clinical trial stage to the final stage of FDA approval. This reflects the high failure 
rate in the drug development process. We also observe that the firm’s AI capability is not 
highly correlated with the firm’s other characteristics. 
3.5.1 AI’s Effect on Drug Development 
We first explore the relationship between a firm’s AI capability and the number of 
drug candidates a firm developed in a year (Table 13). After applying firm and year fixed 
effects and controlling for a firm’s cumulated patent stock, financial ownership status, 
age, total number of employees and R&D expenses, we find that AI capability is 
positively associated with the number of new drugs discovered at the early stage (Column 
1). This effect is separate from IT’s effect (Column 3). Specifically, on average a one-




the number of new drugs candidates discovered in a year. We also focus on the recent 
advances in machine learning from 2007 to 2019 and find the effect to be greater than the 
full sample estimate (Column 5). Similarly, we find about half of the effect of AI comes 
from machine learning (Column 4). We also separately estimate the effect of AI patents 
and AI skills, the two components that make up AI capabilities. Both the estimates are 
positive (Column 6 and 7). Overall, these results support Hypothesis 1. 
However, this effect disappears in the three phases of clinical trials and the final 
stage for FDA approval (Table 14). To examine the later stages of development process, 
we account for the number of drugs in the previous stage to control for the fact that 
having more input can mechanically increase outputs, which would artificially inflate our 
estimates on AI. For example, in order to have drugs reach Phase I of clinical trials, we 
control for drugs developed at the preclinical trial stage at approximately two years 
earlier. Results show that the ability of AI to assist in the later stages is not statistically 
significant, and the size of the effect is also very small, at an order of magnitude lower 
than the estimates for the preclinical trial stage (t-test for their differences is significant at 
p<0.01 level). These results show AI’s limited role in the later stages. All the robust 
standard errors are clustered at the firm level to address the concern of serial correlations 
within each firm. Poisson regressions also show similar results (Appendix). Overall, these 
results provide support for our Hypothesis 2.  
Next, we examine whether AI has an effect on the overall number of drugs being 
approved. Even if AI does not affect later stages, a boost in productivity at the discovery 
stage could still result in more drugs being approved in the end. To show whether AI 




process, we approximate AI capability at the preclinical trial stage using lags. 
Specifically, we use lags of 2, 4, 6 and 8 years to approximate AI capability at the early 
stage for Phase I, Phase II, Phase III and FDA approval respectively.33 These lags are 
chosen based on the average time it takes to advance to each stage of the drug 
development process. Thus, we should observe a positive effect from AI on the overall 
number of drugs being approved if the productivity improvement at the early stage 
propels a greater number of drugs through the later stages. However, both effects from 
the contemporary and lagged AI are not statistically significant (Table 15) and the size of 
the effect is generally very small and even negative at times. These results suggest that 
despite finding more drugs at the earlier stage at the start of the pipeline, they were 
neither chosen nor did they subsequently succeed in the later stages, resulting in no 
additional drugs getting approval.  
To alleviate the endogeneity concern that innovative firms may choose to develop 
AI capabilities, we use instrumental variables derived from the citation-network 
generated from patent citations as described in the methods section. The associated F-
statistic in the first stage is 29.9, passing the threshold of the weak instrument test. The 
2SLS estimate results show consistently that AI capability positively correlates with the 
number of new drugs but only at the earliest stage and not at later stages and that AI does 
not affect the final outcomes on the number of drug approvals (Table 16).  
Table 17 shows results using the full samples of firms. Although there are many 
firms with no AI capabilities, we continue to find that AI has the greatest effect at the 
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preclinical trial stage, but no effect in the subsequent stages. To reduce selection biases 
on firms choosing to invest in AI, we use matching estimators (Table 18). Results are 
consistent with our OLS and 2SLS analysis.  
To examine this phenomenon in greater detail, we conduct drug-level analyses to 
probe whether a firm’s AI capability at the early stage of drug development would affect 
the likelihood of a drug reaching later clinical trial stages and ultimately gaining FDA 
approval (Table 19).34 Here, we use drugs from the full sample of firms. If the drug 
candidates produced by AI at the early stages have high therapeutic value, they should 
have a higher probability of succeeding in later stages. This effect on drug quality should 
be independent of AI’s direct effect in facilitating clinical trials. If superior drug 
candidates can produce statistically significant differences early in the trial, this could 
shorten the clinical trials and thereby save valuable time and financial resources. We use 
both logit and Cox proportional hazards models by linking the probability of a drug 
reaching a later stage to the AI capability of the originating firms and of the licensing 
firms. We use AI capabilities at the earliest drug development stage for the originators to 
approximate when the scientific discovery has occurred. Results from logit models and 
Cox proportional hazards models are reported in Panel A and B of Table 19 respectively. 
We find that AI capabilities at the time when the chemical compound is first developed 
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several years to go through the preclinical trial stage, so we sequentially map its originator’s AI capability 
into its owner’s AI capability in later stages. An alternative measure is using lags of current AI capability 
for AI capability at the early stage as described in our firm-level analysis. We find the two types of metrics 
are highly correlated (b=0.9). We also recognize that some drug could be originated by multiple firms or 
licensed to more than one firms for subsequent drug development in a year. Among these firms that involve 
in the innovation process, we primarily choose to use the firm (that can be an originator or a licensee) with 
maximum AI capability in our drug level analysis, controlling for its associated characteristics. The results 
do not qualitatively change if we use alternative measurement of AI capability, such as average AI 




(originator) do not affect whether the drug gets approved in the end. This suggests that all 
else being equal, AI does not help in producing superior drug candidates that are more 
likely to succeed in Phase II and Phase III of clinical trials and get FDA approval. When 
a drug is licensed to other firms, we find that AI capabilities of the licensees also do not 
affect the probability of a drug succeeding through the later stages. This suggests that AI 
has not enabled drugs that can raise the average likelihood of a drug getting approved, 
supporting Hypothesis 3b. 
3.5.2 AI’s Effect on Drug Novelty 
Next, we explore the mechanism of how AI aids in compound discovery at the 
preclinical trial stage. Results in Table 20 that use both logit and Cox proportional 
hazards models reveal that AI is particularly effective in generating new drug candidates 
when there is already an existing therapy and the drug mechanism is known. All else 
being equal, a one-standard-deviation increase in AI capabilities is associated with a 7% 
increase in odds ratio when the drug mechanism is known (Column 1-Column 3). Results 
are similar when the Cox proportional hazards models are used. These results also 
suggest that AI is more capable of exploiting the existing therapies to find new drug 
candidates than it is in finding treatment where no prior therapeutic drugs are available. 
These results support Hypothesis 4. 
We also examine how a firm’s AI capability can affect the chemical novelty of 
drugs. Table 21 shows that the effect of AI is small and statistically insignificant for both 
incremental drugs (novelty between 0 and 0.3) and for drugs at the more novel end of the 




0.7, the estimate of AI is positive and much greater than estimates on very incremental 
and highly novel drugs (Column 1-Column 3, the differences are significant at p<0.01). 
We further look into each decile increments within this novelty range (Column 4-Column 
7) and find that AI’s effects are the greatest at ranges between 0.4 to 0.5 and 0.5 to 0.6. 
On average a one-standard-deviation increase in a firm’s AI capability is associated with 
a 1% increase in the number of drugs in these two novelty ranges. These results suggest 
that a firm’s AI capability can primarily help in discovering medium-novel drugs rather 
than in discovering either completely novel ones or incremental derivatives of prior 
drugs. Robust standard errors are clustered by firm. The 2SLS and the matching 
estimators show similar results (Appendix).   
As a further validation on AI’s effect on drug novelty, we use an alternative 
novelty measurement on the basis of new molecular entities (NMEs) approved by the 
FDA. This is a conventional benchmark for measuring the pace of pharmaceutical 
innovation (Lanthier et al. 2013; Lanthier et al. 2019) and can complement our analysis 
on chemical novelty. We acquire a list of NMEs that was regulated by the Center for 
Drug Evaluation and Research (CDER) and got approved from 1985 through 2019.35 
These drugs are categorized into three types on the basis of the degree of novelty 
compared to the existing base of drugs: first-in-class, advance-in-class and addition-to-
                                                          
35 This list covers the drug approvals extending from small molecule drugs to new biological products 
(https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-
drug-and-new-biologic-approvals). It includes several available attributes associated with each drug, such 
as the drug’s proprietary name, active ingredient/moiety, whether the drug received a “priority review” by 
the FDA and who its applicant was. We match FDA applicants for the drugs to firm names in our sample, 
and follow the identification approach developed in Lanthier et al. (2013). We identify the associated 
pharmacological class for each drug, based on the mapping between the active moiety name and the FDA-





class drugs.36 We then show how a firm’s AI capability affects drugs in each of these 
innovation categories, tracing back to their development at the initial stage. Table 22 
shows that the relationship between AI and advance-in-class drugs is positive and 
statistically significant. Compared to drugs in the first-in-class and addition-to-class 
categories, advance-in-class drugs are in the middle range of novel and AI seems to have 
its strongest effect on this class.  
We also examine the relationship between AI and drug novelty at the drug level 
(Table 23). We find that AI can increase chemical novelty of drugs. Our results also show 
that medium-novel drugs (chemical novelty score between 0.3 and 0.7 or advance-in-
class drugs) are more likely to progress to a Phase I of clinical trials compared to those 
drugs that are either derivatives of prior drugs or entirely novel. The relative hazard rate 
of entering into a later stage from pre-clinical trials is 2% greater for those AI-driven 
drugs that are at the medium level of novelty. Overall, these support Hypothesis 5.  
We also find a firm’s IT capability has no significant effect on any stage of the 
drug development process in both firm- and drug-level analysis (Table 13, Table 14 and 
Table 20).37 While IT investments are still important to support drug discovery, they do 
not provide the competitive advantages needed in drug development, possibly because 
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pathway for treating a disease condition. Advance-in-class drugs are those drugs that provide major 
improvements within an existing drug class and received a “priority review” designation from FDA. The 
remainder of the drugs in our list are classified as addition-to-class drugs (an addition to a drug class), 
which offer incremental therapeutic benefits. Lanthier et al. (2013) offers drug classification information up 
through 2011, so we use it to validate our determination on drug innovation category. We also refer to the 
classification result from Lanthier et al. (2019) which further updated the categorization mainly on first-in-
class drugs through the first half of 2018. 
37 Removing AI from general IT investment can downward bias the IT estimates due to measurement 
errors. Our alternative robustness tests use AI capability as an instrument for IT capability to tease out the 
portion of IT associated with AI that can empower drug development. We still find significantly positive 




most firms have already invested in IT, and best IT practices may have already diffused 
throughout the industry. Our results show that AI capabilities are primarily responsible 
for the speed up in the early stage of drug development. 
Viewing these results together could also help address certain selection biases that 
are likely to try to use AI across all types of novelty and across all stages of drug 
development, since it is difficult to envision a scenario where a firm chooses to use AI 
only to find drugs of intermediate novelty and when prior therapies already exist. The 
more plausible explanation is that AI can be particularly helpful in this scenario precisely 
because the capabilities it can provide in aiding drug discovery are best suited to making 
discoveries within this set of conditions.  
3.6 Conclusion and Discussion 
Despite immense investments in R&D, drugs developed per capita have declined 
in recent years (Pammolli et al. 2011). We conduct a large-scale examination of the 
pharmaceutical industry for 25 years to examine the impact of AI technologies in 
facilitating the drug development process. The drug development process offers unique 
characteristics to study how AI affects innovation. Instead of treating innovations as a 
single outcome, we can treat them as a process that produces a sequence of intermediate 
outcomes. Using AI patents and AI skills to approximate a firm’s capability in AI, we 
show that AI can speed up drug development at the discovery and preclinical trial stage 
especially in finding chemical compounds in the intermediate novelty range and those 
with known drug mechanisms. However, AI does not affect later stages of drug 




being selected for or succeeding in the clinical trials. Thus, despite increasing drug 
candidates at the early stage, AI does not change the number of drugs being approved by 
the FDA. Our study highlights the distinctiveness of applying AI in different stages of the 
drug innovation process.  
We also advance measurements of AI and innovation by using both patents and 
employee skills. Compared to early IT productivity literature that primarily measures IT 
using dollars invested, our analyses of AI on drug discovery use a multi-dimensional 
measure on AI capabilities (Santhanam and Hartono 2003; Tambe and Hitt 2012). Our 
analyses at both the firm level and drug-product level can systematically examine how AI 
affects different stages of drug development and the novelty of drugs AI helps discover. 
To determine chemical novelty, we draw on domain knowledge in the field of chemical 
informatics to assess the similarity of a chemical structure with all prior structures. Our 
alternative drug novelty measurements use pharmacological class (e.g. first-in-class drug) 
that provides additional evidence about the contributions of AI to certain types of drug 
innovation.  
In sum, we find that AI plays a vital yet narrow role in shaping the drug discovery 
process. This has several important managerial implications. First, AI resources should be 
used for the discovery stage of development when tasks are heavily dependent on 
automatic data processing and reasoning. Second, while drug candidates found through 
AI are generally more novel than those found without AI, AI provides the biggest benefit 
on discovering drug candidates that are intermediately novel; it is of limited use in 
developing either very novel or very incremental drug candidates. Similarly, AI is most 




Lastly, the bottleneck in drug development remains in the stages after preclinical trials 
that require managing organizational, financial, and regulatory constraints that AI is 
currently ill-suited to support.  
Managers should also think about how to fundamentally mitigate the bottleneck 
of drug development and that resides in the later stages. In some areas, AI could provide 
some benefits. For example, firms can investigate the extent to which AI and other 
technological advances, such as monitoring and tracking technologies in the personal 
health industry, can reduce these bottlenecks. As the digitization of medical records 
continues to accelerate, and the management and regulation of patient data continue to 
improve (Food and Drug Administration 2019), it is possible that AI could be applied in 
creative ways to help address current challenges in the later stages of the drug 
development process. For example, AI can help recruiting human subjects for clinical 
trials, potentially save time and resources in R&D (Harrer et al. 2019). The extent to 
which this can accelerate the later stages depends on where the bottleneck lies within the 
later stages—organizational factors that AI has limited impact or operational/scientific 
factors that AI is better suited to facilitate. Furthermore, in severe public health crises, 
downstream organizational and financial factors that prohibit drugs from entering clinical 
trials would be drastically reduced. Accordingly, AI’s effect on FDA approval should 
increase, as there is more capacity for drugs to enter into later stages.  For example, 
during COVID-19, promising drug candidates are given the highest priorities for clinical 
trials and FDA approval. Despite being a low priority for most biotech and 




shifted priority towards finding treatments and vaccines for COVID-19.38 It is possible in 
this case that AI can have a stronger effect for treating COVID-19 than for other 
conditions. 
Alternatively, AI could be improved to better screen drug candidates at the early 
stage that could raise the probability of success in clinical trials. If an effective drug was 
able to show efficacy early and consistently to obtain FDA approval, it would be a 
tremendous benefit for the firm and for the patients. It may also reduce the trial duration 
and avoid reconciling conflicting results from trials in different settings, all of which can 
save valuable R&D resources. Furthermore, the reduction in R&D for the early stage of 
drug discovery as well as substantial M&A in pharmaceutical and biotechnology 
companies have reduced the capabilities of the industry in finding new drug candidates. 
This portends an under-investment in basic research for understanding drug mechanisms 
in the next decade (Kinch 2016). Thus, while AI does not currently change the number of 
FDA approvals, it can play a pivotal role in the future if the bottleneck in the entire drug 
development process shifts to the early stage.  
Although our study has shown limited effect on discovering drugs that are very 
novel or very incremental, the problems AI has at the extremes of the novelty spectrum 
are different. At the novel end, AI has a capability problem: it is incapable of discovering 
truly new treatments for which little or no data are available to detect patterns. By 
contrast, the problem at the incremental end is not due to capability but to price: it is not 
worth the effort and cost of deploying AI to find drugs that constitute a marginal 
                                                          
38 https://phrma.org/en/Coronavirus/PhRMA-Member-Efforts: For example, in AstraZeneca, a team of 
experts across R&D, clinical and regulatory areas places the highest priority on development of a treatment 




improvement over existing drugs. As the cost of AI reduces over time, it should increase 
the comparative advantage in finding incremental drugs. 
The measurement of AI could also improve by tightly linking AI capabilities with 
specific tasks conducted in drug development. Although this is beyond the scope of this 
paper, a task-based examination could provide nuances on how AI can aid in the specific 
tasks used in scientific discovery and their implications for labor and skill requirements 
after AI becomes widely adopted (Felten et al. 2019). This could also help understand 
complementary firm practices that best aid firms to use AI.  Lastly, our study mainly 
examines the novelty of small molecule drugs. As large molecule drugs (known as 
biologics) have received growing interest from the pharmaceutical industry, 















             Drug name: Imatinib Mesylate         Drug name: Bafetinib 
        Molecular formula: C30H35N7O4S     Molecular formula: C30H31F3N8O 
 
Figure 2 : Visualization of the chemical structures of two drugs: Imatinib Mesylate (left 
part of the plot) and Bafetinib (right part of the plot) as well as their maximum common 
substructure highlighted in red. For simplicity and clarity of visualization, the skeletal 
structural representation of chemical compounds is shown featuring the unlabeled 
attachment of hydrogen atoms to carbon atoms represented by the vertices of line 
segment for bonding together. Those atoms other than hydrogen and carbon are explicitly 
labeled in vertices (e.g., N, S, F). The octet rule in chemistry is satisfied to determine 
number of hydrogens attached to carbon atoms and number of line segments bonding the 
atoms. For the identification of maximum common substructure in a pair of chemical 
compounds, we perform an exact matching without allowing any atom or bond 
mismatches to be reflected in this visualization.  
 
 
Early Stage: Compound Discovery  
                      Pre-clinical Trials 
Late Stage: Clinical Trials    
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Figure 3 : Histogram of novelty scores of drugs. We plot the histogram of novelty scores 






Figure 4 : Example of an AI patent that used a logistic regression tree method 





Figure 5 : Rising trend of AI adoption proxied by AI patents. We plot the trend of AI 
patents of pharmaceutical firms used in our analysis. Keywords related to machine 
learning type AI are exemplified by neural network, support vector machine, while 







Figure 6 : Plots of the average number of molecular drugs. We plot the average number 
of molecular drugs developed by the firms in our sample (left subfigure) and the average 
number of molecular drugs at the middle level of entire novelty scores (right subfigure). 
Relative year of zero is the time when the firms initiate with some AI patent stock. We 
observe substantial increasing trends of drug development at pre-clinical stage after firms 












Figure 8 : An illustration of citation-network based instruments. Each firm is represented 
as a node in the network, and interfirm citation flow is represented by an edge. A directed 
edge exists between firm A and firm B if firm A cites a patent from firm B. Firm A is a 
focal pharmaceutical firm that cites a pool of patents from various neighboring firms, 










Table 12 : Summary Statistics and Correlation Table 
 
                
Variables # of obs. Mean  Std dev.  1 2 3 4 5 6 7 8 9 10 11 12 
For ln(Number of 
Drugs):  
               
1. at Early Stage 8,235 0.107 0.39 1.00            
2. at Early Stage, 
Novelty: [0, 0.3] 
8,235 0.032 0.17 0.62 1.00           
3. at Early Stage, 
Novelty: [0.3, 0.7] 
8,235 0.078 0.34 0.92 0.33 1.00          
4. at Early Stage, 
Novelty: [0.7, 1] 
8,235 0.020 0.14 0.35 0.12 0.24 1.00         
5. at Late Stage – FDA 
Approval 
8,235 0.012 0.11 0.57 0.35 0.57 0.18 1.00               
6. ln(AI Stock) 8,235 0.654 0.93 0.12 0.05 0.14 0.04 0.13 1.00       
7. ln(AI Skill) 4,576 0.311 1.12 0.31 0.13 0.32 0.11 0.18 0.24 1.00      
8. ln(Patent Stock) 8,235 3.513 2.22 0.24 0.11 0.25 0.07 0.17 0.56 0.30 1.00     
9. Public Status 8,235 0.264 0.44 0.18 0.10 0.17 0.07 0.16 0.18 0.19 0.36 1.00    
10. ln(Firm Age) 8,235 3.032 0.95 0.08 0.02 0.09 0.00 0.11 0.06 0.14 0.19 0.10 1.00   
11. ln(# of Employees) 8,235 7.480 2.73 0.18 0.10 0.18 0.06 0.14 0.10 0.12 0.12 0.01 0.15 1.00  
12. ln(R&D) 8,235 21.47 2.46 0.04 0.01 0.04 0.04 0.04 0.05 0.06 0.01 -0.15 0.05 0.12 1.00 
                
 
Note: We add one to actual values of the employee and patent related variables as well as firm age and R&D spending to avoid the possibilities of taking a 









Table 13 : AI on Development of Drugs at Early Stage 
 
 (1) (2) (3) (4) (5) (6) (7) 














        
AI Capability 0.0201***  0.0193***  0.0300***   
(0.00441)  (0.00468)  (0.00670)   
IT Capability  0.0218 0.00507     
 (0.0158) (0.0169)     
AI Capability, 
Machine Learning 
   0.00959**    
   (0.00409)    
ln(AI Stock)      0.0358***  
      (0.00835)  
ln(AI Skill)       0.0121* 
       (0.00668) 
ln(Patent Stock) 0.000864 0.0106 0.00104 0.00735 -0.00502 0.00146 0.00523 
 (0.00676) (0.00653) (0.00675) (0.00698) (0.00308) (0.00704) (0.00539) 
Public Status -0.0435** -0.0422** -0.0436** -0.0412** -0.0104 -0.0422** 0.0108 
 (0.0207) (0.0210) (0.0208) (0.0210) (0.0157) (0.0210) (0.0219) 
ln(Firm Age) 0.0241* 0.0225 0.0243* 0.0226 0.0246** 0.0218 0.00972 
 (0.0141) (0.0141) (0.0141) (0.0142) (0.0115) (0.0141) (0.0166) 
ln(# of 
Employees) 
-0.00121 -0.00124 -0.00127 -0.00102 0.00104 -0.00134 0.000785 
 (0.00137) (0.00137) (0.00136) (0.00138) (0.000649) (0.00138) (0.00106) 
ln(R&D) -0.000335 -0.000169 -0.000347 -0.000185 0.00181*** -0.000204 0.00189* 
 (0.00126) (0.00122) (0.00125) (0.00123) (0.000654) (0.00124) (0.00103) 
        
Observations 8,235 8,235 8,235 8,235 4,576 8,235 4,576 
R-squared 0.756 0.754 0.756 0.755 0.867 0.756 0.798 
Year FE YES YES YES YES YES YES YES 
Firm FE YES YES YES YES YES YES YES 
 
Note:  
(1). All the drugs studied own their chemical structures in the database.  
(2). Column 1 shows the results for the drugs developed at early stage in our fixed effect estimations. We take IT capability into account in Column 2-3. In 
Column 4, we examine how machine learning could be linked to the development of drugs. Column 5 shows the estimates on post-2007 sample that captures the 
most recent advances in machine learning. Column 6 and 7 separately estimate the effect of AI stock and AI skills, two components of AI capability.  








Table 14 : AI on Development of Drugs at Late Stage 
 
 (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) 
DV ln(Number 
of Drugs at 
Phase I) 
ln(Number 
of Drugs at 
Phase II) 
ln(Number 
of Drugs at 
Phase III) 
ln(Number 
of Drugs at 
FDA) 
ln(Number 
of Drugs at 
Phase I) 
ln(Number 
of Drugs at 
Phase II) 
ln(Number 
of Drugs at 
Phase III) 
ln(Number 
of Drugs at 
FDA) 
ln(Number 
of Drugs at 
Phase I) 
ln(Number 
of Drugs at 
Phase II) 
ln(Number 
of Drugs at 
Phase III) 
ln(Number 
of Drugs at 
FDA) 
             
AI Capability 0.000847 -0.000846 -0.000744 -0.000409     0.00114 -0.000526 -0.000819 -0.000265 
 (0.00245) (0.00232) (0.00170) (0.00161)     (0.00231) (0.00255) (0.00149) (0.000982) 
IT Capability     -0.000795 -0.00248 -0.000280 -0.00114 -0.00183 -0.00200 0.000466 -0.000901 
     (0.00880) (0.00972) (0.00508) (0.00756) (0.00898) (0.0106) (0.00484) (0.00742) 
ln(# of Drugs at 
Previous Stage) 
0.219*** 0.296*** 0.164*** 0.292*** 0.219*** 0.296*** 0.164*** 0.292*** 0.219*** 0.296*** 0.164*** 0.292*** 
 (0.0337) (0.0430) (0.0352) (0.0644) (0.0337) (0.0429) (0.0352) (0.0644) (0.0337) (0.0430) (0.0352) (0.0644) 
ln(Patent Stock) -0.00113 0.00396 0.000867 -0.00211 -0.000599 0.00364 0.000460 -0.00227 -0.00118 0.00391 0.000879 -0.00213 
 (0.00439) (0.00467) (0.00187) (0.00202) (0.00405) (0.00454) (0.00164) (0.00191) (0.00439) (0.00464) (0.00187) (0.00205) 
Public Status 0.00178 0.00515 0.00488 0.0221* 0.00195 0.00510 0.00477 0.0221* 0.00179 0.00517 0.00488 0.0221* 
 (0.0145) (0.0156) (0.00917) (0.0119) (0.0145) (0.0156) (0.00917) (0.0119) (0.0145) (0.0156) (0.00919) (0.0119) 
ln(Firm Age) 0.00932 0.00421 -0.00347 -0.0151** 0.00893 0.00426 -0.00323 -0.0150** 0.00925 0.00412 -0.00345 -0.0151** 
 (0.0131) (0.0164) (0.00709) (0.00678) (0.0131) (0.0163) (0.00706) (0.00686) (0.0131) (0.0164) (0.00712) (0.00687) 
ln(# of Employees) -0.000866 -0.00230** -0.000189 0.000448 -0.000844 -0.00228** -0.000196 0.000456 -0.000848 -0.00228** -0.000194 0.000457 
 (0.000987) (0.00111) (0.000506) (0.000425) (0.000982) (0.00112) (0.000515) (0.000444) (0.000982) (0.00112) (0.000514) (0.000444) 
ln(R&D) 0.000935 -0.00165 0.000796 0.000959** 0.000945 -0.00165 0.000790 0.000958** 0.000938 -0.00165 0.000795 0.000960** 
 (0.000881) (0.00124) (0.000732) (0.000457) (0.000882) (0.00124) (0.000732) (0.000458) (0.000881) (0.00124) (0.000731) (0.000459) 
             
Observations 6,937 6,937 6,937 6,937 6,937 6,937 6,937 6,937 6,937 6,937 6,937 6,937 
R-squared 0.616 0.698 0.547 0.747 0.616 0.698 0.547 0.747 0.616 0.698 0.547 0.747 
Year FE YES YES YES YES YES YES YES YES YES YES YES YES 
Firm FE YES YES YES YES YES YES YES YES YES YES YES YES 
 
Note:  
(1). All the drugs studied own their chemical structures in the database.  
(2). Column 1-3 shows the results for drugs developed at the clinical-trial stage that includes Phase I/Phase II/Phase III. Column 4 shows the result for drugs 
getting FDA approval. We account for IT capability in Column 5-12.  








Table 15 : The Total Effect of AI on Drug Throughput from Early Stage to Later Stage 
 
 (1) (2) (3) (4) (5) (6) (7) (8) 
DV ln(Number of 
Drugs at Phase I) 
ln(Number of 
Drugs at Phase II) 
ln(Number of 
Drugs at Phase III) 
ln(Number of 
Drugs at FDA ) 
ln(Number of 
Drugs at Phase I) 
ln(Number of 
Drugs at Phase II) 
ln(Number of 
Drugs at Phase III) 
ln(Number of 
Drugs at FDA) 
         
AI Capability 0.00232 -0.000207 -0.000558 -0.000294 0.00200 0.000842 0.000301 0.00203 
 (0.00250) (0.00231) (0.00156) (0.00154) (0.00269) (0.00259) (0.00222) (0.00129) 
AI Capability      0.00220 0.00125 -3.0010-5 -0.00107 
(Early Stage)     (0.00244) (0.00281) (0.00177) (0.00112) 
ln(Patent Stock) 0.00106 0.00334 0.000411 -0.00212 -0.00126 0.00195 -0.000748 -0.00755 
 (0.00430) (0.00386) (0.00174) (0.00184) (0.00516) (0.00544) (0.00333) (0.00606) 
Public Status -0.00482 0.00973 0.0135 0.0212* -0.00412 -0.0131 0.000461 0.0313 
 (0.0131) (0.0164) (0.00880) (0.0115) (0.0147) (0.0171) (0.0152) (0.0223) 
ln(Firm Age) 0.0178** 0.0124 -0.00427 -0.00946** 0.0203 0.0113 -0.00182 -0.0168 
 (0.00889) (0.00946) (0.00424) (0.00425) (0.0152) (0.0252) (0.0202) (0.0152) 
ln(# of Employees) -0.00109 -0.00158 -0.000170 0.000816 -0.00124 -0.00254* -0.00143* 0.00106 
 (0.00105) (0.00116) (0.000527) (0.000497) (0.00106) (0.00138) (0.000761) (0.000665) 
ln(R&D) 0.000677 -0.00136 0.000953 0.00126** 0.000828 -0.00165 0.000946 0.000850 
 (0.00101) (0.00137) (0.000739) (0.000505) (0.000960) (0.00150) (0.000685) (0.000640) 
         
Observations 8,235 8,235 8,235 8,235 6,937 5,677 4,532 3,555 
R-squared 0.575 0.649 0.511 0.661 0.579 0.689 0.549 0.659 
Year FE YES YES YES YES YES YES YES YES 
Firm FE YES YES YES YES YES YES YES YES 
 
Note:  
(1). All the drugs studied own their chemical structures in the database.  
(2). Column 1-3 and Column 5-7 show the results for the drugs developed at the clinical-trial stage that includes Phase I/Phase II/Phase III. Column 4 and 
Column 8 show the results for the drugs getting approval at FDA. Column 5-8 has an additional lagged AI capability in early stage as a control.  










Table 16 : AI on Development of Drugs across Stages (2SLS) 
 
 (1) (2) (3) (4) (5) (6) (7) (8) (9) 

























Drugs at FDA 
Approval) 
          
AI Capability 0.0726** -0.0171 -0.0385 -0.0113 0.00525 -0.0130 -0.0254 -0.00863 0.0152 
 (0.0353) (0.0251) (0.0324) (0.0229) (0.0311) (0.0158) (0.0172) (0.0108) (0.0171) 
ln(# of Drugs at 
Previous Stage) 
     0.222*** 0.301*** 0.164*** 0.290*** 
     (0.0322) (0.0411) (0.0330) (0.0615) 
ln(Patent Stock) -0.0269 0.0113 0.0235 0.00606 -0.00505 0.00676 0.0180* 0.00538 -0.0110 
 (0.0182) (0.0136) (0.0165) (0.0115) (0.0153) (0.00987) (0.0105) (0.00598) (0.00894) 
Public Status -0.0491** -0.00278 0.0137 0.0146 0.0206* 0.00418 0.00936 0.00621 0.0195 
 (0.0208) (0.0130) (0.0168) (0.00916) (0.0124) (0.0144) (0.0145) (0.00891) (0.0127) 
ln(Firm Age) 0.0316** 0.0150* 0.00684 -0.00581 -0.00866 0.00417 -0.00489 -0.00632 -0.00942 
 (0.0155) (0.00882) (0.0104) (0.00505) (0.00623) (0.0132) (0.0156) (0.00751) (0.00943) 
ln(# of Employees) -0.00193 -0.000824 -0.00106 -2.3410-5 0.000741 -0.000673 -0.00196* -8.2510-5 0.000237 
 (0.00155) (0.00105) (0.00123) (0.000626) (0.000691) (0.000950) (0.00104) (0.000508) (0.000503) 
ln(R&D) -0.00101 0.000926 -0.000871 0.00109 0.00119* 0.00106 -0.00142 0.000867 0.000819* 
 (0.00160) (0.00102) (0.00142) (0.000802) (0.000642) (0.000872) (0.00121) (0.000720) (0.000495) 
          
Observations 8,235 8,235 8,235 8,235 8,235 6,937 6,937 6,937 6,937 
Year FE YES YES YES YES YES YES YES YES YES 
Firm FE YES YES YES YES YES YES YES YES YES 
 
Note:  
(1). All the drugs studied have their chemical structures in the database.  
(2). Results are reported from 2SLS estimations. We use total number of neighboring firms with AI capability to instrument for a focal firm’s AI capability. Two 
variations of this instrument are also used: (i) the average number of AI patents and (ii) the average ratio of AI patents in the neighboring firms up to and 
including the observation year after appropriate depreciating factors are applied. The associated F-statistics at first stage are above the threshold and pass the 
weak instrument test.  








Table 17 : AI on Development of Drugs across Stages, with Non-AI Firms 
 
 (1) (2) (3) (4) (5) 
DV ln(Number of Drugs 
at Early Stage) 
ln(Number of Drugs 
at Phase I) 
ln(Number of Drugs 
at Phase II) 
ln(Number of Drugs 
at Phase III) 
ln(Number of Drugs 
at FDA Approval) 
      
AI Capability 0.0102** -0.000855 -0.00159 -0.00101 0.000606 
 (0.00424) (0.00245) (0.00215) (0.00157) (0.00195) 
ln(# of Drugs at 
Previous Stage) 
 0.179*** 0.320*** 0.152*** 0.236*** 
  (0.0161) (0.0234) (0.0167) (0.0312) 
ln(Patent Stock) 0.00500 0.000103 0.00458* 0.00395** 0.000218 
 (0.00561) (0.00350) (0.00264) (0.00194) (0.00167) 
Public Status 0.0120 0.00360 0.00158 0.00379 0.00196 
 (0.0126) (0.00607) (0.00680) (0.00399) (0.00378) 
ln(Firm Age) 0.0370*** 0.0183** 0.0140** -0.00137 -0.00628** 
 (0.0111) (0.00722) (0.00610) (0.00336) (0.00318) 
ln(# of Employees) -0.00432*** -0.000890 -0.00279*** -0.000746** 0.000396 
 (0.00113) (0.000664) (0.000673) (0.000371) (0.000279) 
ln(R&D) 0.595*** -0.0115 0.0165 0.0166** 0.0167** 
 (0.0675) (0.0176) (0.0209) (0.00696) (0.00698) 
      
Observations 28,126 24,661 24,661 24,661 24,661 
R-squared 0.561 0.498 0.596 0.433 0.591 
Year FE YES YES YES YES YES 
Firm FE YES YES YES YES YES 
 
Note:  
(1). All the drugs studied have their chemical structures in the database.  
(2). Results are estimated on the sample that includes both firms with AI capability and firms without.  










Table 18 : AI on Development of Drugs across Stages, with Non-AI Firms (PSM and CEM) 
 
 (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) 
 Propensity Score Matching (PSM) Coarsened Exact Matching (CEM) 
DV ln(Number 
of Drugs at 
Early Stage) 
ln(Number 
of Drugs at 
Phase I) 
ln(Number 
of Drugs at 
Phase II) 
ln(Number 
of Drugs at 
Phase III) 
ln(Number of 
Drugs at FDA 
Approval) 
ln(Number 
of Drugs at 
Early Stage) 
ln(Number 
of Drugs at 
Phase I) 
ln(Number 
of Drugs at 
Phase II) 
ln(Number 
of Drugs at 
Phase III) 
ln(Number of 
Drugs at FDA 
Approval) 
           
AI Capability 0.0188*** 0.000904 -0.000522 -0.00131 -0.000440 0.0107** -0.000507 -0.00112 -3.0610-5 0.00115 
 (0.00469) (0.00292) (0.00243) (0.00185) (0.00158) (0.00445) (0.00293) (0.00246) (0.00211) (0.00114) 
ln(# of Drugs at 
Previous Stage) 
 0.220*** 0.315*** 0.163*** 0.267***  0.209*** 0.321*** 0.171*** 0.214*** 
  (0.0304) (0.0441) (0.0300) (0.0506)  (0.0261) (0.0387) (0.0257) (0.0411) 
ln(Patent Stock) 0.00276 -0.00582 0.000138 0.00428 -0.00155 0.0120 -0.00102 0.00535 0.00534 -0.00115 
 (0.00770) (0.00648) (0.00537) (0.00366) (0.00237) (0.00763) (0.00623) (0.00402) (0.00434) (0.00244) 
Public Status -0.0371* -0.00139 0.00669 0.00211 0.0180* -0.00235 0.00364 0.00148 0.00110 0.00832 
 (0.0192) (0.0131) (0.0142) (0.00809) (0.0101) (0.0146) (0.00972) (0.0104) (0.00652) (0.00630) 
ln(Firm Age) 0.0229 0.0128 0.00400 -0.00819 -0.00851 0.00218 0.0129 0.0120 -0.00175 -0.00440 
 (0.0144) (0.0112) (0.0110) (0.00528) (0.00527) (0.0134) (0.0104) (0.00832) (0.00556) (0.00491) 
ln(# of Employees) -0.00195 -0.00147 -0.00243** -0.000562 0.000306 -0.00273** -0.00102 -0.00391*** -0.00115** 0.000160 
 (0.00138) (0.000961) (0.00108) (0.000509) (0.000405) (0.00127) (0.000909) (0.00100) (0.000580) (0.000412) 
ln(R&D) 0.000144 0.000721 -0.000440 0.00103 0.00103** 0.00258** 0.00178** 0.00150 0.00137* 0.000223 
 (0.00134) (0.000891) (0.00124) (0.000745) (0.000415) (0.00118) (0.000808) (0.000971) (0.000729) (0.000537) 
           
Observations 9,885 8,719 8,719 8,719 8,719 12,858 11,499 11,499 11,499 11,499 
R-squared 0.725 0.608 0.703 0.557 0.741 0.580 0.485 0.622 0.453 0.594 
Year FE YES YES YES YES YES YES YES YES YES YES 
Firm FE YES YES YES YES YES YES YES YES YES YES 
 
Note:  
(1). All the drugs studied have their chemical structures in the database.  
(2). Results are reported by using matching estimators. Column 1-5 shows the results estimated by utilizing propensity score matching approach, while coarsened 
exact matching method is used for Column 6-10.  









Table 19 : Drug-level Analysis: AI on Development of Drugs 
 
Panel A: Logit Model (1) (2) (3) (4) (5) (6) (7) (8) 
 From Early Stage to Phase I  From Phase I to Phase II  From Phase II to Phase III  From Phase III to FDA Approval 
         
AI Capability  
(Originator, Early Stage) 
0.203** 0.200** -0.0382 -0.0371 0.0412 0.0443 0.0359 0.0417 
 (0.0844) (0.0857) (0.0591) (0.0592) (0.0430) (0.0431) (0.0705) (0.0714) 
AI Capability (Licensee)  -0.0602  -0.124  -0.0336  -0.0391 
  (0.0915)  (0.222)  (0.161)  (0.244) 
         
Observations 51,056 51,056 30,460 30,460 21,498 21,498 18,611 18,611 
Controls  YES YES YES YES YES YES YES YES 
Year FE YES YES YES YES YES YES YES YES 
Drug FE YES YES YES YES YES YES YES YES 
 
Panel B: Cox Proportional  (1) (2) (3) (4) (5) (6) (7) (8) 
Hazards Model From Early Stage to Phase I From Phase I to Phase II From Phase II to Phase III From Phase III to FDA Approval 
         
AI Capability  
(Originator, Early Stage) 
0.0309*** 0.0311*** -0.00528 -0.00450 -0.0491 -0.0472 0.0128 0.0121 
 (0.00532) (0.00534) (0.00490) (0.00489) (0.0362) (0.0361) (0.0139) (0.0141) 
AI Capability (Licensee)  0.0276  0.0329  -0.0331  -0.0184 
  (0.0236)  (0.0215)  (0.0390)  (0.0160) 
         
Observations 22,867 22,867 20,770 20,770 11,038 11,038 16,901 16,901 
Controls  YES YES YES YES YES YES YES YES 
Drug RE YES YES YES YES YES YES YES YES 
 
Note:  
(1). In Panel A, the dependent variable is the logit of the probability of drugs progressing forward to a later stage of drug development. Odd-numbered columns 
show the results for the impact of originator’s AI capability on the drugs developed at the clinical-trial stage and getting approval at FDA in our fixed effect 
estimations. Even-numbered columns include an additional AI capability of drug licensee.  
(2). In Panel B, the dependent variable is related to the duration of drugs progressing from one stage to the next in the late stage. Odd-numbered columns show 
the results for the impact of originator’s AI capability on the drugs developed at the clinical-trial stage and getting approval at FDA in our estimations with 
random effect. Even-numbered columns include an additional AI capability of drug licensee.  








Table 20 : Drug-level Analysis: AI on Development of Drugs (with Existing Treatments and Known Mechanisms) 
 
 (1) (2) (3) (4) (5) (6) 
 Logit Model Cox Proportional Hazards Model 
       
If Existing Treatment and Mechanism  0.0122 0.0133 0.0174 0.933** 0.702 1.049 
 (0.0434) (0.0492) (0.0445) (0.441) (0.505) (0.991) 
AI Capability (Originator, Early Stage) 0.173** 0.172** 0.170* 0.0303*** 0.0334*** 0.0305*** 
 (0.0860) (0.0863) (0.0876) (0.00534) (0.00845) (0.00535) 
AI Capability (Originator, Early Stage)  
X If Existing Treatment and Mechanism 
0.0709** 0.0718* 0.0701** 0.114** 0.150* 0.109* 
 (0.0334) (0.0371) (0.0335) (0.0576) (0.0906) (0.0590) 
IT Capability (Originator, Early Stage)  -0.0111   0.00370  
  (0.0431)   (0.0255)  
IT Capability (Originator, Early Stage)  
X If Existing Treatment and Mechanism 
 -0.00155   -0.186  
  (0.0361)   (0.306)  
AI Capability (Licensee)   -0.0794   0.0265 
   (0.0992)   (0.0237) 
AI Capability (Licensee)  
X If Existing Treatment and Mechanism 
  0.0181   0.0832 
   (0.0314)   (0.276) 
       
Observations 51,056 51,056 51,056 22,867 22,867 22,867 
Controls YES YES YES YES YES YES 
Drug FE YES YES YES -- -- -- 
Drug RE -- -- -- YES YES YES 
 
Note:  
(1). Column 1-3 shows the results using the logit model where the dependent variable is the logit of the probability of drugs progressing from the early stage to a 
later stage of drug development. Column 4-6 demonstrates the results estimated from the Cox proportional hazards model where the dependent variable is related 
to the duration of drugs progressing from the early stage to the next in the late stage.  








Table 21 : AI on Development of Novel Drugs 
 





























        
AI Capability 0.00255 0.0169*** 0.00274 0.000355 0.00938*** 0.0101*** 0.00119 
 (0.00160) (0.00395) (0.00201) (0.00160) (0.00278) (0.00289) (0.000997) 
ln(Patent Stock) 0.000230 -0.00396 0.00675** 0.00236 -0.00546 -0.00139 0.000762 
 (0.00263) (0.00490) (0.00333) (0.00206) (0.00342) (0.00241) (0.00117) 
Public Status -0.0110 -0.0439** -0.0127 -0.00764 -0.0222** -0.0240** -0.00508 
 (0.0121) (0.0174) (0.0113) (0.00766) (0.0110) (0.0116) (0.00517) 
ln(Firm Age) 0.00957 0.0212** 0.00309 0.00644 0.0218*** 0.00222 0.00135 
 (0.00703) (0.0102) (0.00924) (0.00433) (0.00722) (0.00592) (0.00313) 
ln(# of Employees) 1.8310-5 -0.000283 -0.00209*** -0.000119 -0.000442 -0.000609 -0.000201 
 (0.000774) (0.00102) (0.000749) (0.000381) (0.000690) (0.000559) (0.000268) 
ln(R&D) -0.000111 -0.000406 -0.000369 -0.000556 -0.000613 0.000123 -0.000222 
 (0.000688) (0.000899) (0.000981) (0.000340) (0.000554) (0.000560) (0.000316) 
        
Observations 8,235 8,235 8,235 8,235 8,235 8,235 8,235 
R-squared 0.460 0.761 0.395 0.473 0.655 0.768 0.537 
Year FE YES YES YES YES YES YES YES 
Firm FE YES YES YES YES YES YES YES 
 
Note:  
(1). All the drugs studied have their chemical structures in the database.  
(2). This table shows the fixed effect estimations for the number of drugs with their novelty scores in each detailed range associated with three categories: 
incremental drugs with novelty score between 0 and 0.3, medium-novel drugs with novelty score between 0.3 and 0.7, and highly novel drugs with novelty 
score greater than 0.7. Column 4-7 examines each decile within the range of medium novelty scores.  







Table 22 : AI on Development of Novel Drugs (Alternative Measurement of Novelty) 
 
 (1) (2) (3) 
DV ln(Number of Drugs ln(Number of Drugs ln(Number of Drugs 
 First In Class) Advance In Class) Addition To Class) 
    
AI Capability -0.00270 0.0338** 0.0170 
 (0.00830) (0.0158) (0.0103) 
ln(Patent Stock) 0.00257 0.00189 0.000162 
 (0.00264) (0.00394) (0.00203) 
Public Status 0.0108 -0.000771 -0.00187 
 (0.0103) (0.0154) (0.0122) 
ln(Firm Age) -0.00623 -0.00387 -0.0166* 
 (0.00818) (0.0116) (0.00997) 
ln(# of 
Employees) 
6.8510-5 0.00148 0.000431 
 (0.00119) (0.00173) (0.00211) 
ln(R&D) 0.00117* -5.7610-5 0.000646 
 (0.000604) (0.00156) (0.000674) 
    
Observations 2,261 2,261 2,261 
R-squared 0.185 0.332 0.173 
Year FE YES YES YES 
Firm FE YES YES YES 
 
Note:  
(1). Results are reported by using fixed effect estimations for the number of drugs in each of innovation 
categories, first-in-class, advance-in-class and addition-to-class drug as identified in Lanthier et al. (2013).  












Table 23 : Drug-level Analysis: AI on Development of Novel Drugs 
 
 (1) (2) (3) (4) (5) (6) (7) (8) (9) 
 Drug Novelty Logit Model Cox Proportional Hazards Model 
          
AI Capability (Originator, Early Stage) 0.0103*** 0.257*** 0.173* 0.268*** 0.221** 0.0342*** 0.0242*** 0.0308*** 0.0282*** 
 (0.00317) (0.0930) (0.0999) (0.0953) (0.102) (0.00547) (0.00590) (0.00535) (0.00610) 
If Low Novelty      0.473***   0.515*** 
      (0.182)   (0.182) 
AI Capability (Originator, Early Stage) 
X If Low Novelty 
 -0.111   -0.102 -0.0354   -0.0297 
  (0.101)   (0.102) (0.0227)   (0.0228) 
If Middle Novelty       0.180***  0.207*** 
       (0.0336)  (0.0337) 
AI Capability (Originator, Early Stage) 
X If Middle Novelty 
  0.143*  0.218**  0.0240**  0.0202* 
   (0.0821)  (0.0975)  (0.0113)  (0.0113) 
If High Novelty        -0.0791 -0.0783 
        (0.520) (0.520) 
AI Capability (Originator, Early Stage) 
X If High Novelty 
   -0.217 -0.281*   -0.0372 -0.0477 
    (0.187) (0.145)   (0.0542) (0.0538) 
          
Observations 29,716 51,056 51,056 51,056 51,056 22,867 22,867 22,867 22,867 
Controls YES YES YES YES YES YES YES YES YES 
Drug FE -- YES YES YES YES -- -- -- -- 
Drug RE -- -- -- -- -- YES YES YES YES 
 
Note:  
(1). Column 1 presents the estimation results about the relationship between AI and chemical novelty of drugs. Column 2-5 shows the results using the logit 
model where the dependent variable is the logit of the probability of drugs progressing from the early stage to a later stage of drug development. Column 6-9 
demonstrates the results estimated from the Cox proportional hazards model where the dependent variable is related to the duration of drugs progressing from the 
early stage to the next in the late stage.  
(2). If Low Novelty, If Middle Novelty and If High Novelty are binary variables for three novelty types. For example, If Middle Novelty indicates whether a drug 
has a chemical novelty score between 0.3 and 0.7 or belongs to “advance-in-class” category. If Low Novelty and If High Novelty are defined analogously based 
on chemical novelty scores and innovation categories.  







CHAPTER 4 : ARTIFICIAL INTELLIGENCE, R&D ALLIANCES AND FIRM 
INNOVATION: AN EXPLORATORY ANALYSIS 
“Fundamentally, AI is the science of knowledge--how to represent knowledge and how to 
obtain and use knowledge.” (Nils J. Nilsson, Artificial Intelligence, 1974)39 
4.1 Introduction 
Alliances are a crucial component of a firm’s strategy to achieve competitive 
advantage (Hagedoorn and Schakenraad 1990; Mowery et al. 1996). Such voluntary 
arrangements between firms, which involve exchanging and sharing new information 
(Gulati 1998; Gulati and Singh 1998), have been argued to enable firms to improve their 
innovative competence (Rothaermel and Deeds 2004; Shan et al. 1994). Not surprisingly, 
firms are increasingly relying on R&D-related alliances to innovate in knowledge-
intensive environments (Hagedoorn 2002; Sampson 2007). R&D alliances offer firms 
another channel to exchange information and acquire new knowledge from their 
collaborative partners (Mowery et al. 1996). Firms that reach outside their boundaries can 
thus enlarge their knowledge base for innovation, generally outperforming their peers in 
terms of innovation performance (Henderson and Cockburn 1994; Von Hippel 2007).  
At the same time, the increase in scope and scale of knowledge-access R&D 
partnerships poses a new challenge for firms to organize innovation (Cassiman and 
Veugelers 2006). Firms need to develop complementary technological capabilities to 
tackle the exponential growth in scientific knowledge and information required for 
innovation. Recent advances in artificial intelligence (AI) have shown the promise of 





substantially improving the efficiency of R&D activity and creating a new playbook for 
innovation itself (Cockburn et al. 2018). Collectively, AI is a set of powerful technologies 
and tools with the objective of learning from human intelligence in performing innovative 
tasks. AI has received renewed interests over the past few years, fueled by explosive 
growth in digitization of human knowledge as well as the advancement of computational 
power and analytics. AI can take advantage of the massive information accessed from a 
variety of knowledge sources across multiple domains and settings, and increase a firm’s 
capacity to apply external knowledge to improve its own innovative performance (Cohen 
and Levinthal 1990; Ravichandran and Giura 2019).   
In this study, we explore the value that AI can create in those firms that engage in 
R&D alliances for innovation. We use as our setting the biotechnology and 
pharmaceutical sector, which in recent years has seen the rapid adoption of AI and 
widespread R&D alliances. By collecting and combining a variety of large-scale datasets, 
we empirically examine the complementary relationship between pharmaceutical firms’ 
development of AI capabilities and their engagement in activities with R&D innovation 
partners, as well as the extent to which pharmaceutical firms that have AI capabilities can 
benefit from R&D alliances (Aggarwal and Hsu 2009; Arora and Gambardella 1990; Hill 
and Rothaermel 2003; Lou and Wu 2020). We primarily use patents and job postings for 
employee skills to measure firms’ AI capabilities and then link to their R&D alliances.  
We find that firms with greater AI capabilities engage in more extensive R&D 
alliances and reap greater innovation benefits. When firms participate in R&D alliances, 
firms with AI capabilities are better at exploiting external information derived from their 




by AI and augmented by firms’ R&D alliances. With the recurring cost of developing AI 
capability to transform the way innovation is performed as well as the tacit nature of 
critical knowledge required for breakthrough discovery, innovations at the intermediate 
level of novelty (as opposed to very incremental or highly novel levels of innovation) can 
be best achieved through firms’ investments in AI and R&D alliances. 
This study illuminates the critical role of the complementary relationship between 
a firm’s AI capability and external R&D alliances as a source of innovation: firms with 
stronger AI capabilities can gain more innovation advantages when coupled with R&D 
alliances. AI itself can enable the exploitation of new information accessible from 
external partners in R&D alliances. Driven by digitization of human knowledge as 
underpinnings of innovation, the expansion in sources of knowledge can provide 
immediate benefits for firms to leverage AI for innovation. These findings, however, are 
at odds with recent empirical evidence showing that the rate of innovation has slowed 
despite expectations that increases in accessible knowledge and improvements in 
information technologies (IT) such as AI would accelerate innovation (Bloom et al. 2020; 
Gordon 2017; Ravichandran et al. 2017). As AI becomes more widely deployed in 
practice and R&D alliances proliferate for knowledge acquisition, both of which continue 
to shape the development of innovation, it’s more important than ever to understand their 
relationship and the way they can facilitate the development of innovation.  
This paper makes several contributions to the literature. To the best of our 
knowledge, this is one of the largest empirical studies on how firms’ development of 
technologies and use of alliances affect their innovation performance. It contributes to the 




strategic alliances. Prior research in this area has primarily examined the relationship 
between firms’ IT adoption and innovation without fully considering the role of their 
external alliance activities (Ravichandran et al. 2017; Tambe et al. 2012; Trantopoulos et 
al. 2017) or on IT-enabled alliances without focusing on final innovation outputs (Tafti et 
al. 2013). Perhaps the studies closest to ours are Ravichandran and Giura (2019) and Chi 
et al. (2010). The former examines a collective set of deals and finds that IT is a 
necessary complementary resource that can facilitate knowledge flows among partners in 
alliances. The latter specifically studies pharmaceutical firms and finds that firms can 
develop IT-enabled knowledge capability to harness the external resources of partners to 
increase their own innovation performance. However, both studies overlook the 
heterogeneity in innovation benefits that can be gained through R&D alliances, and AI as 
a new type of IT that is particularly effective with more information drawn from various 
sources of knowledge.  
4.2 Theory and Hypotheses 
It has been well established in prior studies of innovation that alliances are central 
to a firm’s innovation performance. Alliances help firms overcome the organizational 
barriers in search of new knowledge, bringing them closer to sources of knowledge and 
reaching beyond their existing organizational contexts for new ideas and insights that are 
essential for spurring innovation (Powell et al. 1996; Rosenkopf and Almeida 2003; 
Stuart and Podolny 1996). Interfirm linkages and knowledge spillovers resulting from 
broader alliances create more opportunities for participating firms to access external 
information from their partners (Powell 1998). Alliances thus offer a superior channel 




some of the incentive structures of markets for innovation with the monitoring 
capabilities and administrative controls associated with their internal organizational 
capabilities (Mowery et al. 1996). 
Among the many types of alliances, we focus on R&D alliances, as they have 
been growing substantially and have become an essential part of firms’ ability to thrive in  
knowledge-intensive environments (Hagedoorn 2002; Rothaermel and Deeds 2004). The 
alliances involving R&D activities require more intensive sharing and higher transfer of 
knowledge across organizational boundaries (Oxley and Sampson 2004; Sampson 2007), 
and thus the formation of R&D alliances can be particularly crucial as a source of 
innovation for participating firms (Powell et al. 1996; Rosenkopf and Almeida 2003). 
However, with a substantial increase in complexity and interdisciplinarity of 
knowledge stock required for innovation, innovation benefits driven by R&D alliances 
depend on not only the external knowledge acquired from others and but also the focal 
firm’s own technological capability in the alliance (Klueter et al. 2013; Mowery et al. 
1996). While the increase in scope and scale of knowledge-access transactions allows 
firms to tap into more complementary knowledge to enhance their innovation process, 
management of R&D alliances usually yield nontrivial transaction costs (Hoang and 
Rothaermel 2010). Thus, it’s more important than ever for firms to possess a 
complementary capability that can effectively internalize and manage the acquired 
knowledge resources from alliances (Arora and Gambardella 1990; Hoang and 




Information technologies (IT) have been shown to increase a firm’s ability to 
acquire and integrate external knowledge from its alliance collaborators as a precursor for 
subsequent innovation (Liu and Ravichandran 2015). IT can enable R&D-intensive 
innovation processes, and help a firm to receive higher returns on the investments in the 
R&D-related activities (Bardhan et al. 2013; Kleis et al. 2012). In particular, the firm’s 
innovation performance can be enhanced by IT through its efficient management of 
external knowledge and the reduction of costs in external coordination across 
organizational boundaries (Clemons et al. 1993; Hitt 1999; Ravichandran et al. 2017; 
Trantopoulos et al. 2017). As a new type of IT, AI can be even more instrumental and can 
create the potential of strengthening a firm’s innovation process by efficiently gaining 
new insights from massive information produced in R&D alliances. Firm innovation can 
benefit from AI via more information curated from a larger body of knowledge, 
especially through its ability to quickly search the complex knowledge space and 
integrate external knowledge new to the firm (Agrawal et al. 2018; Wu et al. 2019). R&D 
alliances provide a firm with access to larger knowledge pools, opening up new 
knowledge discovery opportunities. AI-based learning approaches can help to automate 
discovery by assimilating and transforming knowledge across multiple disciplines as 
sources of large-scale data to find effective scientific solutions to more effectively 
innovate (Cockburn et al. 2018).  
Thus, we posit that more innovations can be produced when a firm’s AI capability 
and R&D alliances are reinforced by one another. In other words, firms with a higher 
level of AI capability are expected to accrue more innovation benefits during their R&D 




Hypothesis 1: AI and R&D alliances are complementary to generate new innovations.  
Furthermore, it has been documented that with the explosion of the digitization of 
scientific knowledge as well as an increase in availability of abundant data, AI is well 
suited to fostering innovation (Cockburn et al. 2018). For a focal firm, as external 
knowledge continuously adds to its extant knowledge base through its R&D alliances for 
its AI to leverage, it’s not clear what type of innovation can be most empowered by AI 
and R&D alliances, i.e., whether the innovations are incremental, intermediate, or highly 
novel. 
 Highly novel innovation differs substantially from prior innovation, and thus has a 
limited number of data examples or precedents for AI to consume. AI lacks the ability to 
make decisions based on limited knowledge, especially those decisions to innovate 
involving human creativity and insights (Simon 1977). Indeed, innovation efforts in the 
face of limited information draw heavily upon more tacit knowledge, which is more 
challenging for AI to collect, transfer and use (Nonaka and Von Krogh 2009; Szulanski 
1996; Von Hippel 1994). Developing highly novel innovations may also require a deeper 
understanding of a narrow domain driven by “sticky” information where AI may offer 
limited benefits, as opposed to searching across multiple domains with more information 
expanded by R&D alliances (Taylor and Greve 2006; Weisberg 1999). As a result, the 
development of entirely novel innovations may receive limited benefits from firms’ 
development of AI and external R&D alliances.  
 As for more incremental innovations that are close variants of existing ones, we 




capabilities itself is not an easy task: it requires firms to make substantial upfront 
investments in strategic planning, skills, model training, and data curation. It is 
complicated by more information accessed through the firms’ R&D alliances and fed into 
their AI systems. Using AI to conduct knowledge discovery that firms already know how 
to perform well with existing resources would not provide adequate marginal benefits. 
Firms are likely to already possess the know-how to find the derivatives of their own 
innovations (Krieger et al. 2018), and do not necessarily need AI to do so. Consequently, 
we would expect that the marginal benefit of AI is limited for discovering innovation at a 
low, or very incremental, level of novelty. As codifiable knowledge with an information-
like character can be particularly well-articulated (Aggarwal 2020) and easily processed 
using AI to automatically identify new patterns hidden in the knowledge firms are using 
in order to innovate (Lou & Wu 2019), the development of moderately new, or 
intermediate-level, innovations is more likely to be augmented by AI and R&D alliances. 
Hypothesis 2: AI and R&D alliances are particularly conducive to supporting the 
development of innovation at an intermediate level of novelty.  
4.3 Data and Measurement 
Our empirical setting is focused on the global pharmaceutical firms, which have 
been extensively studied in the innovation literature (Hess and Rothaermel 2011; Klueter 
et al. 2013; Rothaermel and Deeds 2004). Focusing on the knowledge-intensive 
biotechnology and pharmaceutical sector where innovation and knowledge management 
are a critical source of a firm’s competitive advantage can help reduce the systematic 




innovation and alliance activities of pharmaceutical firms offer an ideal setting for our 
empirical study for several reasons. First, the development of novel drug products is a 
key task for the firms to achieve innovation success. This task typically involves five 
phases. The first is the discovery and pre-clinical trials stage where drug candidates are 
proposed to address certain biological targets. Human clinical trials in various sizes are 
then undertaken in the next three phases (Phase I, II, and III). Lastly, if the drug is proven 
to be successful, it would gain the FDA’s approval and start a market launch. In 
particular, we focus on the upstream drug innovation process, which involves the 
discovery and pre-clinical trials stage. This part is more inventive, involving broad 
searches of external information and aggregation of an entire body of knowledge for each 
firm to develop novel drug candidates (Eklund 2018; Fleming 2001; Kapoor and Klueter 
2015). It requires a firm to possess the ability to access, acquire and integrate new 
knowledge from a broad spectrum of scientific disciplines such as biochemistry, 
molecular biology, physiology, and pharmacology, to name a few, and from outside its 
boundaries (Henderson and Cockburn 1994).  
Second, the knowledge-rich pharmaceutical industry is characterized by firms’ 
reliance on a wide range of interorganizational activities for the production of new 
innovation. As a larger amount of innovation gain can be derived for firms through 
knowledge seeking, propagation and learning from outside parties, the scope and scale of 
interorganizational collaborations and alliances in the industry have grown rapidly 
(Powell et al. 1996). Pharmaceutical firms increasingly access and exploit new external 
information by engaging in alliances with their R&D partners. R&D-intensive alliances 




technological knowledge for partner firms to enhance their competence in developing 
drugs.  
Third, as developing a typical drug is extremely costly, the pharmaceutical 
industry has fully recognized the importance of improving the efficiency of the drug 
discovery process, and the need to harness the power of new technologies to advance 
R&D activities (DiMasi et al. 2016; Hess and Rothaermel 2011). Artificial intelligence 
has the potential to aid the drug discovery process in novel ways. As knowledge needed 
for discovering drug candidates is becoming more codifiable through the process of 
digitization, new knowledge for developing drug candidates could be inferred and 
produced from the common knowledge representation and interrelated concepts. AI can 
be even more effective with more and richer data collected from various sources of 
knowledge, especially those in a more explicit form (Agrawal et al. 2018). It can be used 
to find hidden and subtle linkages in vast amounts of digital data across a variety of 
disciplines to make predictions about innovation, which would be extremely labor 
intensive or not possible for humans to perform. Furthermore, the underlying new 
patterns from the digitized knowledge can be easily learned by AI itself through 
reviewing massive examples to generate novel insights for developing innovation 
(Agrawal et al. 2018; Wu et al. 2020). Hence, the predictive drug candidates discovered 
from AI could serve as a useful starting point to improve efficiency in the drug 
innovation process.  
For example, with an ultimate goal of developing drugs in silico instead of in the 
lab, Novartis is actively expanding its own AI capability and digital transformation by 




way innovative drugs can be developed.40 It developed Systematic Transformation 
Initiative for Development Excellence (STRIDE),41 a digital infrastructure system that 
manages the digitization of medical records and clinical trials. Predictive analytics would 
then leverage the power of massive digitized knowledge to propose new treatments. In 
the meanwhile, Novartis is also dedicated to nurturing successful collaborative 
partnerships with other biotechnology and pharmaceutical companies to complement its 
drug development pipeline and core innovation capabilities.42  
Start-ups are also leveraging AI and R&D alliances to facilitate drug discovery. 
BenevolentAI, based in the UK, has already created its own AI platform by bringing 
together and analyzing previously disparate data records, ranging from clinical trials and 
patient records to patents and academic publications across a variety of scientific 
disciplines. Deep learning43 has been applied to produce the knowledge graph for 
hypothesis generation and validation, and to infer the interplay between numerous 
biological entities such as genes, proteins, diseases and drug candidates (Fleming 2018), 
which may fundamentally reshape the “idea production function” in drug discovery 
(Cockburn et al. 2018). In addition, BenevolentAI has also entered into strategic 
collaborations with Neuropore Therapies, which is committed to faster evaluation and 
validation of novel molecular targets to accelerate the discovery of new drugs.44 
                                                          
40 https://www.novartis.com/our-focus/data-and-digital/artificial-intelligence/ai-at-novartis 
41 Novartis Seeks Hidden Cures in Machine Learning, AI, https://www.informationweek.com/big-data/big-
data-analytics/novartis-seeks-hidden-cures-in-machine-learning-ai/d/d-id/1332269  
42 https://www.novartis.com/our-company/novartis-partnering 







For our empirical analysis, the timespan of our sample compiled from a number 
of large-scale datasets ranges from 2010 to 2019, a period that witnessed a rapid growth 
in new application orientation of AI as well as a proliferation of contemporary alliance 
activities in the biotechnology and pharmaceutical sector (Cockburn et al. 2018; Lou and 
Wu 2020; WIPO 2019). We first discuss how we measure alliance-related variables, and 
then the measurements pertinent to firm innovation investment and AI capabilities. The 
large-scale datasets we draw upon for our measurements are also discussed.  
R&D Alliances: Data on R&D alliance activities in the biotechnology and 
pharmaceutical industries are mainly collected from the Biosci database (BiosciDB) 
(Edwards 2018).45 The database widely tracks interfirm R&D contracts and agreements, 
and has provided the most comprehensive records of biopharma R&D alliances since the 
early 1980s.46 It gathers deals from multiple sources to ensure the reliability of records 
about interfirm R&D collaborations. As alliance activities are the main focus of our 
study, acquisition events are omitted in our analysis. For each alliance event, we can 
observe the role of each participant. It is classified as either “R&D” company that is 
primarily responsible for the R&D process and knowledge creation for new innovations 
or “client” company that is getting access to novel information and may offer financial 
                                                          
45 https://www.bioscidb.com/. The BiosciDB database is founded by Mark G. Edwards who was also the 
founder of the Recap, a leading database of alliance contracts and agreements widely used for studying 
R&D partnerships in the biotechnology and pharmaceutical industries (Lee et al. 2015). According to 
BiosciDB, there was a period of time where Recap stopped getting the unredacted contracts that are 
available through the Freedom of Information Act (FOIA). As such, we believe BiosciDB offers a broader 
coverage of contemporary alliance events of the pharmaceutical companies. In particular we rely on five 
major sources for the data collection: 1. press releases; 2. contracts filed with the SEC; 3. deal-specific 
corporate presentation slides; 4. deal-specific financial notes in 10-Q and 10-K; 5. unredacted FOIA 
contracts. We thank Inna Shtargot, product manager of BiosciDB as well as Mark G. Edwards for 
answering our questions with respect to data collection, access and analysis.  
46 Compared to some alternative alliance databases such as Securities Data Company (SDC) Platinum 
database on Joint Ventures and Alliances (Schilling 2009), the BiosciDB database offers a much wider 




support and payment for the specific technologies from its R&D collaborators (Aggarwal 
and Hsu 2009; Lee et al. 2015). The R&D company usually provides more basic 
technological knowledge or materials required for developing the fundamental 
technologies for new inventions especially in joint R&D alliance events, whereas the 
client company converts the accessible information from the R&D collaborator to new 
innovation applications (Robinson and Stuart 2007b). This categorization has been well 
defined in both academic and practical analysis of the R&D partnerships in the 
biotechnology and pharmaceutical sector (Edwards 2007; Robinson and Stuart 2007a; 
Robinson and Stuart 2007b). The database also provides information about size of deals 
that is a summation of all upfront, R&D and milestone payments. 
Apart from organizing the alliance records at the transaction level, we aggregate 
them at the firm level for our empirical study. As a firm’s access to information provided 
via partnerships with other firms does not instantaneously affect its innovation 
performance, we examine each firm’s alliance portfolio, and use the stock of alliances 
that a firm participated in, as listed in BiosciDB, since its first alliance event (Klueter et 
al. 2013). We calculate a firm’s alliance stock with an annual depreciation rate of 15%. 47 
In addition, as firms with more prior alliance experience are better at taking advantage of 
alliances to receive more innovation benefits from their partners (Hoang and Rothaermel 
2005; Lee et al. 2015), we also measure alliance experience of each participating firm as 
the total number of alliances that it engaged in from its first alliance up to the current one 
(Ravichandran and Giura 2019).  
                                                          
47 We also perform another set of robustness checks by testing the stock-based variable without 
depreciation, as well as the four-year stock of R&D alliances used in Klueter et al. (2013). Our results 




Drug Innovation: The primary goal of the pharmaceutical industry is to develop new 
drugs. Innovating new drugs requires tremendous R&D investment. The innovation 
process is clearly defined and can be separated in two stages: in the upstream stage firms 
make efforts towards creating new knowledge; in the downstream stage firms’ efforts 
move towards commercialization of the new knowledge (Kapoor and Klueter 2015). Our 
study is thus focused on the upstream discovery and pre-clinical trials stage of the process 
as it intensively builds on firms’ internal R&D capabilities and also external R&D 
alliances in developing innovative drugs.     
 Our datasets about drug discovery are collected from two sources: the Informa 
Pharmaprojects database and the investigational drug database from Clarivate Analytics. 
The databases have been extensively used in the empirical study of global pharmaceutical 
firms and linked to their partnership activities (Eklund 2018; Hess and Rothaermel 2011; 
Kapoor and Klueter 2015; Klueter et al. 2013; Krieger et al. 2018; Sosa 2013). The 
databases track each stage of the drug innovation process, from the compound discovery 
and pre-clinical stage to the worldwide market launch. Thus, we can observe each firm’s 
drug portfolio, and count the drug candidates developed before clinical trials to measure 
pharmaceutical firms’ effort in creating new knowledge and inventions for developing 
new drugs. We notice that ownership of a drug candidate can be changed through 
mergers and acquisitions (M&A). Thereby, we resort to various sources of datasets 
including SDC Platinum data and Zephyr database from Bureau van Dijk to take into 
consideration the transfer of drug patents and the associated rights and ensure that drugs 





Since discovering drugs with novel chemical properties is critical for firms in 
outperforming their competitors, we examine the chemical novelty of a drug discovered 
at the early stage of the innovation process, which will progress into later stages. This 
measurement can often be a good proxy for drug therapeutic impact afterwards, and has 
been tested to influence drug risks and revenues (Krieger et al. 2018).  
Collectively, we measure the novelty of 13,699 drugs based on their chemical 
structure48 by employing advanced computational methods from the chemical informatics 
literature (Backman et al. 2011; Cao et al. 2008). To do so, we first compute the 
similarities of each pair of molecules for drug candidates in our databases. For each focal 
drug candidate at its initial development stage, we measure its drug similarity by 
comparing its chemical adjacency with all of its previously developed drugs (Krieger et 
al 2018).49 In particular, we rely on the simplified molecular-input line-entry system 
(SMILES) code for each drug, which is a chemical notation language mainly designed for 
digital processing (Weininger 1988). It allows for rigorous structure specification and 
encodes chemical structures as short ASCII strings, with each component used to 
describe and identify atoms, bonds, rings, and other compound shapes. We convert the 
SMILES codes of drugs to their graph representations and use the graphs to compute 
pairwise similarity scores (Backman et al. 2011; Cao et al. 2008). The pairwise similarity 
                                                          
48 The information is missing for large molecule drugs (known as biologics) that require a more 
complicated synthesis of substances needed for their manufacturing. Those drugs for which chemical 
structures are available generally belong to the class of small molecule drugs produced by chemical 
synthesis. Small molecule drugs are of crucial importance to the pharmaceutical industry, making up over 
80% of the drug market and serving as the basis for drug development (Krieger et al. 2018; Otto et al. 
2018). We also draw on the “Similarity Property Principle,” a central concept in chemistry, that states that 
structurally similar molecules should also have similar physicochemical properties and biological activities 
(Johnson and Wiley-Interscience 1991). 
49 We also restrict the previous drugs to be within a certain time range so that our novelty score is not 
automatically decreasing for irrelevant structural reasons as the base of comparison becomes larger over 




score between any drugs, X and Y, is then measured topologically by the “Tanimoto 
coefficient,” which is the ratio of the atoms in the maximum common substructure 
(MCS) that appears in both X and Y and all unique atoms that appear in either X or Y50 
(Cao et al. 2008; Krieger et al. 2018; Nikolova and Jaworska 2003): 
𝑆𝑖𝑚𝑖𝑙𝑎𝑟𝑖𝑡𝑦𝑋,𝑌 =  
𝑁𝑋&𝑌
𝑁𝑋+ 𝑁𝑌− 𝑁𝑋&𝑌
 ,  (1) 
where 𝑁𝑋 and 𝑁𝑌 are the total number of atoms in the chemical structure of drug X and 
drug Y, respectively, and 𝑁𝑋&𝑌 is the total number of atoms in Maximum Common 
Substructure (MCS) that appear in both drugs X and Y. Hence, a similarity score of zero 
suggests that the two drugs have no identical components. A similarity score of 1 
indicates that they have the same set of atoms and bonding, though it does not imply that 
the two molecules are identical because MCS does not take into account the orientation in 
space for each drug molecule.51 Although these very similar drugs may have different 
chemical properties, on average, they are still much more similar to each other than with 
other drug molecules. In addition, it’s likely that the similarity in molecular structure 
can’t precisely predict functional properties. However, the chemical informatics research 
has shown on average that molecular similarity can be a good proxy for capturing a 
substantial variation in the degree of drug novelty by quantitatively documenting certain 
properties of chemical compounds without needing further medical examinations on 
humans or animals (Wawer et al. 2014).  
                                                          
50 Conventionally the calculation includes all non-hydrogen atoms. 




Once all pairwise drug similarity scores are calculated, we compute the novelty 
score for each drug candidate using its maximum similarity score to all previously 
developed drug candidates. For the identification of a set of previously developed drugs, 
we use the time when they were first initiated the development. Therefore, as the novelty 
measure is based on the ex-ante chemical structure at the earliest development stage, the 
measure does not conflate with an ex-post measure of success such as in receiving FDA 
priority or being the first in the market to treat a rare disease. As the pairwise similarity 
score is between 0 and 1, we define the novelty of drug i as: 
𝐷𝑟𝑢𝑔 𝑁𝑜𝑣𝑒𝑙𝑡𝑦𝑖 = 1 − max
𝑗∈𝑃𝑖
𝑆𝑖𝑚𝑖𝑙𝑎𝑟𝑖𝑡𝑦𝑖,𝑗,  (2) 
where 𝑃𝑖 is all drug candidates that developed prior to the initial development of the focal 
drug i and entered at least the Phase I stage of clinical trials (Krieger et al. 2018). Thus, a 
drug candidate with a higher novelty score should have a lower maximum similarity 
score with its precedents and possess a molecular structure that is more distinct from its 
previous drug candidates.52 Figure 3 plots the distribution of the drug novelty scores, 
consistent with what is shown in Krieger et al. (2018). To measure drug novelty at the 
firm level, we compute the total number of drugs within a set of novelty ranges for each 
firm in a particular year. We do not use the average of novelty scores of a firm’s drugs in 
our study because some firms may not have developed any drugs in a specific year.  
                                                          
52 Krieger et al. (2018) discuss several limitations to the Tanimoto similarity metric. We have no perfect 
structural and functional correspondence. The research literature in chemical informatics has studied this 
problem and shown that the Tanimoto similarity score is still useful for measuring drug quality and novelty. 
In addition, despite the broad coverage of drug information in our databases, it is possible that we may still 
miss drugs at the earliest stage of development that are not recorded in the database. We address this issue 
by using year fixed effect estimations in our firm-level regression analyses. We also test alternative 
measures for the novelty of a given drug by comparing it to early drug candidates that reached at least 




Patent Stock: Patents play a unique role as a stimulus for developing new drugs. 
Pharmaceutical firms undertake substantive patenting activities for their new drugs 
because patents are the most effective way to protect their drug innovation from 
imitations and substitutions (Abrams and Sampat 2017; Cohen et al. 2000; Hemphill and 
Sampat 2011; Levin et al. 1987), and prevent firms from freeloading and underinvesting 
in creating new inventions, and associated R&D activities (Gilchrist 2016). As 
pharmaceuticals represent one of the few notable high-patenting industry sectors, we can 
use patents to measure a firm’s investment in R&D in drugs.  
We use global patents from a worldwide patent statistical database, PATSTAT, 
created by the European Patent Office (EPO).53 PATSTAT offers bibliographical data for 
over 100 million patents from 90 patent-issuing authorities from both leading 
industrialized and developing countries going back as far as the nineteenth century. It 
provides patent records with rich information that contains patent application year, patent 
technology classes as defined by the International Patent Classification (IPC) or 
Cooperative Patent Classification (CPC) systems, citations, title, abstract, and legal 
entities (e.g., firms or any organizations) filing the patent application. The identity of 
each patent owner has been identified: whether the patent owner is a business enterprise, 
higher education institution, governmental agency or individual (Du Plessis et al. 2009). 
The database also provides comprehensive standardization of the original name of 
                                                          
53 We leverage the PATSTAT data in the version 2017b to cover patent records up to 2017. As Google 
launched its public datasets of worldwide patents on BigQuery in 2017 
(https://cloud.google.com/blog/products/gcp/google-patents-public-datasets-connecting-public-paid-and-
private-patent-data), we further augment our patent data to cover the recent time period from 2017 to 2019 
by using global patents through Google Patents Public Datasets. We adopt similar approaches to match 




patentees (Magerman et al. 2006). These global patents serve as critical indicators of 
innovation activities for all companies in the world.  
To examine patent activities of firms in the pharmaceutical industry, we first 
match the firm names from our drug database to patent assignees in global patent 
databases. Taking into account the merger and acquisition activities of firms in the 
biotechnology and pharmaceutical sector from SDC Platinum and the Zephyr database 
from Bureau Van Dijk, we adjust the assignee names of patents accordingly in order to 
represent the original company filing the patent. For each matched pharmaceutical firm, 
we also acquire patent filing years, IPC-based technology classifications, titles, abstracts, 
and citations for its patents. By and large we use the patent filing year (as opposed to the 
publication year) because it more closely approximates the time when the firm produced 
and had the innovation described in the patent available (Griliches et al. 1986; Hall et al. 
2005). The accumulated stock of patent applications that the firm has applied, with an 
annual depreciation rate of 15%,54 is used to measure a pharmaceutical firm’s general 
investment in patent inventions for its drug innovations (Aggarwal and Hsu 2013; Hall 
1990).  
Knowledge Flows and Technological Overlap: R&D alliances serve as effective 
conduits through which information can flow to the focal firm from its partner. In our 
pharmaceutical context, we can examine the extent to which knowledge can be leveraged 
by client firms and accessed from their R&D partners. As R&D alliances largely rely on 
                                                          
54 To measure patent stock we apply a standard perpetual inventory equation with declining balance 
depreciation (Hall 1990):  𝑃𝑡 = (1 − 𝛿)𝑃𝑡−1 + 𝑅𝑡, where 𝑃𝑡 is the end-of-period patent stock and 𝑅𝑡 is the 





the knowledge base of partnering firms and their patenting activities, recent studies have 
used patent citation data to capture the changes in the citation patterns of client firms to 
their R&D partners before and after their alliance events in order to trace the knowledge 
flow through which the creation of new knowledge of a firm, embodied by patent stock, 
can be influenced by that of its partners (Almeida et al. 2002; Mowery et al. 1996; Oxley 
and Wada 2009; Ravichandran and Giura 2019). Thus, for each focal client 
pharmaceutical firm in an R&D alliance, its knowledge flow is calculated as the 
difference between its post-alliance citations to its partner firm and pre-alliance ones. As 
the pharmaceutical firms present high-patenting activities, we compute the number of 
partner patent citations two years before the deal for pre-alliance citations, and the 
number of partner patent citations two years after the deal for post-alliance citations.55 
For example, if a client company in the pharmaceutical industry enters into an alliance in 
2014, we analyze its patents that have cited its partner firm participating in the alliance. 
The pre-alliance partner patent citations are thus calculated as total number of citations to 
the partner in patents applied for in 2012 and 2013, while the post-alliance partner patent 
citations are calculated as the number of citations to the partner in patents applied for in 
2015 and 2016. We take the difference between its partner firm citations after the alliance 
and partner firm citations before the alliance to arrive at the knowledge flow to the client 
firm. Since the client firm can access and acquire new information from its allied R&D 
partners, we would expect a higher rate of citation of its partner firm’s patents in the new 
patents applied for by the client firm (Oxley and Wada 2009). Note that patents are by 
                                                          
55 Using other years’ lags such as one-year and three-year lags produces similar estimation results in our 




definition examples of codified knowledge, so we can use patent citations to proxy the 
flow of explicit information through alliances (Mowery et al. 1996).  
Furthermore, we use patent technology classes to measure “technological 
overlap” between participants in each deal, based on their patents applied for in the five 
years prior to their alliance announcement year. As a firm’s patent technology classes are 
important indications of its areas of technological expertise, following the method 
developed in Jaffe (1986), for each deal, we use the angular separation of the patent 
technology class distribution vectors (Fi, Fj) of the partner firms (firm i and firm j), which 
are defined over International Patent Classification (IPC) System-based technology 
classes (Oxley and Wada 2009). This measure can capture the proximity of technological 
knowledge between firm i and firm j, and allow us to understand the extent to which a 
client firm is familiar with its alliance partner’s knowledge in various technological areas.  
More precisely, we use 𝐹𝑖
𝑐 to represent the number of patents assigned to firm i in 
technology class c. Thus, we can represent the patent class distribution vector for firm i 
as 𝐹𝑖 = (𝐹𝑖
1, … , 𝐹𝑖
𝑐), and similarly, use 𝐹𝑗 = (𝐹𝑗
1, … , 𝐹𝑗
𝑐) for firm j ’s patent class 
distribution vector. The technological overlap between firm i and firm j is calculated as: 








.  (3) 
Artificial Intelligence (AI) Capability: AI capability of each pharmaceutical firm is 
measured through all of its patents and skill demands in AI from job postings. Patents 
(both drug patents and other types) can directly gauge the ability of a firm to generate AI-




firm. For a comprehensive measurement of AI capabilities we investigate a wide range of 
concepts, definitions, and fundamentals that support AI, subfields within AI and 
applications of AI in a variety of problem domains (Cockburn et al. 2018; Vamathevan et 
al. 2019; WIPO 2019; Yao et al. 2010). 
As pharmaceutical firms have strong incentives to patent all molecules or active 
ingredients that could potentially have pharmacological value (Krieger et al. 2018), 
patents are thus a good proxy to measure a firm’s AI capability in developing drugs. We 
use three steps to identify whether a patent uses or contributes to AI technologies. We 
start with the latest International Patent Classification (IPC) or Cooperative Patent 
Classification (CPC), which is linked to patents. The United States Patent and Trademark 
Office (USPTO) provides a clear patent class relating to the raw technical component of 
AI. Class 706 for “Data Processing – Artificial Intelligence” consists of a large set of 
subclasses including “machine learning” and “neural network”. We therefore apply the 
IPC or CPC concordance for this class to obtain the classification code that is used for 
classifying global AI patents. However, the narrow scope of AI classification codes may 
miss patents that employ AI to solve problems in other domains without contributing to 
the fundamental advances in AI. In response to this, we expand the scope of collections 
for AI patents beyond what is classified by the patent offices, leveraging the content-
based information available in our patent documents. We construct a comprehensive list 
of validated words and phrases pertaining to AI and search for these terms in both the 
titles and abstracts of our patents. Specifically, Cockburn et al. (2018) define three 
interrelated technological subfields within AI to characterize the evolution of 




accepted Association of Computing Machinery (ACM) Computing Classification System 
(CCS), which accounts for the dynamic change of AI technologies (WIPO 2019). This 
method has been used for over 50 years to organize the concept and trends of 
technologies, and can significantly resolve the lack of consensus on AI categorizations 
and avoid subjective classifications. We use three major hierarchies in CCS that 
developed AI-related phrases for classification: (i) the “artificial intelligence” hierarchy 
that is comprised of AI functional applications such as natural language processing, 
computer vision, knowledge representation and reasoning, simulation of human cognitive 
tasks, and AI techniques used to realize those functions; (ii) a “machine learning” 
hierarchy that unveils numerous learning-based AI techniques; and (iii) a “life and 
medical sciences” hierarchy under the “applied computing” category that covers activities 
concerning intelligent computing for producing medicines. Furthermore, our vocabulary 
list also contains phrases related to a variety of AI technologies from outside vendors for 
drug development. Those well-known off-the-shelf AI tools and systems such as PyTorch 
and TensorFlow are included for our textual analysis (Raymond et al. 2019). We also test 
on several variants of these keywords in our dictionary, but they do not qualitatively 
change the classifications of AI patents. 
Similar to the influence of firms’ alliance activities related to the drug 
development process, the contributions of AI to drug development are also not 
instantaneous, so we track the development of AI over years and use the accumulated 
stock of AI patents that the firm has applied for, with 15% per year for the depreciation 
rate (Hall 1990). Our stock-based variables align with the spirit of the standard 




the existing repertoire of knowledge and research resources dedicated to the production 
of new knowledge (Jones 2005; Romer 1990), which is beneficial for the estimation of 
their effect on the upstream of drug development with a particular focus on knowledge 
creation.  
Additionally, in order to measure skill demands in AI, we use a large-scale job 
posting dataset from a leading analytics company that collects the data from over 40,000 
online job boards worldwide (Alekseeva et al. 2019). The specific needs of 
pharmaceutical firms for AI skills can complement our AI patent metric since some AI-
related capabilities critical to drug development are not patented. Both the skill 
requirements and job titles listed in each of the job postings are scrutinized for our 
classifications. Similar to how we classify AI patents, we search for AI-related words in 
skills in each job posting as used in patents to identify AI skills of employees in each 
pharmaceutical firm in our sample. The job title classification from O*NET is also 
applied to identify AI-related positions, similar to the way IT or analytics labor is 
identified in prior research studies (Tambe and Hitt 2012; Wu et al. 2020). We identify 
job titles listed with AI-related skills, and thus view anyone with AI-related job titles as 
possessing AI skills. Individual-level skills can then be aggregated at the firm level. In 
the process of aggregation, firm- and occupation-specific factors pertinent to the 
likelihood of posting for a job are assumed to be uncorrelated.56 Hence, we can use ’j 
=xj /Lj to estimate our firm-level sample rate, where xj is the total number of employees 
across all occupations obtained from all job postings for firm j, and Lj is the total number 
                                                          
56 As such matchings may vary systematically across firms, we can address this issue by using estimation 




of employees for firm j reported in the Crunchbase, PitchBook or Bureau van Dijk Orbis 
databases. Lastly, we estimate AI skills at firm j by scaling the number of AI employees 
found in-sample at firm j by the sampling rate 𝜃𝑗′. Thus, AI capability in a firm can be 
computed by standardizing each AI-related dimension and adding them together.57 
AI capability = std(std(AI patents) + std(AI skills)).  (4) 
Control Variables: Three databases—Crunchbase, PitchBook and Bureau van Dijk 
Orbis—are mainly used to retrieve other firm characteristics such as firm ownership 
status, firm age, workforce size and R&D expenses. The databases provide a wide 
coverage of both public and private global pharmaceutical firms. First, we account for a 
firm’s financial ownership status over years (variable Public Status = 1 when the firm is 
publicly held, otherwise Public Status = 0), which has been shown to influence 
organizational innovation outcomes (Aggarwal and Hsu 2013). Next, we control for firm 
age, which is the difference between the observation year and the founding year of each 
firm in our sample. The founding year of each firm is acquired from BioCentury BCIQ 
data, as well as EDGAR, Moody’s, Renaissance Capital and Thomson Financial 
Securities Data. We also take into account the employee size of each firm, which usually 
acts as an indicator of a firm’s investment and experience in drug innovation. This also 
helps us adjust the scaling rate of AI skills found in our sample. Lastly, information about 
firms’ R&D expenses is collected from multiple data sources, including Compustat 
Global and BioCentury BCIQ database, in addition to the Bureau van Dijk Orbis database 
that we primarily rely on for our empirical analysis.  
                                                          
57 The results are similar when the first principle component of AI patents and AI skills is taken to measure 




4.4 Empirical Strategy and Identification 
In total, our final sample is comprised of 614 firms in the biotechnology and 
pharmaceutical sector (185 firms with AI capabilities) that engaged in over 3,000 deals 
related to R&D activities for drug innovation between 2010 and 2019. Our empirical 
analysis is undertaken at both firm level and deal level to systematically measure the 
effect of firms’ AI capabilities and R&D alliance events on their innovation performance.  
Firm-level Analysis: To examine the degree of complementarity between firms’ AI 
capabilities and participation of R&D alliances, we first perform correlation tests with 
estimations in the form of conditional correlations as shown in Equation 5. If two 
corporate practices are complements, we would anticipate these practices tend to cluster: 
firms with one practice are more likely to have the other (Arora and Gambardella 1990; 
Brynjolfsson and Milgrom 2013). AI as a new type of IT can lower the “cost” of 
participating in R&D alliances and raise the benefit of exploiting information obtained 
from the alliances. Thus, there should be positive correlations among pharmaceutical 
firms’ adoption of AI and engagement in alliances: Firms’ increased use of AI should be 
associated with larger alliance portfolios for accessing external information provided by 
alliance partners. This can be reflected through β1 in Equation 5.  
𝐴𝑙𝑙𝑖𝑎𝑛𝑐𝑒𝑠𝑖𝑡 = β0 + β1 𝐴𝐼 𝐶𝑎𝑝𝑎𝑏𝑖𝑙𝑖𝑡𝑦𝑖𝑡 + +𝐶𝑜𝑛𝑡𝑟𝑜𝑙𝑠𝑖𝑡 + 𝑦𝑡 + 𝛾𝑖 +  𝜖𝑖𝑡 .  (5) 
Though the correlation test is straightforward and can provide the greatest power 
when firms are optimally matching complementary practices, it is more sensitive to 
potential bias resulted from unobserved heterogeneity in the costs or benefits of changing 




method to mitigate the bias is to undertake complementarity tests by examining 
performance differences between individual firms that can be driven by the adoption of 
potentially complementary practices. Therefore, we directly tie the interaction of 
pharmaceutical firms’ AI capabilities and alliance activities to their innovation 
performance measured by number of drug candidates in development in a particular year, 
as shown in Equation 6. 
ln(𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝐷𝑟𝑢𝑔𝑠)𝑖𝑡 = β0 +  β1 𝐴𝐼 𝐶𝑎𝑝𝑎𝑏𝑖𝑙𝑖𝑡𝑦𝑖𝑡 +  β2 𝐴𝑙𝑙𝑖𝑎𝑛𝑐𝑒𝑠𝑖𝑡 
+  β3 𝐴𝐼 𝐶𝑎𝑝𝑎𝑏𝑖𝑙𝑖𝑡𝑦 × 𝐴𝑙𝑙𝑖𝑎𝑛𝑐𝑒𝑠𝑖𝑡 + 𝐶𝑜𝑛𝑡𝑟𝑜𝑙𝑠𝑖𝑡 + 𝑦𝑡 + 𝛾𝑖 +  𝜖𝑖𝑡 .  (6) 
The coefficient of interest is β3 for the interaction term added in the performance 
test as shown in Equation 6. In estimating the models, we also incorporate a set of time-
varying firm-specific characteristics such as patent stock, ownership status, firm age, 
workforce size and R&D spending as additional controls. Firm fixed effects (𝛾𝑖) are 
controlled, as they can give rise to a large fraction of the variances in pharmaceutical 
firms’ innovation productivity (Henderson and Cockburn 1994). Year fixed effects (𝑦𝑡) 
are also added in our firm-level analysis because there can be substantial variations in 
propensity of developing drugs across time and those temporal shocks can also be 
controlled accordingly. Besides accounting for the total number of drugs with molecular 
structures developed within the discovery and pre-clinical trial stage, we also examine the 
extent to which the novel drugs can be developed by firms with AI capabilities coupled 
with alliances with external partners. We calculate the number of drugs in three novelty 
categories—very incremental, intermediate and highly novel drugs—and estimate 




As optimal match of concurrent organizational practices is key to examining 
complementarity, we believe the complementarity tests by themselves can be immune to 
some type of endogeneity problems (Wu et al. 2020). Consistent estimation results 
derived from both correlation tests and performance tests can lend us more confidence to 
claim that the results are not subject to econometric issues. However, there are two 
endogenous factors that may further result in upward bias in our estimates.  
First, reverse causality may occur when firms with greater slack resources are 
more likely to devote more technology investments for innovation. To address this 
concern, we harness an instrumental variable approach and use neighboring firms (firms 
that cite each other in patents)’ AI capabilities to instrument for one’s own AI capability. 
We first construct the patent citation network for each client pharmaceutical firm in our 
sample in which each node is a firm, and each link is the aggregate patent citations. For 
example, if firm A cited firm B’s patents 3 times in the current year, a directed link 
between A and its direct neighboring firm B would have a weight of 3. For a focal client 
firm’s AI capability, we use total number of neighboring firms with AI capabilities as an 
instrument. Two variations of this instrument are also derived for our analysis: (i) the 
average number of AI patents and (ii) the average ratio of AI patents in the neighboring 
firms. Firms cited by our focal client pharmaceutical firms are not necessarily 
competitors as they vary substantially in what industries and geographical locations they 
are in. This should shield them from common industry or region-specific shocks that may 
render the instruments invalid. 
Second, we also address the possible endogeneity issue of the R&D alliances in 




firm, we follow the idea of using lagged values of its partner firms’ resources and 
investments as instruments for its alliances (Tafti et al. 2013), and mainly use two-year 
lagged changes in total patent stock and employee size of its partner firms in alliances.  
Deal-level Analysis: Our firm-level analysis can be undertaken to uncover the innovation 
benefits manifested in the presence of AI and R&D alliances. But it’s not well understood 
how AI can promote innovation through R&D alliances. Thus, we parse all the deals for 
alliances associated with firms’ innovation activities to examine the underlying 
mechanisms. Specifically, we examine interfirm knowledge flows in every alliance. AI-
powered systems can provide advanced infrastructure to enhance the way knowledge is 
accessed, transferred and applied from dispersed sources, and thereby build on the 
external knowledge to enable the creation of new knowledge. The codified knowledge, 
which can often be described as information or data, can be particularly amenable for AI 
to process and realize the full potential of knowledge transfer. It is in a more explicit 
form and easier to be integrated with the existing knowledge base (Nonaka and Takeuchi 
1995). The expanded set of knowledge can thus be fed into AI-based models, becoming 
the basis to drive future innovation development.  
Therefore, in our analysis at the deal level, in Equation 7, for each focal client 
pharmaceutical firm engaged in an R&D alliance i, we link its knowledge flows from its 
R&D partners with its AI capability, controlling for its technological overlap with partner 
firms, prior alliance experience and relevant firm characteristics as described in the firm-
level analysis. We also examine how AI can enhance the capability of knowledge access 
and exploitation on the basis of the knowledge stock of participating firms in each 




Knowledge flows can also be viewed as a process through which one firm is impacted by 
the knowledge of its partner firm in an alliance (Argote and Ingram 2000). A larger 
existing knowledge stock can offer more opportunities for knowledge processing and 
thus inflows to the client pharmaceutical firm from its R&D partners, broadening the 
scope for complementarity to exploit (Cassiman and Veugelers 2002; Cassiman and 
Veugelers 2006; Ravichandran and Giura 2019). Our interfirm knowledge flow 
measurement draws on citation patterns in a client pharmaceutical firm's patent portfolio, 
which capture the changes in the relationship of its knowledge portfolio to that of its 
allied firm (Mowery et al. 1996).  Alliance knowledge stock is measured as total number 
of patents partnering firms applied for within a five-year window before their alliance. To 
account for the varying propensity of patenting activities across time, the year when the 
alliance is announced (𝑦𝑡) is also controlled in our analysis (Ravichandran and Giura 
2019).  
ln(𝐾𝑛𝑜𝑤𝑙𝑒𝑑𝑔𝑒 𝐹𝑙𝑜𝑤𝑠)𝑖𝑡 = β0 + β1 𝐴𝐼 𝐶𝑎𝑝𝑎𝑏𝑖𝑙𝑖𝑡𝑦𝑖𝑡 +  β2 𝐴𝑙𝑙𝑖𝑎𝑛𝑐𝑒 𝐾𝑛𝑜𝑤𝑙𝑒𝑑𝑔𝑒 𝑆𝑡𝑜𝑐𝑘𝑖𝑡 +
 β3 𝐴𝐼 𝐶𝑎𝑝𝑎𝑏𝑖𝑙𝑖𝑡𝑦𝑖𝑡  ×  𝐴𝑙𝑙𝑖𝑎𝑛𝑐𝑒 𝐾𝑛𝑜𝑤𝑙𝑒𝑑𝑔𝑒 𝑆𝑡𝑜𝑐𝑘𝑖𝑡 + 𝐶𝑜𝑛𝑡𝑟𝑜𝑙𝑠𝑖𝑡 + 𝑦𝑡 + 𝜖𝑖𝑡 .  (7) 
As deal size sums up R&D and milestone payments for the technological 
knowledge of R&D partners from client pharmaceutical firms, we also explore whether 
AI can enhance value creation through alliances. Firms with advanced technological 
capabilities may conduct substantial investment in external R&D alliances for new 
knowledge that can be used to enhance their innovation performance. 





Table 24 displays model-free summary statistics and bivariate correlations among 
our variables. On average firms in our sample own about a stock of three alliances with 
external partners.  
Firm-level Analysis: Table 25 shows the results from the correlation test for 
complementary relationship between AI capability and external alliances of each 
pharmaceutical firm in our sample. We estimate a model with firm and year fixed effects 
(Column 1 in Table 25), and then also control for financial ownership status, age, number 
of employees and R&D expenditure (Column 2 in Table 25). On average, a one-standard-
deviation increase in a firm’s AI capability is associated with about 0.2 additional 
alliances (p<0.01). These results suggest that firms with greater AI capabilities are more 
likely to enter into an alliance or have an additional active alliance. AI and alliances can 
be complements as observed in our sample.  
Next, we perform performance tests to examine whether increasing innovation 
benefits of investments in AI can be manifested in the presence of increasing levels of 
R&D alliances. We find that on average, other factors held constant, while a 
pharmaceutical firm’s AI capability per se is positively related to its number of drugs 
developed in a year, its interaction with alliance activities can lead to an additional 
increase in drug innovation. The interaction term implies that a one-standard-deviation 
increase in AI capability is associated with about 5.35% (p<0.05) increase in innovation 
productivity in pharmaceutical firms that are one-standard-deviation above the mean in 




results that there is a positive effect of interaction between AI capabilities and R&D 
alliances on the number of new drug candidates a firm develops. The associated F-
statistics at first estimation stage pass the weak instrument test. Overall our empirical 
results show support for Hypothesis 1.  
Moreover, we consider the chemical novelty of drugs and examine how they can 
be influenced by firms’ AI capabilities and R&D alliances. Recall that we categorize 
novelty as either incremental, intermediate, or highly novel. We find that all else being 
equal, while AI and R&D alliances have no effect on incremental drugs with novelty 
between 0 and 0.3 or those drugs at the highly novel end of the spectrum (novelty 
between 0.7 and 1), their interactions are positively associated with intermediate novel 
drugs, whose novelty scores fall into the range between 0.3 and 0.7, at 5% significance 
level (Column 3 in Table 26 and Table 27). Collectively, our results suggest innovation at 
the intermediate (or middle) range of novelty can benefit more from adoption of AI and 
participation in R&D alliances.  
Viewing these results as a whole can also help us mitigate certain simple 
scenarios of selection biases (Lou and Wu 2020; Wu et al. 2020). It is hard to envision a 
specific condition under which AI selectively complement external R&D alliances for 
exploitation of new information, which only contributes to discovery of drugs at the 
intermediate level of novelty. 
Then we probe into the mechanisms through which AI can take advantage of 




Deal-level Analysis: We find that on average a one-standard-deviation increase in a client 
pharmaceutical firm’s AI capabilities is associated with about 0.1% increase in its 
knowledge inflows as captured by the difference in post-alliance and pre-alliance patent 
citations to its partners, with or without additional controls for other firm characteristics 
as used in our analysis at the firm level (Column 1 and 2 in Table 28). These results 
suggest that AI can enhance the receptivity to accessing external knowledge and can 
benefit the exploitation of new knowledge to develop innovation.  
As knowledge flow is contingent on the knowledge stocks of firms in their 
alliances, we then examine whether AI can improve a firm’s ability to exploit information 
from within and outside its boundaries (Argote and Ingram 2000). While we consistently 
find AI can facilitate the exploitation of external information to client pharmaceutical 
firms, these firms can experience a significantly higher boost in knowledge processing 
from the interaction between AI and total knowledge stock of allied firms (Column 3 in 
Table 28). Firms can either draw on their own knowledge base or use the knowledge 
from their partners external to them, so we further break down the total alliance 
knowledge stock and examine the knowledge stock of focal client firms and that of their 
partners. We find that there is a much stronger interaction effect of AI and the knowledge 
stock of partner firms than that of AI and the knowledge stock of focal client firms. This 
result suggests that knowledge transfer is primarily driven by the capability of AI to 
apply external knowledge accessed from focal firms’ partners, which can be used as a 
future basis for innovation development (Column 4 in Table 28).  
We also utilize size of deals available in our dataset as a dependent variable to 




shows that on average a firm’s AI capability is positively associated with the deal values, 
suggesting that those AI firms conducted substantial investment in external R&D 
alliances to acquire and exploit essential knowledge to improve their development of 
innovation.  
In addition, we note that across all of our deal-level analyses, we control for 
technological overlap between firms in their alliances. Consistent with findings in 
Ravichandran and Giura (2019), the coefficient of technological overlap is persistently 
positive and statistically significant (p<0.01) in our estimations. This suggests that it can 
be more effective for the client firm to access and synthesize new knowledge in some 
discipline it is familiar with than that in areas the firm is unfamiliar with (Inkpen 1998; 
Ravichandran and Giura 2019).  
4.6 Concluding Remarks 
By examining innovation activities of pharmaceutical firms on a large scale, this 
study establishes the complementarity between their AI capabilities and external R&D 
alliances as a key determinant of variations in innovation performance. Firms need to 
develop AI to better capitalize on information provided by R&D alliances (Ravichandran 
and Giura 2019). R&D alliances can allow firms with greater AI capabilities to gain 
immediate access to and exploit a larger set of knowledge for innovation. The “received 
wisdom” can be particularly helpful in facilitating innovation at the intermediate level of 
novelty (Lou and Wu 2020; Mowery et al. 1996), as opposed to the very incremental or 
highly novel innovation. In the longer term, those pharmaceutical firms without adequate 




information or even AI-related knowledge from their partners to increase their overall 
innovation capability in a more effective way. 
Compared to prior research that studied the relationship among IT, alliances and 
innovation, our study provides improvements in measurements of AI and innovation 
using both patents and employee skills. We offer a multi-dimensional view on AI 
capabilities (Santhanam and Hartono 2003; Tambe and Hitt 2012) instead of following 
earlier efforts that measure IT using dollars invested. As the pharmaceutical firms are 
chosen for the purpose of reducing the heterogeneity in measuring innovation across all 
areas, we draw on domain knowledge of the specific industry sector to assess the firms’ 
innovation outputs. Our analyses at both firm level and alliance level can systematically 
examine how AI and R&D alliances can be complementary to generate innovation and 
the type (i.e., level of novelty) of innovation they can facilitate.  
Our study offers some important managerial implications to practitioners 
managing AI and R&D alliances for innovation. Managers should be aware that the value 
of partnerships can be enhanced by the joint adoption of advanced technologies such as 
AI. Furthermore, as the cost of AI continues to decline, using AI for finding more 
incremental innovations at the lower end of the novelty spectrum will become cost 
effective in the future; and at the higher end of the novelty spectrum, it’s also likely that 
entirely novel innovation could be supported when new capabilities of AI continue to be 
developed and an ever-expanding array of information can be accessed through external 




This paper lays the groundwork for future research. For example, besides inter-
organizational knowledge flows, it is suggested that firms with decentralized intra-
organizational structure generally invest more in technology and can receive greater 
return from it (Wu et al. 2019). Thus, it would be intriguing to examine some internal 
attribute of organizational structure, such as the composition of teams that can leverage 
knowledge flows facilitated by AI across organizational boundaries. Gaining a better 
understanding of the integration of AI with proper organizational design as a whole that 
presents a comprehensive landscape of firms’ innovation development can be a fruitful 





Table 24 : Summary Statistics and Correlation Table 
 
             
Variables # of 
obs. 
Mean  Std 
dev.  
1 2 3 4 5 6 7 8 9 
1. ln(Number of 
Drugs)  
4,882 0.08 0.28 1.00         
2. ln(AI Stock) 4,882 0.25 0.68 0.10 1.00        
3. ln(AI Skill) 4,882 0.31 1.08 0.15 0.32 1.00       
4. Alliances 4,882 2.63 7.26 0.46 0.29 0.38 1.00      
5. ln(Patent Stock) 4,882 3.77 1.81 0.13 0.40 0.27 0.32 1.00     
6. Public Status 4,882 0.42 0.49 0.11 0.13 0.16 0.13 0.20 1.00    
7. ln(Firm Age) 4,882 2.88 0.75 0.10 0.19 0.17 0.24 0.25 0.12 1.00   
8. ln(# of 
Employees) 
4,882 5.90 2.57 0.13 0.21 0.19 0.20 0.19 0.01 0.15 1.00  
9. ln(R&D) 4,882 20.15 3.11 0.02 0.16 0.10 0.10 0.06 -0.13 0.13 0.19 1.00 
             
 







Table 25 : Relationship Between AI and R&D Alliances 
 
 (1) (2) 
DV Alliances Alliances 
   
AI Capability 0.209*** 0.175*** 
 (0.0632) (0.0650) 
ln(Patent Stock)  0.113** 
  (0.0576) 
Public Status  0.203 
  (0.126) 
ln(Firm Age)  -0.287 




  (0.0170) 
ln(R&D)  0.00203 
  (0.0155) 
   
Observations 4,882 4,882 
R-squared 0.942 0.942 
Year FE YES YES 
Firm FE YES YES 
 
Note:  
(1). Column 1-2 presents the results by estimations with fixed effects at the firm level.  








Table 26 : AI, R&D Alliances, and Firm Innovation 
 
 (1) (2) (3) (4) 








  Novelty: 0-0.3) Novelty: 0.3-0.7) Novelty: 0.7-1) 
     
AI Capability 0.0138** 0.00423 0.00937* 0.00191 
 (0.00616) (0.00425) (0.00478) (0.00163) 
Alliances 0.0131 -0.00467 0.0289** 0.00543 
 (0.0185) (0.0128) (0.0144) (0.00490) 
AI Capability X 
Alliances 
0.0535** 0.00137 0.0421** -0.00594 
 (0.0246) (0.0170) (0.0191) (0.00650) 
ln(Patent Stock) -0.00455 -0.00347 0.00176 -0.00229 
 (0.00547) (0.00378) (0.00424) (0.00145) 
Public Status 0.0373*** 0.0270*** 0.00857 -0.00312 
 (0.0119) (0.00824) (0.00926) (0.00316) 
ln(Firm Age) 0.0514*** 0.0127 0.0388*** 0.00351 
 (0.0185) (0.0128) (0.0144) (0.00489) 
ln(# of Employees) -0.00179 -0.000816 -0.00146 0.000467 
 (0.00161) (0.00111) (0.00125) (0.000427) 
ln(R&D) 0.00396*** 9.7010-5 0.00388*** 0.000146 
 (0.00146) (0.00101) (0.00114) (0.000388) 
     
Observations 4,882 4,882 4,882 4,882 
R-squared 0.654 0.535 0.688 0.548 
Year FE YES YES YES YES 
Firm FE YES YES YES YES 
 
Note:  
(1). All the drugs studied have their chemical structures in the database.  
(2). Column 1 presents the result for all drugs developed by firms from estimations with fixed effects at the 
firm level. Column 2-4 shows the fixed effect estimations for the number of drugs with their novelty scores 
in each detailed range associated with three categories: incremental drugs with novelty score between 0 and 
0.3, medium-novel drugs with novelty score between 0.3 and 0.7, and highly novel drugs with novelty 
score greater than 0.7.  
(3). All interactions are formed from variables that are appropriately centered.  









Table 27 : AI, R&D Alliances, and Firm Innovation (2SLS) 
 
 (1) (2) (3) (4) 








  Novelty: 0-0.3) Novelty: 0.3-0.7) Novelty: 0.7-1) 
     
AI Capability 0.132* 0.0272 0.118** 0.00728 
 (0.0794) (0.0553) (0.0583) (0.0215) 
Alliances -0.00431 -0.0206 -0.00224 -0.00746 
 (0.0256) (0.0179) (0.0188) (0.00694) 
AI Capability X Alliances 0.0736** 0.0339 0.0567** 0.00656 
 (0.0332) (0.0231) (0.0244) (0.00898) 
ln(Patent Stock) -0.0217 -0.00543 -0.0160 -0.00319 
 (0.0162) (0.0113) (0.0119) (0.00439) 
Public Status 0.0188 0.0241** -0.00801 -0.00365 
 (0.0151) (0.0106) (0.0111) (0.00410) 
ln(Firm Age) 0.0259 0.00339 0.0187 0.00320 
 (0.0183) (0.0128) (0.0135) (0.00497) 
ln(# of Employees) -0.00254 -0.00109 -0.00202 0.000418 
 (0.00179) (0.00125) (0.00131) (0.000484) 
ln(R&D) 0.00333** 0.000201 0.00307*** 0.000125 
 (0.00142) (0.000991) (0.00104) (0.000385) 
     
Year FE YES YES YES YES 
Firm FE YES YES YES YES 
 
Note:  
(1). All the drugs studied have their chemical structures in the database.  
(2). Column 1 presents the result for all drugs developed by firms from the 2SLS estimation. Column 2-4 
reports the 2SLS estimations for the number of drugs with their novelty scores in each detailed range 
associated with three categories: incremental drugs with novelty score between 0 and 0.3, medium-novel 
drugs with novelty score between 0.3 and 0.7, and highly novel drugs with novelty score greater than 0.7.  
(3). All interactions are formed from variables that are appropriately centered.  
(4). We use total number of neighboring firms with AI capability as an instrument for a focal firm’s AI 
capability. Two variations of this instrument are also employed for the analysis: (1) the average number of 
AI patent stock and (2) the average ratio of AI patent stock in the neighboring firms. To instrument for a 
firm’s total alliance stock, we mainly use two-year lagged values of partner firms’ resources and 
investment such as their total patent stock and number of employees (Tafti et al. 2013). The associated F-
statistics at first stage are greater than the threshold and pass the weak instrument test.  

















Table 28 : AI, Knowledge Stock, and Knowledge Flows 
 









     
AI Capability 0.000726* 0.00128*** 0.00122** 0.00148*** 
 (0.000431) (0.000489) (0.000492) (0.000497) 
Alliance Knowledge Stock   0.000464  
   (0.00243)  
AI Capability X Alliance Knowledge Stock   0.00659**  
   (0.00285)  
Knowledge Stock (Focal Firm)    4.6710-5 
    (0.00263) 
AI Capability X Knowledge Stock (Focal Firm)    0.00573* 
    (0.00326) 
Knowledge Stock (Partner Firm)    0.00171 
    (0.00189) 
AI Capability X Knowledge Stock (Partner Firm)    0.0132*** 
    (0.00236) 
Technological Overlap 0.0802*** 0.0810*** 0.0765*** 0.0726*** 
 (0.00831) (0.00835) (0.00846) (0.00846) 
Alliance Experience -2.3710-6 7.5110-6 -8.4610-6 -4.6110-6 
 (1.1610-5) (1.2510-5) (1.2910-5) (1.3010-5) 
Partner Alliance Experience 5.0510-5* 5.1110-5* 4.4610-5 -4.6110-6 
 (2.8310-5) (2.8310-5) (2.8910-5) (3.1110-5) 
Public Status  -0.00327 -0.00395 -0.00381 
  (0.00241) (0.00244) (0.00245) 
ln(Firm Age)  -0.00119 -5.6910-5 -0.000472 
  (0.00101) (0.00103) (0.00103) 
ln(# of Employees)  -0.000605 -0.000826 -0.000678 
  (0.000494) (0.000503) (0.000507) 
ln(R&D)  -0.000213 -0.000201 -0.000289 
  (0.000443) (0.000445) (0.000445) 
     
Observations 3,763 3,763 3,763 3,763 
R-squared 0.033 0.035 0.042 0.050 
Year FE YES YES YES YES 
Firm Control NO YES YES YES 
 
Note:  
(1). The dependent variable is a natural logarithm of difference of firms’ citations to their partners before 
and after alliances. We examine the knowledge transferred into the firms in our sample. Column 1 presents 
the result about AI’s effect when several firms’ control variables are not considered, while Column 2-4 
controls for these firm characteristics in the analyses. Column 2 serves as the baseline for our estimations 
after firms’ characteristics are controlled in our analyses. Column 3 demonstrates the effect of AI and total 
knowledge stock of participating firms in the alliances, while Column 4 decomposes total knowledge stock 
and shows the result about the effect of AI and knowledge stock of client pharmaceutical firms and their 
partner respectively.  
(2). All interactions are appropriately centered.  










Table 29 : AI, R&D Alliances, and Deal Size 
 
 (1) (2) 
DV ln(Deal Size) ln(Deal Size) 
   
AI Capability 0.125*** 0.0672*** 
 (0.0234) (0.0257) 
Technological Overlap 1.880*** 1.835*** 
 (0.406) (0.398) 
Alliance Experience 0.00207*** 0.000259 
 (0.000657) (0.000700) 
Partner Alliance Experience 0.000309 0.000958 
 (0.00142) (0.00139) 
Public Status  -0.173 
  (0.132) 
ln(Firm Age)  0.0729 
  (0.0501) 
ln(# of Employees)  0.155*** 
  (0.0273) 
ln(R&D)  0.0812*** 
  (0.0228) 
   
Observations 1,302 1,302 
R-squared 0.179 0.220 
Year FE YES YES 
Firm Control NO YES 
 
Note:  
(1). The dependent variable is a natural logarithm of deal size available in our data. Column 1 presents the 
result about AI’s effect when several firms’ control variables are not considered, while Column 2 controls 
for these firm characteristics in the analyses.  
(2). The interaction is appropriately centered.  














For Chapter 2 :  





Figure A1 : Converting all data analytics-related metrics to full-text-resume based 
measures. Our measurement of data analytics skills comes from three data sources: 1) 
resume data with detailed job description from 1988 to 2007; 2) resume data with job 
titles from 1988 to 2010 (these are updates from the same resume source as (1), so they 
are consistent); 3) job review data from 2008 to 2013. The boundary years for all the data 
sources tend to be more incomplete and are thus not good candidates for calculating 
scaling factors. Thus, to scale source (2) to source (1), we use 2006 as the common year 
to create scales because 2007 is a boundary year and contains only a subset of the firms 
in 2006. This serves to translate job-title-based metrics to full-text-based metrics from the 
same resume data source. We also translate two different data sources that both use job 
titles to measure analytics skills (to scale from source (3) to (2)). We primarily use 2009 
as the common year to scale because it is not a boundary year. However, when a firm 
exists in 2008 and 2010 but not in the year 2009, we also use these years to scale. When 
we cannot find the firm in any of the overlapping years, we scale by using the industry 









Figure A2 : An illustration of instrument variables. We assume each firm (on the left 
“Before” plot) has 10 employees with data analytics skills. Accordingly Firm A has 
access to 30 employees with data talent. Now Firm B hired 5 more data analytics 







Table A1 : Taxonomy Used to Classify Data Analytics Skills 
 
General: Business intelligence, Data analysis, Data center, 
Data driven, Data fusion, Data integration, Data 
mining, Data warehouse 
System oriented: Cassandra, Cloud computing, Distributed system, 
Hadoop, HBase, Google File System, MapReduce 
Algorithms & Methodology 
oriented: 
A/B test, Ensemble learning, Genetic algorithm, 
Machine learning, Natural language processing, 
Neural network, Network analysis, Optimization, 
Pattern recognition, Predictive modeling, 
Regression modeling, Signal processing, 
Simulation, Supervised learning, Unsupervised 
learning, Visualization 
 
Note: The Sovren resume parser (http://www.sovren.com) provides us with the text mining and skills-based 
semantic matching algorithms that map free-form text responses to a taxonomy of skills. It is also used by a 
number of online job sites to facilitate skills-based resume searches (among other activities). We then classify 
data analytics skills by the taxonomy. The table shows the list of keywords we use that appear more frequently 
in the resume data. We also test several variants of these words, but they don’t lead to significant differences 










 Public Firms Private Firms  





ln(Firm age) 2.033 0.875 2.655 0.800 -0.622*** 
ln(VC inflows stock 
(in $M)) 
1.203 1.520 0.522 1.078 0.681*** 
ln(Total assets  
(in $M)) 
4.598 1.849 5.295 2.681 -0.697*** 
ln(Emp w/ college+) 5.561 2.278 6.087 2.965 -0.526*** 
      
Sample after matching is used 
 Public Firms Private Firms  





ln(Firm age) 2.118 0.713 2.221 0.720 -0.103*** 
ln(VC inflows stock 
(in $M)) 
0.756 1.216 0.836 1.280 -0.079 
ln(Total assets 
(in $M)) 
4.703 1.929 4.573 2.351 0.129 
ln(Emp w/ college+) 5.603 2.389 5.741 2.462 -0.139 
 
Note: We report and compare the characteristics of two groups of firms: those going public and those not. 
The observed firm characteristics have significant differences across the two groups in our full sample. Our 
matching method is then employed to ensure that the two groups have (approximately) similar distribution 
of these characteristics and the selection bias could be mitigated. We find that the differences have been 
reduced for VC financing, total assets and labor quality after matching. Though the difference of firm age 










Table A3 : Data Analytics, Firm Public Status and Innovation Quality (Heckman with 2SLS) 
 
Model: Heckman + IV (1) (2) (3) (4) (5) (6) (7) (8) (9) 
DV ln(Orig) ln(Gen) ln(Fwd citations, ln(Reuse ln(Reuse ln(New-comb ln(New-comb ln(Novelty ln(Novelty 
   w/in 4 yrs) Global) Local) Global) Local) Global) Local) 
          
Public -0.0686*** -0.0662*** -0.175*** -0.0147 0.00240 -0.0828*** -0.0554** -0.00630 -0.0565** 
 (0.0240) (0.0246) (0.0594) (0.0268) (0.0205) (0.0304) (0.0243) (0.00556) (0.0256) 
ln(Data) 0.0522 0.0384 0.235** 0.0699 0.0915*** 0.0282 0.0434 -0.0148 -0.0284 
 (0.0462) (0.0508) (0.111) (0.0476) (0.0337) (0.0446) (0.0518) (0.0105) (0.0570) 
Data X Public 0.107** 0.0941** 0.0263 0.106** 0.0704** 0.103* 0.123*** -0.00666 0.0823* 
 (0.0450) (0.0430) (0.0964) (0.0416) (0.0359) (0.0552) (0.0445) (0.0109) (0.0439) 
ln(Firm age) 0.0373 0.0591 -0.178 0.0380 0.0194 0.0998 0.0992 0.00758 0.0893 
 (0.0672) (0.0711) (0.156) (0.0612) (0.0478) (0.0748) (0.0628) (0.00997) (0.0722) 
ln(VC inflows stock) -0.0379 -0.0194 0.0787 -0.0356 -0.0210 -0.0435 -0.0549 -0.00728 -0.0330 
(0.0427) (0.0405) (0.0965) (0.0358) (0.0323) (0.0438) (0.0436) (0.00593) (0.0402) 
ln(Total assets) 0.106*** 0.0955*** 0.237*** 0.0582*** 0.0294* 0.103*** 0.0766*** 0.00540* 0.0801*** 
 (0.0224) (0.0196) (0.0708) (0.0215) (0.0175) (0.0286) (0.0207) (0.00321) (0.0264) 
ln(Emp w/ college+) -0.00491 -0.000566 -0.0186 -0.00453 -0.00746 0.00275 -0.00229 0.00129 0.00742 
(0.00611) (0.00756) (0.0157) (0.00577) (0.00474) (0.00600) (0.00744) (0.00131) (0.00627) 
IMR -0.00196 -0.0383 2.285** -0.169 -0.101 -0.264 -0.447 -0.0303 -0.270 
 (0.529) (0.495) (1.138) (0.426) (0.368) (0.500) (0.469) (0.0696) (0.574) 
          
Observations 13,262 13,262 13,262 13,262 13,262 13,262 13,262 13,262 13,262 
# of firms 2,113 2,113 2,113 2,113 2,113 2,113 2,113 2,113 2,113 
Year FE YES YES YES YES YES YES YES YES YES 
Firm FE YES YES YES YES YES YES YES YES YES 
 
Note: 
(1). Instrumental variables for data analytics: 1) total number and fraction of employees with data analytics skills in a firm’s existing hiring network; 2) total 
number and fraction of neighbors that started to use an enterprise resource planning (ERP) 3) total number and fraction of neighbors that started to use Human 
Capital Management (HCM) systems. 
(2). All models also control for firms’ total number of patents as well as relevant intangible asset such as advertising asset, but including it or not does not change 
our results.  
(3). All interactions are appropriately centered. 
(4). IMR: inverse Mills ratio calculated from the probit model to predict the probability of a firm’s going public. 
(5). Standard errors are bootstrapped and reported in parentheses. 










For Chapter 3: 
Artificial Intelligence on Drugs: A Large-Scale Examination of AI and Drug Innovation 
 
B.1 A Dictionary of Exemplar Keywords to Identify AI Patents or Skills  
3d imaging  conditional random field  genetic algorithm  logic program  motion capture  robot 
adaboost  data mining  graphical model  logic system  natural language  scikit-learn 
anomaly detection  decision tree  hadoop  logistic regression  neural network  semantic analysis  
artificial intelligence  deep learning  hidden markov  machine intelligence  objective function  stochastic gradient 
descent  
augmented reality  defuzzification  hyperspectral imaging  machine learning  pattern recognition  supervised learning  
cloud computing  dimensionality reduction  ibm watson maximum entropy  predictive analysis  support vector machine  
cluster analysis  evolvable hardware  inference engine  maximum a posteriori  predictive model  tensorflow 
computational biology  expert system  information extraction  maximum likelihood  pytorch unsupervised learning  
computational control  feature selection  keras mechatronic  random forest  virtual reality  
computer vision fuzzy logic  knowledge base motif discovery  reinforcement learning  xgboost  
 









B.2 Summary Statistics and Correlation Table for the Full Sample 
 
Table B1 : Summary Statistics and Correlation Table, with Non-AI Firms 
 
                
Variables # of obs. Mean  Std dev.  1 2 3 4 5 6 7 8 9 10 11 12 
For ln(Number of Drugs):                 
1. at Early Stage 28,126 0.096 0.33 1.00            
2. at Early Stage, 
Novelty: [0, 0.3] 
28,126 0.033 0.18 0.67 1.00           
3. at Early Stage, 
Novelty: [0.3, 0.7] 
28,126 0.059 0.27 0.79 0.15 1.00          
4. at Early Stage, 
Novelty: [0.7, 1] 
28,126 0.017 0.13 0.28 0.07 0.12 1.00         
5. at Late Stage – FDA 
Approval 
28,126 0.008 0.08 0.34 0.13 0.38 0.12 1.00        
6. ln(AI Stock) 28,126 0.191 0.58 0.07 0.01 0.10 0.03 0.09 1.00       
7. ln(AI Skill) 15,674 0.175 0.79 0.16 0.04 0.19 0.06 0.12 0.22 1.00      
8. ln(Patent Stock) 28,126 3.176 1.76 0.13 0.03 0.16 0.04 0.12 0.37 0.22 1.00     
9. Public Status 28,126 0.238 0.43 0.12 0.05 0.12 0.04 0.08 0.09 0.13 0.25 1.00    
10. ln(Firm Age) 28,126 2.705 0.79 0.04 0.00 0.07 0.02 0.10 0.16 0.13 0.14 0.10 1.00   
11. ln(# of Employees) 28,126 6.640 2.50 0.07 0.01 0.10 0.02 0.09 0.15 0.09 0.09 -0.05 0.09 1.00  
12. ln(R&D) 28,126 17.29 3.40 -0.09 -0.07 -0.08 0.00 -0.07 0.04 0.09 0.03 -0.01 0.13 -0.21 1.00 
                
 
Note: We add one to actual values of the employee and patent related variables as well as firm age and R&D spending to avoid the possibilities of taking a 






B.3 AI on Development of Novel Drugs Using Poisson Regressions 
 
Table B2 : AI on Development of Drugs with Novelty, Early Stage 
 
 (1) (2) (3) (4) (5) (6) (7) 


























        
AI Capability 0.180*** 0.0666 0.187*** 0.102 -0.0492 1.116*** 0.417 
 (0.0240) (0.0674) (0.0261) (0.105) (0.307) (0.391) (0.416) 
ln(Patent Stock) 0.0542 0.0473 0.0266 -0.0275 0.411 -0.102 -0.00228 
 (0.0423) (0.0920) (0.0530) (0.172) (0.311) (0.335) (0.359) 
Public Status 0.0296 0.182 -0.0661 -0.0432 0.984 -1.202 -0.847 
 (0.119) (0.227) (0.151) (0.398) (1.253) (1.361) (1.359) 
ln(Firm Age) 0.187** 0.0653 0.176 0.511** -0.325 0.322 -1.384 
 (0.0895) (0.189) (0.120) (0.248) (0.555) (0.831) (0.909) 
ln(# of Employees) 0.0794*** 0.0208 0.117*** 0.165** -0.0698 0.0424 0.0468 
 (0.0248) (0.0393) (0.0352) (0.0830) (0.200) (0.207) (0.179) 
ln(R&D) -0.0226 -0.00482 -0.0548 0.242 0.381 -0.00640 0.435 
 (0.0274) (0.0517) (0.0342) (0.163) (0.369) (0.116) (0.422) 
        
 
Note:  
(1). We perform Poisson regressions that model the raw number of drugs with firm and year fixed effect on 
the same sample for early stage of drug development as shown in the main body of the paper. All the drugs 
studied have their chemical structures in the database.  
(2). Column 1 shows the results for all the drugs developed at the early stage, while Column 2-4 looks into 
three ranges of novelty scores based on molecular structures of drugs. Results using alternative novelty 
metrics that examine drug pharmacological classes are shown in Column 5-7.  






Table B3 : AI on Development of Drugs, Late Stage 
 
 (1) (2) (3) (4) 
DV Number of 
Drugs  
at Phase I 
Number of 
Drugs  
at Phase II 
Number of 
Drugs  
at Phase III 
Number of Drugs  
at FDA Approval 
     
AI Capability 0.0791 0.00723 -0.0544 0.148 
 (0.0521) (0.0436) (0.107) (0.133) 
Number of Drugs 
at Previous Stage 
0.0644*** 0.286*** 0.272*** 0.370*** 
 (0.0173) (0.0299) (0.0677) (0.137) 
ln(Patent Stock) -0.0869 0.0427 -0.144 -0.120 
 (0.0946) (0.0960) (0.229) (0.293) 
Public Status 0.262 -0.0433 -0.595* 0.446 
 (0.241) (0.184) (0.360) (0.493) 
ln(Firm Age) 0.354 0.521** 2.388*** 0.958 
 (0.273) (0.242) (0.811) (1.038) 
ln(# of 
Employees) 
-0.0303 -0.0641* -0.159** 0.0377 
 (0.0342) (0.0348) (0.0709) (0.151) 
ln(R&D) 0.0312 -0.0713** -0.102 0.318** 
 (0.0523) (0.0292) (0.0682) (0.143) 
     
 
Note:  
(1). We perform Poisson regressions that model the raw number of drugs with firm and year fixed effect on 
the same sample for late stage of drug development across different phases as shown in the main body of 
the paper. All the drugs studied have their chemical structures in the database.  












B.4 Results Estimated by Cox Proportional Hazards Model without Random Effect 
 
Table B4 : Drug-level Analysis: Cox Proportional Hazards Model without Random Effect 
 
 (1) (2) (3) (4) (5) (6) (7) (8) 
 From Early stage to Phase I  From Phase I to Phase II  From Phase II to Phase III  From Phase III to FDA Approval 
         
AI Capability  
(Originator, Early Stage) 
0.0326*** 0.0325*** 0.00422 0.00439 0.00643 0.00688 -0.00633 -0.00534 
 (0.00421) (0.00421) (0.00347) (0.00347) (0.00480) (0.00481) (0.00835) (0.00834) 
AI Capability (Licensee)  0.00810  0.0238  0.0216  -0.0170 
  (0.0186)  (0.0150)  (0.0198)  (0.0129) 
         
Observations 22,867 22,867 20,770 20,770 11,038 11,038 16,901 16,901 
Controls  YES YES YES YES YES YES YES YES 
Drug RE NO NO NO NO NO NO NO NO 
 
Note:  
(1). In this drug-level analysis, the dependent variable is related to the duration of drugs progressing from one stage to the next in the late stage. Odd-numbered 
columns show the results for the impact of originator’s AI capability on the drugs developed at the clinical-trial stage and getting approval at FDA in our 
estimations without random effect. Even-numbered columns include an additional AI capability of drug licensee.  












B.5 Results for AI’s Effects on Development of Novel Drugs (2SLS, PSM and CEM) 
 
 
Table B5 : AI on Development of Novel Drugs (2SLS) 
 





























        
AI Capability 0.0236 0.0626* 0.0132 -0.00610 0.0552* 0.0417* -0.00853 
 (0.0219) (0.0337) (0.0304) (0.0150) (0.0329) (0.0233) (0.0138) 
ln(Patent Stock) -0.0109 -0.0281 0.00123 0.00576 -0.0296* -0.0181 0.00589 
 (0.0112) (0.0175) (0.0157) (0.00814) (0.0166) (0.0120) (0.00731) 
Public Status -0.0132 -0.0487*** -0.0138 -0.00696 -0.0270** -0.0274** -0.00406 
 (0.0115) (0.0174) (0.0119) (0.00752) (0.0121) (0.0116) (0.00516) 
ln(Firm Age) 0.0126* 0.0278** 0.00460 0.00551 0.0284*** 0.00678 -4.8510-5 
 (0.00698) (0.0120) (0.00983) (0.00467) (0.00963) (0.00715) (0.00333) 
ln(# of Employees) -0.000269 -0.000907 -0.00223*** -3.1210-5 -0.00107 -0.00104 -6.8010-5 
(0.000836) (0.00121) (0.000851) (0.000419) (0.000962) (0.000723) (0.000296) 
ln(R&D) -0.000381 -0.000992 -0.000503 -0.000473 -0.00120 -0.000283 -9.7310-5 
 (0.000738) (0.00122) (0.00104) (0.000386) (0.000966) (0.000754) (0.000337) 
        
Observations 8,235 8,235 8,235 8,235 8,235 8,235 8,235 
Year FE YES YES YES YES YES YES YES 
Firm FE YES YES YES YES YES YES YES 
 
Note:  
(1). All the drugs studied have their chemical structures in the database.  
(2). Results are derived from 2SLS estimations. We primarily use total number of neighboring firms with AI capability to instrument for a focal firm’s AI 
capability. We also use two variations of this instrument: (i) the average number of AI patents and (ii) the average ratio of AI patents in the neighboring firms. 
The associated F-statistics at first stage are above the threshold and pass the weak instrument test.  
(3). Column 1-3 estimates the impact of AI capability on three novelty ranges corresponding to incremental drugs, medium-novel drugs and brand-new drugs. 
Column 4-7 examines each decile within the range of medium novelty scores.  










Table B6 : AI on Development of Novel Drugs, with Non-AI Firms (PSM and CEM) 
 
 (1) (2) (3) (4) (5) (6) (7) (8) 





























         
AI Capability 0.0188*** 0.00336 0.0156*** 0.00325 0.0107** 0.00402 0.00749** 0.00330 
 (0.00469) (0.00217) (0.00416) (0.00211) (0.00445) (0.00260) (0.00381) (0.00210) 
ln(Patent Stock) 0.00276 -0.00184 -0.00183 0.00555 0.0120 -0.000847 0.00637 0.00331 
 (0.00770) (0.00474) (0.00553) (0.00366) (0.00763) (0.00579) (0.00487) (0.00424) 
Public Status -0.0371* -0.0108 -0.0372** -0.00614 -0.00235 -0.00387 0.00349 -0.000935 
 (0.0192) (0.0114) (0.0161) (0.0103) (0.0146) (0.00919) (0.0121) (0.00616) 
ln(Firm Age) 0.0229 0.0110 0.0196* 0.00128 0.00218 0.00762 0.00223 -0.00908 
 (0.0144) (0.00762) (0.0101) (0.00932) (0.0134) (0.00801) (0.00821) (0.00837) 
ln(# of Employees) -0.00195 -0.000325 -0.000834 -0.00207*** -0.00273** -0.000868 -0.00117 -0.00153*** 
 (0.00138) (0.000784) (0.00105) (0.000716) (0.00127) (0.000861) (0.00104) (0.000472) 
ln(R&D) 0.000144 -0.000106 0.000111 -0.000835 0.00258** 0.000512 0.00245*** -0.000603 
 (0.00134) (0.000833) (0.000959) (0.000975) (0.00118) (0.000725) (0.000895) (0.000577) 
         
Observations 9,885 9,885 9,885 9,885 12,858 12,858 12,858 12,858 
R-squared 0.725 0.464 0.731 0.392 0.580 0.418 0.555 0.372 
Year FE YES YES YES YES YES YES YES YES 
Firm FE YES YES YES YES YES YES YES YES 
 
Note:  
(1). All the drugs studied have their chemical structures in the database.  
(2). Results are reported by using matching estimators for the number of drugs with their novelty scores in each detailed range. Column 1-4 shows the results 
estimated by utilizing propensity score matching approach, while coarsened exact matching method is used for Column 5-8.  
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